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Metabolic dysregulation in the form of insulin-resistant type 2 diabetes mellitus leads 
to premature death and disability, primarily as a consequence of vascular dysfunction. 
This relates to accelerated atherosclerosis, diminished vascular repair and 
dysfunctional angiogenesis. A number of complementary systems exist to regulate 
insulin sensitivity, and maladaptive activation of these may contribute to 
pathophysiology. SHIP2 is a lipid phosphatase which catalyses the conversion of 
phosphatidylinositol (3,4,5)-triphosphate (PI(3,4,5)P3) to phosphatidylinositol (3,4)-
biphosphate PI(3,4)P2 in insulin responsive tissues. It therefore suppresses activation 
of signalling cascades downstream of phosphoinositide-3-kinase (PI3K), consistent 
with a negative role of SHIP2 in insulin signalling. However, the effects of SHIP2 
manipulation on metabolic and vascular function have not been clearly elucidated.  
We hypothesised that SHIP2 inhibition would have favourable effects on insulin-
mediated glucose lowering, vascular repair and angiogenesis. Studies were primarily 
performed on mice with germline endothelium-specific (ECSHIP2Δ/+), or whole body 
inducible (SHIP2iΔ/+) SHIP2 catalytic domain haploinsufficiency, using a Cre-lox 
approach. A complementary model was explored in human umbilical vein endothelial 
cells (HUVECs) using shRNA-mediated knockdown or pharmacological inhibition of 
SHIP2. 
ECSHIP2Δ/+ mice exhibited impaired vascular formation in the developing postnatal 
retinas, associated with increased endothelial PI3K/AKT signalling and Nox2-mediated 
vascular oxidative stress. Alterations in these signalling intermediates and superoxide 
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generation were recapitulated in HUVECs. This was associated with defects in 
endothelial cell migration and polarisation, although no differences in proliferative 
capacity were observed. SHIP2iΔ/+ mice had enhanced whole body glucose disposal 
and insulin sensitivity. They exhibited skeletal muscle hypervascularity in the context 
of hindlimb ischaemia, which was manifest as increased vessel thickness without 
alterations in vessel abundance. No differences in re-endothelialisation after denuding 
arterial injury were apparent in this model. 
In conclusion, SHIP2 activity appears critical in preservation of metabolic and vascular 
homeostasis during health and disease. Elements of this role may relate to 
suppression of oxidative stress that arises from unrestrained PI3K-Nox2 signalling. 
Further exploration to extend our mechanistic understanding is required, but the 
findings of this project suggest that caution is warranted before SHIP2 inhibition can 
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1.1   Diabetes mellitus and cardiovascular disease 
1.1.1 Overview 
Nutrient delivery has to be coordinated with energy storage and cell growth in normal 
physiology. This coupling enables regulation of a plethora of cell processes, including 
glucose, lipid and protein metabolism [1]. Multiple systems are implicated in these 
homeostatic processes, of which the insulin and insulin-like growth factor 1 (IGF-1) 
signalling cascades are pivotal. However, in the context of environmental stresses 
posed by chronic, caloric excess, metabolic dysregulation can ensue. This may 
manifest as insulin resistance with secondary glucose intolerance, defined clinically as 
pre-diabetes and type II diabetes mellitus (DM) [2]. These conditions are associated 
with significant morbidity and mortality, relating primarily to microvascular 
dysfunction and accelerated atherogenesis in the macrovasculature.  
 
1.1.2 Epidemiology 
As a consequence of an ageing population and increased prevalence of truncal 
obesity, type 2 DM has become a major global public health burden. World Health 
Organisation (WHO) estimates indicate that 550 million people are likely to suffer 
from the disorder by 2030, a projected increase of 50% compared to contemporary 
data [3]. Over 25% of patients presenting to hospital with acute myocardial infarction 
(MI) have comorbid DM [4], and indeed, this proportion is substantially higher when 
those with evidence of impaired glycaemic control (pre-diabetes) are included [5]. It is 
also strongly associated with chronic heart failure (CHF), with several studies quoting 






1.1.3 Cardiovascular morbidity and mortality 
The burden of disease imposed by DM relates primarily to increased cardiovascular 
sequelae. The Framingham study was a landmark study in highlighting this association, 
and was based on 20 years of surveillance data with a reported 2-3 fold enhanced risk 
[8]. Macrovascular disease constitutes the predominant burden, with ischaemic heart 
disease, CHF, cerebrovascular events and peripheral vascular disease (PVD) all strongly 
implicated [9]. Patients with DM appear to develop these sequelae 15 years earlier 
than the general population [10]. Those with pre-diabetes are also at increased 
cardiovascular risk (see Figure 1-1) [11]. 
Improving therapeutic strategies in the contemporary era have played a significant 
role in reducing morbidity associated with cardiovascular disorders [12]. However, 
despite these interventions, it appears that the presence of DM continues to confer a 
prognostic disadvantage. This extends beyond morbidity into mortality risk. In the 
context of acute MI, for instance, patients with DM have an adjusted risk of all-cause 
death which is nearly 50% higher [13]. This adverse prognosis has also been shown in 







Figure 1-1 – Evolution of diabetes and its association with vascular dysfunction. 
Adapted from Wheatcroft et al. Diabet Med 2003; 20(4):255-68 [15]. 
Insulin sensitivity is reduced as type II DM develops. Initial, compensatory  
hyperinsulinaemia results in glucose homeostasis until manifestation of frank DM.  
There is a progressively increased risk of atherogenesis throughout this period. 
 
1.1.4 Atherothrombosis 
The macrovascular risk associated with DM primarily relates to accelerated 
atherosclerosis in large and medium-sized arteries [16]. For many decades, it was 
considered that atherosclerosis was principally a pathophysiological process of lipid 
accumulation within the arterial wall [17]. However, despite aggressive strategies to 
improve lipid profile via lifestyle measures and pharmacotherapy, it is evident from 
epidemiological studies that cardiovascular disease continues to be associated with 





atherogenesis is a multi-faceted disease process and can be perhaps best described as 
an ‘inflammatory’ disorder involving vessel walls [18].  
 
1.1.4.1 Endothelial dysfunction 
The pathology of atherosclerotic lesions in patients with DM is in many regards 
indistinguishable from those without DM, although lesions are generally more 
advanced and diffusely distributed [19]. A unifying concept to explain initiation of 
atherogenesis is that of ‘endothelial dysfunction’ [20]. It refers to a subtle alteration in 
endothelial phenotype (discussed later) that precedes structural changes in the 
arterial wall. This unfavourable shift is accelerated by systemic components of whole 
body insulin resistance syndrome, such as hyperglycaemia, dyslipidaemia and 
hypertension, and triggers a complex disturbance of endothelial biology that permits 
progression of the atherogenic cascade [21]. An overview is provided in Figure 1-2. 
 
1.1.4.2 Fatty streak and foam cells 
Atherosclerosis is a chronic disease and typically take decades to manifest clinically. 
However, the earliest discernible lesion is the so-called ‘fatty streak’ which is often 
present in young adults [22]. Cholesterol levels, and particularly low-density 
lipoprotein (LDL) cholesterol, are deemed as major contributors to susceptibility. 
However, it is worthy of note that patients with DM do not classically have raised LDL 
levels, but rather an abnormal dyslipidaemic profile consisting of small, dense LDL in 
combination with low high-density lipoprotein (HDL) and elevated triglycerides [23]. 
Other features such as endothelial permeability and biosynthesis of the basement 





The fatty streak occurs as a response to receptor-mediated endocytosis of LDL, and 
other apoB-containing lipoproteins, across the endothelium with trapping in the 
arterial intima [25]. Once sequestered, lipids contained in LDL are modified, for 
example by fusion, enzymatic cleavage, incorporation into immune complexes and 
oxidation, mediated by cells of the vessel wall [26]. The pro-inflammatory effects of 
oxidised LDL result in recruitment of monocytes to the intima, and terminal 
differentiation of these into macrophages. Oxidised LDL can then be internalised by 
macrophages via scavenger receptor class A (SRA)-I, SRA-II, CD36, LOX-1 and CXCL16 
[27]. These lipoproteins are targeted to the lysosome, where their cholesteryl esters 
are hydrolysed to unesterified cholesterol. This free cholesterol is delivered to the 
endoplasmic reticulum (ER), where acyl-coenzyme A:cholesterol acyltransferase 1 
(ACAT1) mediates predominant conversion back to esterified forms where it is stored 
as cytoplasmic lipid droplets [28]. A progressive accumulation of these droplets results 
in the formation of ‘foam cells’, named so because of the morphological appearance 
of soap bubbles. These foam cells characterise lesion progression from early to 
intermediate stage, and in combination with T lymphocytes, are the pathological 
hallmark of lipid streaks. 
 
1.1.4.3 VSMC remodelling and necrotic core  
Foam cells directly and indirectly mediate the release of chemokines and cytokines, 
such as interleukin-1 (IL-1) and tumour necrosis factor (TNF)-α, and promote 
endothelial cell expression of adhesions receptors including integrins and selectins 
[29]. These mediators can orchestrate mobilisation, adhesion, transmigration and 





of the inflammatory process. Supplementary release of growth factors such as platelet 
derived growth factor (PDGF), fibroblast growth factor (FGF) and tissue factor results 
in stimulation of vascular smooth muscle cells (VSMCs) which mediate vascular 
remodelling [30]. Under normal physiological states, VSMCs in the media produce the 
main components of the ECM found in the intimal layer, such as collagen and elastin, 
in addition to enzymes required for the delicate equilibrium between ECM synthesis 
and degradation [21]. In the context of atherogenesis, however, a transition into a 
proliferative and synthetic phenotype occurs. Indeed, the migration of VSMC into the 
vascular intima defines intimal thickening, provides the major source of ECM in the 
plaque and contributes to the formation of a fibrous cap [31].  
Sequential deactivation and apoptosis of foam cells within the lesion results in the 
formation of a necrotic core [32], which is essential in the development of a rupture-
prone plaque. This region is also impregnated with oxidised lipids and tissue factors, 
making it highly thrombogenic when exposed to circulating blood [33]. The lipid-rich 
core is overlaid by a fibrous cap, with its constituents primarily derived from VSMCs 
and their synthesis of ECM components, namely collagen and proteoglycans. There is 
also involvement of macrophage-derived foam cells, albeit to lesser proportions [34]. 
 
1.1.4.4 Plaque rupture and acute thrombus 
Such advanced lesions often remain stable for years, and can remain entirely 
asymptomatic if non-occlusive. However, activated T cells may stimulate production 
of matrix metalloproteinases (MMP’s), collagenases, elastases and stromelysin, by 





destabilising effects by reducing quantities of collagen-synthesising cells within the 
plaque [36]. Degradation of the fibrous cap can result in exposure of the underlying 
necrotic core and surrounding extracellular components, such as collagen and von 
Willebrand factor (vWF) to circulating blood, resulting in acute plaque rupture and 
activation of endogenous haemostatic cascades. Although these processes are crucial 
in physiological haemostasis, their activation in the context of acute plaque rupture 
generates thrombus within the already narrowed vascular lumen [37]. If this causes 
sufficient impairment of blood flow, ischaemic injury occurs downstream and is 
typified by clinical presentations such as acute MI.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Studies suggest that propensity for acute rupture depends upon plaque constituents 
and vulnerability, rather than extent of stenosis [38]. Factors that enhance 
vulnerability to rupture are associated with presence of DM, and include thinned 
fibrous cap, increased macrophage infiltration, increased size of necrotic core and 
reduced abundance of VSMCs [39]. The extent of plaque vascularisation has also been 
implicated in instability [40]. In the early phases of atherogenesis, plaque 
neovascularisation may have anti-apoptotic effects, whilst facilitating lesion growth 
[40]. In more advanced lesions, however, release of cytokines secondary to local 
inflammation can result in dysregulated neointimal proliferation of microvessels 
which are leaky, fragile, of poor quality and hence susceptible to rupture [41]. Studies 
in humans have reported higher proportions of neovessel formation in the most 
advanced atherosclerotic plaques, with increased abundance in those with DM [42]. 
Expression of proteolytic enzymes, such as MMP’s, is also increased by 





Platelets initiate plaque thrombosis upon detection of ECM and necrotic core 
constituents, and their aggregation is augmented in the setting of insulin resistance by 
reduced NO bioavailability, altered calcium regulation, oxidative stress and increased 
circulating vWF. Notably, atheromatous plaques in those with DM have been shown 
to exhibit increased intracoronary thrombus compared to controls [44]. 
Normoglycaemic patients with insulin resistance, and those with type II DM, have 
altered circulating components of the coagulation and fibrinolytic pathways, with 
increased levels of plasminogen activator inhibitor (PAI)-1 particularly implicated [45]. 
PAI-1 binds to tissue plasminogen activator (tPA) to inhibit its conversion of 
plasminogen to plasmin, an enzyme that is essential to degrade fibrin clots. Indeed, 
PAI-1 levels are lowered in patients with DM by weight reduction and 
pharmacotherapies, such as metformin and thiazolidinediones [46]. Hyperglycaemia 
can also directly cause post-translational modification of coagulation proteins, such as 
fibrinogen. This results in a fibrin clot which is denser, with thinner fibres, and is more 







Figure 1-2 – Pathogenesis of atherothrombosis. 
Initiation occurs via endothelial dysfunction. This is associated with subsequent oxidative stress, leucocyte recruitment and lipoprotein deposition. Formation of 
foam cells characterise lesion progression, with sequential apoptosis resulting in a necrotic core. Rupture of its fibrous cap precipitates endogenous haemostatic 






1.2   Vascular endothelium 
1.2.1 Overview 
The vascular endothelium is a monolayer compromised of approximately 1014 cells 
[48]. It divides the vessel lumen from surrounding cells and thus provides a direct 
mechanical interface between blood and tissue [49]. However, beyond its role as a 
structural barrier, it expresses insulin receptors and is therefore metabolically active 
with a critical role in physiological regulation. Its functions include transport of 
nutrients and solutes across the endothelium, and release of a plethora of 
vasoprotective components such as nitric oxide (NO) [21]. The endothelium is also a 
key mediator of endogenous responses to tissue and vascular injury, as part of 
processes broadly defined as ‘vascular regeneration’ (or angiogenesis) and ‘vascular 
repair’, respectively. 
 
1.2.2 Nitric oxide (NO) 
1.2.2.1 Historical perspective 
NO was first discovered as a clear, colourless gas by Joseph Priestley in 1772 [50]. It 
was subsequently established as an atmospheric pollutant, but the concept that it 
plays a fundamental role in vascular homeostasis was not apparent until two centuries 
later. The first experiments showed that the presence of endothelial cells was 
essential for acetylcholine (Ach)-mediated relaxation in aortas isolated from rabbits 
[51]. This process was influenced by an endogenous mediator termed endothelium 






1.2.2.2 Synthesis via NOS 
NO can be synthesised by one of three isoforms of nitric oxide synthase (NOS): 
endothelial (eNOS), neuronal (nNOS) and macrophage/inducible (iNOS). These are 
encoded by genes on chromosomes 7, 12 and 17, respectively [53]. For all three, NO 
synthesis depends upon binding of the enzyme to the calcium-regulatory protein 
calmodulin. However, iNOS is fundamentally different from the other two isoforms in 
that activity is independent of intracellular calcium concentration [54]. Of the three, 
iNOS is not constitutively present and expression is induced only in specific contexts 
such as inflammation or infection. It is the constitutively expressed eNOS that is 
implicated in the production of NO within the vascular endothelium, and an overview 
is provided in Figure 1-3.  
The amino acid L-arginine is the main eNOS substrate for NO biosynthesis, but several 
co-factors are also required, including nicotinamide adenine dinucleotide phosphate 
(NADPH), flavin mononucleotide, flavin adenine nucleotide, tetrahydrobiopeterin 
(BH4), calmodulin and a haem group. It occurs in a two-step process. The first stage 
involves electron transfer from NADPH to the haem group, which hydroxylates L-
arginine to form the intermediate N-hydroxyl L-arginine [55]. This is then oxidised to 
form NO, with the formation of L-citrulline as a by-product. Once synthesised, NO 
diffuses across the cell membrane of endothelial cells and enters VSMCs where 
activation of guanylate cyclase occurs. This catalyses the reaction of guanosine 





pyrophosphate [56]. cGMP is an important secondary messenger which determines 
many of the biological targets implicated in vascular function.  
 
 
Figure 1-3 – NO synthesis within the vasculature. 
eNOS synthesis via insulin signalling results in formation of NO, with L-arginine as the primary 
substrate. This activates guanylate cyclase and catalyses cGMP production in VSMCs. 
 
1.2.2.3 Metabolism 
In plasma, NO is oxidised to nitrite which is stable for a period of several hours. 
However, in whole blood, the nitrite is rapidly degraded into nitrate [57]. Basal blood 
concentrations of nitrate, therefore, appear to be of a magnitude 100 fold greater at 
around 15-60µM [58]. In humans, this excess nitrate is excreted predominantly in the 
urine. NO also appears to be rapidly oxidised to higher oxides of nitrogen, such as 





effects relating to inflammation, diabetes and cardiovascular disease [59]. Other 
interactions of NO exist with haem-containing proteins, such as myoglobin and 
deoxyribonucleic acid (DNA), in addition to thiols which is deemed to be an important 
step in oxidant modification of protein cysteine residues [60]. 
 
1.2.2.4 Physiological effects              
NO has a broad range of physiological effects, owing in large part to the fact that 
eNOS expression and activation can be regulated by multiple stimuli, including insulin, 
shear stress and vascular endothelial growth factor (VEGF) [50]. Promotion of 
enzymatic activity occurs predominantly via phosphorylation at the serine 1177 
residue [48], but other post-translational modifications include palmitoylation, most 
commonly associated with the covalent addition of fatty acids such as palmitic acid to 
cysteine, nitrosylation and O-GlcNAcylation [61]. 
There is continuous, basal synthesis of NO to maintain vasodilatory tone in vessels, 
with most of its effects exerted on the arterial system rather than in veins. Consistent 
with this, treatment with specific NOS inhibitors produces a hypertensive response in 
rats [62]. Pharmacological agents such as glyceryl trinitrate (GTN) and sodium 
nitroprusside (SNP) have functional effects after conversion into NO, via cGMP-
dependent mechanisms as described [63]. Indeed, the beneficial effects of 
angiotensin-converting-enzyme (ACE) inhibitors may be related to amplification of the 
actions of bradykinin, which potentiates NO release through calcium-dependent 





NO is also implicated in retarding the progression of atherogenesis. It has inhibitory 
effects on platelet adhesion and aggregation, which is again dependent on cGMP [65]. 
However, there is a synergistic association with prostacyclin release from the 
endothelium, which operates through enhanced bioavailability of cyclic adenosine 
monophosphate (cAMP) to impede aggregation. Platelets may themselves synthesise 
NO which provides a regulatory negative feedback loop. It is also implicated in 
attenuation of local inflammatory responses, by limiting leukocyte-endothelial cell 
interactions through downregulation of surface glycoproteins. This includes CD11 and 
CD18 on leukocytes, and intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1) on endothelial cells [66]. NO has additional 
suppressive effects on the mitogenesis and proliferation of fibroblasts and VSMCs 
[67]. This appears to be through cGMP-independent mechanisms. Hence, NO appears 
to participate heavily in the provision of an overall anti-atherogenic and anti-
thrombotic environment within the vasculature to preserve normal physiology. 
Consistent with this perception, polymorphisms of the eNOS gene (Glu298  Asp) 
have been associated with detrimental changes in brachial flow-mediated vessel 
dilatation and carotid intima-media thickness, two markers of early atherosclerosis 
[68]. This increased susceptibility is supported by results from a meta-analysis of case-
control studies though significant inter-study heterogeneity was noted [69].   
 






 ‘Vascular repair’ denotes re-endothelialisation of existing conduit vessels, and refers 
primarily to the response to injury in the context of atherogenesis or revascularisation 
with stenting procedures [70]. Though contexts are highly heterogeneous, vascular 
repair relies broadly upon generation and recruitment of bone marrow-derived cells, 
particularly leukocytes, and proliferation and migration of endothelial cells adjacent to 
the site of insult to restore a seamless endothelial monolayer [71]. Notably, whilst 
bone marrow-derived cells may promote this process via paracrine mechanisms, they 
do not directly contribute to the neo-endothelium [72] [73].  
‘Vascular regeneration’ is a diverse, context-dependent process which encompasses 
de novo vessel formation and vascular network expansion in response to physiological 
and pathological insults. Various sub-definitions exist. ‘Vasculogenesis’ refers to de 
novo vessel development in utero and arises from heterogeneous mesenchymal 
progenitor cells [74]. Subsequent maturation and remodelling of neovessels into 
larger, functional conduits by exerted shear stress is referred to as ‘arteriogenesis’, 
with luminal enlargement and recruitment of mural cells [75]. In the adult, vessels are 
quiescent once formed. However, endothelial cells retain the ability to send and 
respond to pro-angiogenic stimuli, such as VEGF. Activation results in a complex 
cascade of cell processes involving guided sprouting, proliferation, anastomosis and 
regression to create a complex hierarchical plexus. 
‘Angiogenesis’ specifically defines sprouting of neovessels from existing vasculature 
[76]. In pathological contexts, i.e. tissue injury, the two primary triggers are chronic 
tissue ischaemia and inflammation, though there is a reciprocal and co-existent 





subcategorised as developmental when occurring during the embryonic/foetal period 
and postnatal, with mechanisms somewhat distinct from pathological angiogenesis. 
Lastly, ‘collateral growth’ refers to the expansive remodelling of pre-existing collateral 
vessels, in response to local arterial or arteriolar occlusion, to salvage the region of 
ischaemia. 
 
1.2.3.2 Endothelial progenitor cells (EPCs) 
The recruitment of endothelial progenitor cells (EPCs) into the circulation has been 
proposed as a potential mechanism of endogenous vascular repair and regeneration 
[78]. However, there is considerable debate regarding the existence, definition and 
function of such cells, both in the context of physiology and pathology. Multiple 
stimuli have been identified to mobilise putative EPCs into the circulation of humans, 
including pro-inflammatory cytokines, chemokines, VEGF and physical activity [79]. 
Regulatory mechanisms remain poorly understood, though experimental studies have 
indicated that EPC mobilisation in response to VEGF or exercise is critically reliant on 
NO bioavailability [80] [81]. Furthermore, exercise-induced EPC mobilisation into the 
circulation is impaired in men of South Asian ethnicity, who demonstrate endothelial 
dysfunction and increased preponderance of atherosclerosis [82]. 
Culture-derived EPCs are characterised based on expression of the haematopoietic 
surface marker CD34 [83]. It is likely that population subsets exist, and indeed some 
early outgrowth cells are now recognised to be monocytic in origin but expressing a 
subset of non-specific ‘endothelial’ surface markers [84]. The relevance of these cells 





EPCs (also known as myeloid angiogenic cells) do not demonstrate significant 
proliferative capability and do not appear to directly integrate into vascular structures. 
Instead, they may provide paracrine stimulation of resident cells to orchestrate repair 
and also offer a pro-angiogenic milieu to promote vascular regeneration [85]. In 
contrast, ‘late-outgrowth’ EPCs (also known as outgrowth endothelial cells) very 
closely mimic endothelial cell function and gene expression. These cells are highly 
proliferative, with a progenitor hierarchy and can directly form new vessels. As 
highlighted, however, evidence from in vivo murine studies has shown that bone 
marrow-derived cells do not incorporate directly into the endothelial monolayer after 
injury, but may promote repair via paracrine mechanisms [73].  
 
1.2.3.3 Cell motility 
Cell motility has an essential role in the biology of organisms. It occurs as a response 
to gradients of chemokines (‘chemotaxis’), extracellular matrix density (‘haptotaxis’), 
electric fields (‘electrotaxis’) or substrate rigidity (‘durotaxis’) [86]. In prokaryotes, this 
process is important in the sourcing of nutrients depending on the temporal 
characteristics of chemoattractant signals [87]. In eukaryotes, however, these 
mechanisms are intrinsic to survival and have therefore been optimised through 
evolutionary development [88]. As a consequence, there appears to be broad 
generalisation in the harnessing of temporal and spatial information across a 
spectrum of cell types, including amoebae, neurones, leucocytes and endothelial cells. 
Cell motility in these contexts are crucial for various cell processes implicated in 





response of neutrophils to sites of active infection and the pathogenic process of 
tumour cell invasion and metastatic spread. Crucially, it is critical to the endogenous 
protective responses during vascular repair and regeneration. An exploratory 
discussion of underlying stages and mechanisms is now provided. 
 
1.2.3.3.1 Stages of cell migration 
An overview of the stages implicated in cell migration is provided in Figure 1-4. The 
first step in cell motility is determination of the direction of motion. It is apparent that 
even during random migration, cells have an inherent ability to control directional 
persistence, i.e. the duration during which migration is sustained in a specific direction 
[90]. However, cells also are able to respond to external chemotactic cues such as 
VEGF (‘directional sensing’), which results in spatial asymmetry via a polarised 
morphology that provides distinction between cell front and rear [91].  
A consequence of polarisation is the protrusion of cytoplasm as a sheet-like structure 
at the leading edge of the cell. This region is defined as the ‘lamellipodium’ [92]. 
Depending on cell type, this can vary in breadth from approximately 1-5µm. It is 
devoid of organelles but instead exhibits concentrated actin filaments (and associated 
proteins) of inherent polarity, which can be coordinated and cross-linked into a 
lattice-like meshwork by filamin to enhance cell rigidity as it extends. Filaments can 
also be grouped into cylindrical bundles. If these are contained within the 
lamellipodial region, they are referred to as ‘microspikes’. If these precursors protrude 
beyond the cell edge as finger-like protrusions, conventional nomenclature defines 





chemotactic stimuli to detect and transmit changes, and can support residual, slow 
migration in the absence of lamellipodia [94]. It is clear, however, that extension of 
lamellipodia and filopodia is coupled with the engagement of protein complexes to 
drive local actin polymerisation [95]. In particular, the balance between actin 
branching and elongation influences persistence, and speed, of lamellipodial 
protrusions. For instance, persistent branching results in a stiffer, actin network that 
generates more persistent but slower protrusion [96]. Moreover, integration of 
positive and negative feedback loops enables oscillatory behaviour of the 
lamellipodium, i.e. sequential protrusion and retraction, which contributes to the fine-
tuning of cell steering during chemotaxis [97]. 
Once cell directionality is established, the next stage involves cell adhesion via 
interaction between integrin receptors and ECM, with the cell front appearing to be a 
preferential locus [98]. These adhesion sites initially appear as small aggregates, which 
expand in size and intensity (‘focal adhesions’) to provide anchorage for cell migration. 
In addition to the protrusive force and anchorage, a separate contractile force is 
necessary for cell migration [99]. This is an active myosin II-dependent process that 
results in contraction of actin filaments, including those linked to integrin receptors 
and hence bound to ECM ligands [100]. Of note, the local substratum also exerts an 
adhesive traction in an opposing direction. This balance must also incorporate the 
asymmetry in traction between cell front and rear, enabling forward attachments to 
remain whilst those at the rear are released [101]. Exact mechanisms are not fully 
appreciated, but may relate to cytoskeletal tension and key signalling intermediates 





of the cell enables tail retraction and disassembling of adhesions to complete the cycle 
[102]. These myosin filaments also appear to extend to the sides of the cells and 
appear to suppress the formation of lateral filopodia which may otherwise evoke the 
tendency for deviations in movement [103]. 
 
 
Figure 1-4 – Stages of cell migration.  
Lamalice et al. Circ Res 2007; 100(6):782-94 [104]. 
Filopodia act as chemotactic sensors and establish cell directionality with protruding 
lamellipodia. Focal adhesions provide anchorage to the ECM with filament-mediated 






1.2.3.3.2 Key signalling proteins  
It is evident that spatial orchestration of signalling proteins is critical in mediating the 
dynamics of cell motility. In multiple cell types, it has been shown that there is local 
accumulation of proteins expressing plekstrin homology (PH) domains, which bind 
membrane phosphoinositides, notably phosphatidylinositol (3,4,5)-triphosphate 
(PIP3), at the leading edge of cells [105]. This in turn can activate guanine nucleotide 
exchange factors (GEFs) such as Vav [106] and SOS [107], which are implicated in 
spatial activation of the Rho family of guanosine triphosphate (GTP)ases. This family of 
proteins, which includes the Rac subfamily and Cdc42, provide critical regulation of all 
cellular processes involved in the cytoskeletal remodelling and dynamics that results 
in motility [108]. Rho GTPases switch between an inactive GDP-bound state, which is 
sequestered and cytosolic, and an active GTP-bound conformation which can be 
targeted to cell surfaces by post-translational modifications [109].  
Activated Cdc42 interacts specifically with Wiskott-Aldrich-syndrome protein (WASP), 
and its family member N-WASP [110]. It then mediates activation of the Arp2/3 
complex which directly promotes branching of actin filaments [111]. Two other 
proteins known to bind and activate Arp2/3 are cortactin and Abp1, and have been 
putatively suggested as actin network stabilisers [112]. Other implicated proteins 
include α-actinin and filamin. Indeed, filamin is able to associate with signalling 
proteins such as Rho GTPases through its C-terminal domain, and may therefore 
additionally provide a docking site for signal interactions in close vicinity [113]. Arp2/3 





WASP family, suppressor of cAMP receptor (Scar)/WAVE, which itself is activated by 
adapter protein Irsp53 in response to Rac [114].  
More recently, a direct interaction between Irsp53 and Cdc42 has been determined, 
occurring through a partial Cdc42/Rac interactive binding (CRIB) motif [115]. This can 
bind the Ena/vasodilator-stimulated phoshoprotein (VASP)-family protein Mena and 
initiate filopodia formation, hence providing an Arp2/3-independent mechanism. Both 
Cdc42 and Rac can activate the serine/threonine p21-activated kinase (PAK) family, by 
disrupting its autoinhibitory conformation [116]. These engage in multiple 
downstream effects. Notably, expression and activation of myosin light chain (MLC) is 
enhanced which is deemed vital for cell adhesion and anchorage [117]. In addition, 
phosphorylation of Lim kinases (LIMK) can inhibit the depolymerising activity of cofilin 
and hence regulate turnover in the lamellipodium [118]. Production of 
serine/threonine Rho-stimulated kinases (ROCK) via phosphoinositide-3-kinase (PI3K) 
signalling can have potentiating effects via MLC and LIMK phosphorylation [119]. 
ROCK also plays a role in the assembling of focal adhesions, by activating focal 
adhesion kinase (FAK). This is additionally activated by integrin receptor/ECM 
interactions, and functions as an adapter protein to recruit proteins such as talin, 
paxillin and p130Cas which allow anchorage of actin filaments [120]. 
Directional cell migration also involves reorientation of the Golgi towards the leading 
edge, with GOLPH3 implicated as a potential effector of phosphatidylinositol 4-
phosphate (PtdIns(4)P) that bridges the organelle with the actin cytoskeleton to 
enable effective trafficking [121]. Consistent with this notion, GOLPH3 overexpression 





signalling proteins highlighted above, it is apparent that nitric oxide (NO) is a strong 
regulator. There is early upregulation of NO in endothelial cells activated by VEGF 
[123], and specific inhibition of NO abrogates its chemotactic effects [124]. Moreover, 
in bovine lung endothelial cells, administration of NO appears to augment migratory 
capacity in response to VEGF exposure [125].  
 
1.2.3.4 Vasculogenesis 
The cardiovascular system constitutes the first functional organ in the embryo, with 
de novo vessel formation arising from mesenchymal precursors, defined as angioblasts 
[126]. These assemble as vascular cords prior to differentiation into endothelial cells. 
One important distinction between vessels is that of arteries and veins, which is 
determined by pathways specifying identity. In particular, the Notch pathway is 
upregulated in arteries and suppressed in veins, even prior to the onset of flow [127]. 
In zebrafish, Sonic Hedgehog upregulates VEGF which in turn elevates Notch 
components [128]. Transcriptional factors such as FOXC1 and FOXC2 also drive arterial 
specification by interacting with Notch and VEGF signalling. It was initially postulated 
that the venous fate occurred by default, but it is now apparent that active regression 
of Notch signalling is required by the nuclear receptor COUP-TFII [129]. Crucially, the 
process of arterial-venous differentiation has distinct phenotypic plasticity, as 
evidenced by endothelial cell differentiation in the developing embryo, neonatal 








ECM proteins form a layer around endothelial cells defined as the basement 
membrane [131]. Its composition must be altered with proteolytic breakdown to 
initiate cell migration and onset of vessel sprouting. This is mediated by activation of 
proteinases, such as MMP’s, plasminogen activators and tryptases, and angiopoietin-2 
(Ang-2)-stimulated detachment of mural cells [132]. These processes also liberate 
matrix-bound VEGF and activate pro-angiogenic chemokines such as IL-1β. A critical 
balance is important for effective sprouting, as excessive ECM degradation may result 
in a lack of matrix support for branch development [133].   
Subsequent endothelial cell specification into tip and stalk cells occurs, mediated 
predominantly by the Notch pathway. In utero blockade of Notch increases tip cell 
formation, indicating that this phenotype is the default response to pro-angiogenic 
signals such as VEGF [134]. Endothelial cells at the angiogenic front use tip cells and 
their emerging filopodia to migrate along the VEGF gradient, with expression of 
guidance receptors such as ROBO4, UNC5B, PLEXIN-D1 and semaphorins to probe the 
environment [76]. These are followed by a column of stalk cells which, in comparison 
with tip cells, have lower abundance of filopodia but much greater proliferative 
capacity and can form a vascular lumen [135]. Notch signalling is deemed critical for 
stalk cell specification. Dynamic shuffling of tip-stalk cell position occurs at the 
angiogenic front with regular exchange, dependent upon Notch/DII4 signalling in 
response to VEGF [136]. Moreover, tip and stalk cells ought not to be considered as 
defined cell fates because dynamic transition between the phenotypes is required to 





Lumen formation occurs through different mechanisms [138]. There appears to be 
coalescence of intracellular vacuoles which associates with those in adjacent cells in a 
process termed ‘cell hollowing’. However, contemporary studies also implicate direct 
alterations of cell morphology, driven by VEGF and ROCK, that rearrange the actin 
cytoskeleton and adherens junctions to create a vascular lumen (‘cord hollowing’). 
Direct interactions between adherens junctions on adjacent tip cells (‘fusion’) expands 
the network, promoted by macrophage activity though not a pre-requisite [139]. 
Lumen extension results in the initiation of blood flow, which remodels connections. 
In zebrafish, shear stress results in upregulation of miR-126 to modulate PI3K and 
mitogen-activated protein kinase (MAPK) signalling [140]. This stage reflects the 
formation of a primitive vascular labyrinth, akin to P5 in a mouse retina. 
It is evident that insulin-dependent PI3K/AKT signalling contributes towards VEGF 
expression. This may be partially mediated by upregulation of hypoxia-inducible factor 
(HIF)-1α suggestive of overlapping expression profiles in response to both insulin and 
hypoxia [141]. Diabetic mice appear to have inhibited HIF-1α activity and VEGF 
production in response to soft tissue ischaemia [142]. Nanoparticle-mediated delivery 
of the insulin sensitizer pioglitazone augments VEGF-mediated neovascularisation in a 
murine model of hindlimb ischaemia [143]. Significantly, however, insulin-resistant 
disorders in humans are broadly associated with elevated basal VEGF concentrations, 
potentially suggestive of ‘VEGF resistance’ [144]. This may reflect downstream 
signalling defects or inadequate resolution of underlying hypoxic drive due to poor 







Subsequent remodelling of the vascular plexus results in a complex, hierarchical 
network of arteries, veins and capillaries and maturation from nascent into durable 
vessels. This roughly correlates with P18 of a mouse retina. The Eph-Ephrin system is 
critical in establishing demarcation, with EphrinB2 as a marker for arterial endothelial 
cells and VSMCs, and EphB4 for veins [145]. Indeed, EphrinB2 expression also extends 
into capillaries midway between terminal arterioles and post-capillary venules. The 
system also contributes to the formation of arteriovenous anastomoses by arresting 
cell migration at the interface. 
Stability is conferred by deposition of ECM components into the basement 
membrane, and recruitment of mural cells. Pericytes confer direct cell-cell contact 
with endothelial cells in capillaries and immature vessels, whilst VSMCs envelop 
arteries and veins [146]. TGF-β signalling enables mural cell differentiation, migration 
and proliferation [147]. Indeed, mice with TGF-β knockdown demonstrate impaired 
vascular morphogenesis resulting from defects in mural cell development. Signalling 
via the PDGF-β pathway also plays a role by recruiting mesenchymal progenitors. 
Embryonic deficiency in PDGF-β results in bleeding, vessel fragility and enlargement 
[148]. Components derived from mural cells, such as angiopoietin-1 (Ang-1), can 
additionally activate the endothelial receptor Tie-2, which promotes endothelial 
quiescence and maturation of intercellular junctions [149]. FGF signalling mediates 
adhesion of adherens junctions to preserve vascular integrity [150]. Notch signalling 





degeneration and the clinical disorder termed cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) [151].  
Once maturation has adequately progressed, oxygen and nutrient delivery reduces 
VEGF expression and a transition towards a quiescent phenotype. Endothelial cells 
also adopt a survival phenotype to preserve integrity of the vessel lining. Intracrine 
VEGF activity is particularly implicated through influences on the PI3K/AKT pathway. 
Endothelium-specific deficiency of VEGF in mice results in bleeding, vascular rupture 
and microinfarcts [152]. Established blood flow and its accompanying shear stress can 
have direct anti-apoptotic effects. This involves KLF2-mediated upregulation of eNOS 
and the anti-coagulant thrombomodulin, which preserves vessel dilatation and clot 
disintegration [153]. Flow may equally determine conditional regression of neovessels 
in the context of non-perfusion, as a physiological mechanism of perfusion-demand 
matching. Disruption of interactions between endothelial cells and pericytes also 
heightens propensity for regression [154]. 
 
1.2.3.7 Collateral growth 
Distal capillaries enable local flow to individual cells whilst proximal arterioles 
determine bulk perfusion of large tissue regions. In the context of arterial or arteriolar 
occlusion with accompanying ischaemia, pre-existent collaterals can mature and 
expand into an extensive network via angiogenesis and arteriogenesis (‘collateral 
growth’) to improve perfusion to the depleted region. Hypoxia is the principal 
stimulus, through HIFs which upregulate pro-angiogenic genes such as VEGF [155]. 





recruitment of leukocyte subsets, such as monocytes, that produce proteinases to 
facilitate VSMC migration and proliferation. Consistent with this, pro-inflammatory 
cytokines such as TNF-α have been shown to positively modulate arteriogenesis [156] 
whilst depletion of monocytes was functionally associated with impaired growth 
[157].  
 
1.3   Insulin signalling in health 
1.3.1 Overview 
The insulin/insulin like growth factor (IGF-1) system is crucial for nutrient 
homeostasis, particularly coordination of systemic glucose metabolism. In addition to 
tissues directly involved in metabolism, such as skeletal muscle, liver and adipose 
tissue, insulin receptors are also expressed in vascular tissue, cardiac myocytes, 
leukocytes and human bone marrow-derived stem cells. Insulin therefore has diverse 
effects on metabolism and cardiovascular homeostasis. Insulin signalling is initiated by 
intrinsic receptor tyrosine kinase (RTK) activity of the ligand-bound insulin receptor, 
and orchestrates a complex, highly integrated cascade of downstream signalling 
events, particularly via the PI3K/AKT and Grb2/MAPK pathways.  
 
1.3.2 Historical perspective 
The first postulation that a substance released by the pancreas might be involved in 
metabolic homeostasis was in 1889, by German scientists Minkowski and von Mering. 
This was based on laboratory studies in dogs where total pancreatic resections 





Banting, a surgeon from Toronto, Canada [159]. They administered saline 
preparations of pancreas to dogs via intravenous injection and noted a discernible 
lowering of blood glucose. In the subsequent year, experiments were extended to 
human subjects with marked findings. Banting was a subsequent recipient of the 
Nobel Prize in 1923 for his work.  
 
1.3.3 Synthesis, release and regulation 
The gene encoding insulin is located on the short arm of chromosome 11, and is 
synthesised in the pancreatic β-cells of the islets of Langerhans as its precursor, 
proinsulin [160]. Vesicles transport pro-insulin to the Golgi apparatus of these cells, 
where the abundance of calcium and zinc enables formation of soluble, pro-insulin 
hexamers [161]. Cytoplasmic enzymes subsequently convert pro-insulin into insulin 
and C-peptide. These insoluble products are secreted into the circulation by 
exocytosis. As with other hormones, secretion can be manipulated by changes in 
synthesis due to transcriptional, translation and post-translational modifications in the 
Golgi apparatus. Chronic alterations in insulin release may occur through changes in β-
cell mass and differentiation [162].  
Glucose is the principle stimulus for insulin release. However, other nutrient 
secretagogues including amino acids and fatty acids are also implicated. Hormones 
such as glucagon and glucagon-like peptide-1 (GLP-1) can act as mediators, in addition 
to regulation from neural stimuli via cholinergic and adrenergic pathways [163]. In 
normal health, insulin secretion is typically biphasic. The initial rapid phase relates to 





both stored and newly synthesised insulin [164]. It is evident that complex, pleiotropic 
processes form regulatory feedback loops which preserve homeostasis in normal 
physiology [165]. 
 
1.3.4 Physiological effects 
1.3.4.1 Metabolism  
Insulin is the primary hormone which regulates macronutrient balance and 
coordinates this with cellular energy metabolism [166]. Insulin is critical for the non-
constitutive membrane transit of glucose, which is mediated via ATP-independent 
glucose transporter (GLUT) proteins. There are five subtypes, which enables 
heterogeneity in response of cell types according to function [167]. GLUT4 is the 
transporter implicated for responses to insulin in dependent metabolic tissues such as 
the liver, skeletal muscle and adipose tissue, and is transported to cell membranes as 
a result of insulin-stimulated PI3K/AKT signalling. In the fed state, it has overall 
anabolic effects in muscle. This occurs through promotion of glycogen and lipid 
synthesis, whilst suppressing hepatic gluconeogenesis and lipolysis. Uptake into 
adipose tissue constitutes approximately 10% of the total mediated by insulin 
stimulation [168]. In comparison, uptake into hepatocytes is not insulin-dependent, 
yet it determines 30% of whole-body glucose availability in tissues.  
 
1.3.4.2 Haemodynamics 
Beyond classical metabolic tissues, the insulin receptor is also expressed in vascular 





human bone marrow-derived stem cells [169]. This can result in diverse effects on the 
cardiovascular system. 
Signalling in the endothelium can produce an array of vascular responses which, in 
healthy conditions, help to augment tissue perfusion during periods of glucose 
disposal. Vasodilatory effects are mediated by insulin-dependent release of NO [170], 
through heterogeneous mechanisms occurring in distinct stages. Within a few 
minutes, dilatation of terminal arterioles enhances capillary recruitment but without 
concomitant alterations in total blood flow [171]. Subsequent increases in total blood 
flow are mediated by dilatation of larger resistance vessels, and is maximal at 2 hours. 
This has been demonstrated in skeletal muscle in humans at both physiological (100-
500pM) [172] and supraphysiological [173] insulin concentrations.  
In addition to vasodilatory effects, insulin also induces opposing vasoconstriction. This 
is governed principally by sympathetic activation, presumed α-adrenergic, and has 
been demonstrated in rats [174] and humans [175]. The synthesis and release of 
endothelin-1 (ET-1) from the endothelium is also implicated, via MAPK signalling. In 
VENIRKO mice with endothelium-specific deletion of the insulin receptor, expression 
of eNOS and ET-1 is reduced and steady state blood pressure appears lower on both 
low- and high-salt diets [176]. Results from assessment of plasma ET-1 levels in 
humans appear ambiguous, but as a paracrine factor, the local concentrations may be 
more functionally relevant. In support of this proposition, insulin-mediated 





These opposing forces result in negligible, overall effects on systemic blood pressure 
in the context of health [178]. Insulin is also known to have effects on nephrons, by 
promoting sodium retention in the distal convoluted tubules. This has been observed 
in healthy individuals [179] and in patients with DM [180]. However, these effects are 
small and there is resultant, secondary natriuresis consequent to enhanced renal 
perfusion [181]. Hence, it is unlikely that the renal action of insulin plays a substantial 
role in modulation of blood pressure.      
It is more firmly apparent, however, that a critical regulation appears to exist between 
vasoconstrictor and vasodilator actions as a result of insulin signalling. Indeed, a 
transition in this balance may be important in promoting endothelial dysfunction 
associated with systemic insulin resistance.  
 
1.3.4.3 Coupling of metabolic and haemodynamic physiology 
Insulin appears to be crucial in effective coupling of metabolic and haemodynamic 
physiology. Endothelial signalling mediates capillary recruitment and increased total 
blood flow, as described above. This enhanced perfusion facilitates the delivery and 
disposal of substrates, namely insulin and glucose, to metabolic tissues. In humans,  
there appears to be a dose-dependent response between insulin, glucose mobilisation 
and skeletal muscle blood flow [182]. This appears to be mediated by NO, as trends 
are abrogated in the context of NG-monomethyl-L-arginine (NMMA), a competitive 
eNOS inhibitor [183]. There is also increasing evidence that myocardial blood flow is 





regional variations in perfusion that are associated with the extent of glucose uptake 
[184].    
 
1.3.5 Insulin signalling cascade 
1.3.5.1 Insulin receptor 
The gene encoding the insulin receptor is located on the short arm of chromosome 19 
[163]. The protein structure is a hetrotetramer consisting of two extracellular α and 
two transmembrane β glycoprotein subunits linked by disulphide bonds [185]. It 
constitutes a subfamily of RTK, which also includes the highly homologous IGF-1 
receptor [186]. Hybrid complexes involving the insulin receptor and IGF-1 receptor 
also exist. 
An overview of insulin signalling cascades is provided in Figure 1-5. Binding of its 
substrate, insulin, to the α subunit of the receptor results in a conformational change 
of the β subunit and allows binding of ATP (adenosine triphosphate) [185]. This 
facilitates autophosphorylation, conferring tyrosine kinase activity. In view of its 
potential for profound and diverse metabolic sequelae, stringent regulation of the 
activity of the insulin receptor is required. This is achieved, in part, by the existence of 
two splice isoforms, either with or without exon 11 [187]. These have differential 
expression patterns in tissues and differing affinities for insulin and IGF-1 [188]. 
Control of activity is also achieved by negative regulators. One such class are tyrosine 
phosphatases, particularly protein tyrosine phosphatase 1B (PTP1B). In vivo models 
with PTP1B knockout demonstrate enhanced insulin signalling [189]. Other proteins, 





bound protein 10 (Grb10), regulate function by modifying intrinsic kinase activity or 
binding to downstream targets [190]. Additionally, downregulation via ligand-
mediated receptor internalisation is a feature of the majority of insulin-resistant 
states, including DM [191]. 
 
1.3.5.2 Insulin-receptor substrates (IRS) 
In contrast to many other RTKs, insulin and IGF1 receptors directly recruit specialised 
adaptor proteins. These become tyrosine phosphorylated in response to receptor 
activation, but also allow diverse negative regulatory mechanisms to occur [192]. 
These are collectively termed insulin receptor substrates (IRS), and there are six 
identified isoforms, IRS1-6 [193]. Out of these, IRS1 and IRS2 are the most 
ubiquitously expressed [194, 195]. Their localisation in proximity to the insulin 
receptor is determined by the PH and phosphotyrosine-binding (PTB) domains at the 
N terminus. The central and C terminus regions of IRS contain multiple tyrosine 
phosphorylation sites which, once activated, bind to ‘docking’ proteins containing Src-
homology-2 (SH2) domains. In broad terms, proteins bearing SH2 domains can be 
subdivided into two classes: SH2 enzymes such as PI3K, and SH2 adaptor proteins such 
as growth factor receptor-bound protein 2 (Grb2). In the case of the latter, there is no 
intrinsic activity but instead, signal transmission is by direct protein-protein 
interactions [196]. The two most important mediators are PI3K and Grb2, so 
downstream signalling cascades for both shall now be discussed. 
 





PI3Ks can be classified according to sequence homology and substrate affinity into 
three broad classes, I-III [197]. Relatively little is known about classes II and III, though 
the latter is implicated in the regulation of vesicle trafficking [198]. Class I PI3Ks have 
been more extensively studied. Class I can be subdivided into IA, which are activated 
by RTK, and IB which instead are modulated by G-protein-coupled receptors (GPCR). 
Both are involved in the regulation of cell polarity and motility through effects on 
cytoskeletal dynamics via activation of the Rho family of GTPases (see Section 
1.2.3.3.2) [89]. Class IA PI3K are most strongly implicated in downstream insulin 
signalling. The protein is a heterodimer, and composed of a p85 regulatory unit (85 
kDa), stoichiometrically in excess, which provides basal allosteric inhibition of a p110 
catalytic unit (110 kDa). The regulatory component is flanked by two SH2 domains, 
which can bind to phosphorylated residues on adapter proteins such as IRS [199]. This 
binding results in conformational changes that reverse basal inhibition. It also recruits 
the complex to the plasma membrane where it is in close proximity to its substrate, 
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), which becomes 
phosphorylated on the 3’ position of the inositol ring into phosphatidylinositol (3,4,5)-
triphosphate (PIP3) [200]. This is a lipid secondary messenger that is able to activate 
multiple downstream cascades by binding to proteins that manifest specific PH 
domains [201].  
Two PH-bearing proteins of particular relevance are phosphoinositide-dependent 
kinase (PDK) 1/2 and AKT, also termed protein kinase B (PKB). AKT is a 
serine/threonine kinase that mediates the predominant metabolic effects of insulin, 





exist in mammals, AKT1-3, each encoded by a different gene. AKT2 is specifically 
enriched in insulin-sensitive tissue and is the isoform most strongly implicated in 
metabolic pathology [202]. Specificity of action for the different isoforms is dependent 
upon temporal and spatial segregation in addition to downstream targets. 
Recruitment to the cell membrane by PIP3 enables phosphorylation of AKT by PDK 1/2 
at the threonine 308 residue. However, a second phosphorylation at the serine 473 
residue of AKT is required for full activation, and this appears to be mediated by a 
complex of mTOR and rapamycin-insensitive companion of mTOR (RICTOR) through 
poorly defined mechanisms [203]. Direct, negative regulators of AKT include the 
enzymes phosphatase-2A (PP2A) and PH-domain leucine-rich-repeat protein 
phosphatase (PHLPP) [204]. 
Activated AKT has multiple downstream targets which allows regulation of an array of 
cellular functions. In metabolic tissues, it results in phosphorylation and inhibition of 
the Rab-GTPase-activating protein, AS160 [205]. This precipitates alterations in actin 
dynamics required for the translocation of cytosolic glucose transporter protein 4 
(GLUT4)-containing vesicles to the plasma membrane, which directly facilitates 
glucose uptake into cells [206]. GLUT1 transporters are also implicated in glucose 
metabolism, but in contrast, they are not located intracellularly. Hence, they are not 
translocated in response to insulin, and are instead involved in basal glucose uptake 
[207]. AKT also promotes glycogenesis through inhibition of glycogen synthase kinase 
3 (GSK3) [208] and synthesis of fatty acids through activatory effects on ATP citrate 





stoichiometric mTOR-RICTOR complex and resultant phosphorylation of eukaryotic 
translation initiation factor 4E-binding protein (4E-BP1) [210].  
In addition to metabolic regulation, activated AKT has a critical role in vascular 
homeostasis. In endothelial cells, it causes direct phosphorylation of eNOS at its serine 
1177 residue, enhancing calcium-induced activation and production of NO [211]. This 
is an independent pathway from eNOS activation mediated by calcium signalling in 
response to shear stress and other modulators such as acetylcholine, serotonin and 
bradykinin [212], although a certain degree of pathway convergence exists [213]. AKT 
is also imperative in promotion of cell survival and cell cycle progression. Cell cycle 
transition is achieved by inhibition of the forkhead family of transcription factors 
(FOXO), retinoblasma-like 2 (RBL2) and p27Kip1 [214]. Its pro-survival effects occurs 
through inhibition of FOXO-mediated transcription of proteins such as BCL2-like 11 
(Bim) and Fas-ligand (FasL), which are pro-apoptotic [215].  
 
1.3.5.4 Grb2/MAPK pathway 
Whilst the PI3K pathway broadly relate to metabolic and vascular function, the 
Grb2/MAPK pathway predominantly mediates insulin’s mitogenic effects [185]. Grb2 
binds to phosphorylated IRS or Shc, which are both activated in response to insulin 
binding to its receptor. Bound Grb2 enables recruitment of the guanine nucleotide-
exchange factor son-of-sevenless (SOS) followed by downstream activation of the 
GTPase Ras and subsequently Raf. A cascade of signalling events results in the 
phosphorylation of the dual specificity kinases MEK (and ERK) 1/2 (MAPK) on 





targets, which includes the transcription factor ELK1 and p90 ribosomal protein S6 
kinase (p90RSK), both implicated in gene expression, cellular differentiation and 
mitogenesis [216]. Moreover, there is promotion of the expression of adhesion 
markers on endothelial cells which enables leucocyte recruitment. Signalling 
potentiates the release of ET-1 which has potent vasoconstrictor and potentially pro-
atherogenic effects [217]. ET-1 can also directly increase IRS-1 phosphorylation 
leading to impaired PI3K signalling in VSMCs [218], and has been found to impair 
GLUT4 translocation in adipocytes [219]. ERK is also involved in negative regulatory 
feedback loops by direct, inhibitory phosphorylation of IRS1 on serine residues [220].  
 
 





Activatory autophosphorylation of the insulin receptor in response to ligand binding recruits 
IRS. Subsequent activation of the PI3K/AKT pathway enables tissue-specific effects on glucose 
translocation and NO synthesis, whilst Grb2/MAPK pathway activation has broad mitogenic 
effects. 
 
1.3.5.5 Complexity of the signalling network 
The pathways described above provide a linear description of the signalling cascades 
involved in insulin responses. However, the process involves considerable intricacy 
and complexity, due in substantial part to a multitude of inter-related pathways with 
positive and negative feedback communication [221]. As mentioned, the insulin 
receptor itself has two isoforms with functional heterogeneity. There are at least six 
IRS proteins, which all have the capacity to interact with a plethora of targets, 
including eight forms of the PI3K regulatory subunit and three known subclasses of 
the catalytic unit. Activation of AKT as a consequence of PIP3 production can itself 
result in one of three potential isoforms, with divergent functions. Further critical 
regulation of this expansive network is achieved through extensive cross-talk between 
pathways and intracellular localisation of signalling targets.  
 
1.4   Insulin signalling in disease  
1.4.1 Overview 
Insulin resistance is a critical pathophysiological determinant of the metabolic and 
vascular dysregulation implicated across the spectrum of dysglycaemia. Systemic 
components are encompassed by the ‘metabolic syndrome’, a clustering of factors 





associated with obesity. The presence of insulin receptors in many non-metabolic 
cells, such as vascular endothelium and leukocytes, suggests that cellular insulin 
resistance may directly contribute to the progression of diabetic vascular disease 
independent of systemic metabolic perturbations. Moreover, these systemic and 
cellular changes caused by insulin resistance may interfere with endogenous vascular 




Figure 1-6 – Interplay between systemic components and cell subtypes in diabetic  
vascular disease. 
There are multiple systemic components depicted in the metabolic syndrome. In combination 
with cellular insulin resistance, these are implicated in progression of atherogenesis as well as 







1.4.2 Genetic predisposition 
Insulin resistance can be broadly defined as a loss of the normal temporo-spatial 
signalling cascades activated by the binding of insulin to its receptor. At a molecular 
level, direct mutations of the insulin receptor are not commonly implicated in insulin 
resistance within populations [222]. Resistance can occur secondary to IRS-1 
polymorphisms with increased serine phosphorylation [223]. This causes direct 
inhibition of tyrosine phosphorylation, and a subsequent suppression of downstream 
PI3K-mediated signalling. In humans, rare mutations within the YMXM motif of the 
IRS-1 gene are associated with insulin resistance [224]. In mice, homozygous deletion 
results in a mild, resistant phenotype [225]. Polymorphisms of the regulatory p85 
subunit appears to affect glucose homeostasis, though an association with DM has not 
yet been established [226]. Nonetheless, polygenic influences are likely to be important 
considering the significant heritable component of insulin resistance and DM [227].  
 
1.4.3 Systemic insulin resistance 
1.4.3.1 The metabolic syndrome 
Perhaps the most significant contributors to systemic insulin resistance are 
environmental influences. The ‘metabolic syndrome’ describes the aggregation of 
factors, promoted by obesity, and insulin resistance [228]. They characterise the 
broader metabolic and vascular dysregulation that develops in the natural history of 
DM, including pre-diabetes, and collectively have pro-atherosclerotic effects. Whilst 
various diagnostic criteria exist, these generally describe the co-existence of central 





also include factors such as inflammation, oxidative stress and pro-thrombotic 
tendency (see Figure 1-7). Although the incremental value of the syndrome beyond its 
constituent parts has been questioned, it serves as an important reminder that insulin 
resistance is a unifying driver of pro-atherogenic phenomena.  
 
 
Figure 1-7 – Components of the metabolic syndrome.  
Adapted from Cubbon et al. Curr Vasc Pharmacol 2012; 10(3):271-84 [229]. 
There is a clustering of risk factors that are promoted by obesity and characterise the broader 
metabolic and vascular dysregulation implicated in the natural history of DM. 
 
1.4.3.2 Hyperglycaemia 
In the context of insulin resistance, the earliest change that develops in the 
myocardium in animal models is impaired glucose uptake [230]. This relates to 
reductions in GLUT4 protein expression and translocation, and interestingly precedes 





muscle biopsies from people with DM [231]. Hyperglycaemia itself, however, can 
potentiate insulin resistance. It can result in the formation of advanced glycation end 
products (AGE) [232]. This can cause serine phosphorylation of docking proteins such 
as IRS-1 and IRS-2, with inhibiting downstream signalling as described above. By 
binding of AGE to specific receptors termed RAGEs, there is also Nox2-mediated 
promotion of vascular oxidative stress (see Section 1.4.3.5) [233]. Reactive oxygen 
species (ROS) create a pro-inflammatory milieu, through activation of transcription 
factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB). Shunting 
of excess intracellular glucose through the hexosamine biosynthesis pathway results 
in modification of proteins, such as AKT, via O-linked N-acetylglucosamine (O-
GlcNAcylation). This is associated with increased vascular calcification in the context of 
DM [234]. Hyperglycaemia also activates protein kinase C (PKC) which augments 
monocyte recruitment, foam cell formation and promotes switching to a synthetic 
VSMC phenotype which enables cell migration and proliferation [235]. Consistent with 
this observation, atherosclerosis-prone mice with genetic deletion of PKC display 
reduced atherosclerosis [236].  
A significant elevation of AGE has been found in patients with type II DM compared to 
healthy and type I DM patients [237]. Moreover, their abundance appears to be 
increased in patients with DM and coronary disease compared to those without 
coronary disease [238]. Glycated haemoglobin (HbA1c) levels appear to correlate with 
AGE, and pharmacotherapy with agents that lower blood glucose and AGE is 





retinopathy. However, no similar associations have yet been observed in the context 
of macrovascular disease [239]. 
 
1.4.3.3 Dyslipidaemia 
As alluded to previously, the dyslipidaemic profile precipitated by obesity and 
characteristic of the metabolic syndrome comprises elevated triglycerides, low HDL 
and small, dense LDL [23]. Triglycerides are the source of excess free fatty acids (FFA) 
which can result in lipotoxicity through various mechanisms. In skeletal muscle, they 
appear to induce mitochrondrial dysfunction, resulting in reduced FFA oxidation and 
mitochondrial superoxide generation [240]. The subsequent increase in levels of 
intracellular metabolites, including fatty acyl coenzyme A (CoA) and diacylglycerol, 
promotes novel PKC and inhibitory phosphorylation of IRS-1 leading to insulin 
resistance. Concurrently, mitochondrial dysfunction further promotes an oxidative 
environment through activation of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases (see Section 1.4.3.5.2) [241]. Furthermore, this is associated with 
dysregulated adipocytokine production, and activation of pro-inflammatory cascades 
that are directly implicated in insulin resistance (see below) [242]. Lastly, ceramide is a 
derivative of saturated FFAs. Increased levels have been found in skeletal muscle of 
human subjects with obesity [243], and it appears to directly inhibit AKT signalling and 
GLUT4-mediated glucose translocation in response to insulin stimulation [244]. It has 
also been shown to contribute to oxidised LDL-induced calcification of human VSMCs, 






1.4.3.4 Pro-inflammatory adipocytokines 
Chronic inflammation is an important driver of atherosclerosis [246]. As discussed, it is 
intrinsically coupled with the lipotoxicity and glucotoxicity of the metabolic syndrome 
and aggravated by oxidative stress (see Section 1.4.3.5). Dysfunctional visceral adipose 
depots are a particularly important contributor of systemic inflammation, due to 
altered adipocytokine (or adipokine) secretion profiles. Adipokines are a diverse group 
of cytokines derived from adipose tissue, and include interleukin (IL)-1β, IL-6, tumour 
necrosis factor (TNF)-α, adiponectin, leptin and visfatin, amongst many others [247]. 
Their impact extends beyond adipose tissue biology and wider metabolic homeostasis, 
with direct effects on vascular function also being apparent.  
TNF-α activates various serine kinases, including c-Jun N-terminal kinases (JNK) and 
inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ), which results in 
inhibitory phosphorylation of IRS-1 and IRS-2 [248]. The expression of SOCS-3 is also 
enhanced, which antagonises the interactions between insulin receptor and IRS and 
facilitates proteasomal degradation of the latter [249]. Consistent with the role of 
chronic inflammation in insulin resistance, elevated levels of the inflammatory marker 
C-reactive protein (CRP), whose expression is promoted by TNF-α, has been identified 
as a potential risk factor in diabetogenesis [250].  
Adiponectin is generally less abundant in insulin-resistant states. It is broadly 
considered as an anti-inflammatory cytokine, and appears to suppress atherosclerotic 
burden in apolipoprotein E-deficient mice [251]. Levels also appear to be inversely 
predictive of coronary plaque calcification and fibrous cap vulnerability [252] [253]. 





independent predictor of acute cardiovascular events and early in-stent re-stenosis 
[254]. Visfatin has similarly been suggested as an indicator of plaque burden, and 
correlates with markers of myocardial necrosis in the context of ST-elevation 
myocardial infarction (STEMI) [255].    
 
1.4.3.5 Oxidative stress 
Oxidative stress plays an instrumental role in amplifying the downstream effects that 
occur through constellation of the above stressors, with modulatory roles in the 
context of lipotoxicity, hyperglycaemia and pro-inflammatory adipocytokines. In view 
of this, it is worthwhile exploring the concept of oxidative stress in further detail. 
 
1.4.3.5.1 ROS metabolism 
‘Oxidative stress’ refers to a disrupted spatio-temoral balance between production of 
oxidants, in particular ROS, and their scavenging by anti-oxidant defences [256]. This 
results in detrimental modification of lipids, proteins and nucleic acids. ROS 
encompasses highly reactive derivatives of oxygen (O2). They can be loosely 
categorised into free radicals, such as superoxide (O2-) and peroxynitrite (ONOO-), and 
non-radicals such as hydrogen peroxide (H2O2) and ozone (O3) [257]. An overview of 
ROS synthesis and metabolism is depicted in Figure 1-8. Formation may occur through 
dysfunctional mitochondrial respiration and uncoupled eNOS activity, arising from 
depleted cofactors or direct enzymatic modification. Moreover, membrane-bound 
enzymes such as NADPH oxidases (NOX) are particularly implicated within the  





superoxide dismutase (SOD), which results in the formation of H2O2 [257]. H2O2 is 




Figure 1-8 – ROS synthesis and metabolism.  
Adapted from Ali et al. Diabetes Management 2015; 5(3):203-13 [258]. 
Formation of superoxide occurs via membrane-bound NOX enzymes, mitochondrial activity 
and uncoupled eNOS. The action of SOD results in breakdown of superoxide into hydrogen 
peroxide, which undergoes further degradation. 
 
1.4.3.5.2 NADPH oxidases 
There are currently five known homologues of the NOX enzyme (NOX1-5) [259]. Nox2 





produces O2-. It was first isolated from phagocytes where it was shown to produce a 
‘respiratory burst’ of ROS to enable the anti-microbial response [261]. Its activity is 
dependent upon a catalytic subunit (gp91phox), whose function is also reliant on 
binding of various cytosolic components such as p40phox, p47phox and Rac [262]. 
Nox1 has structural homology with Nox2 and also results in O2- production. It is 
present in the vascular wall but most strongly expressed in colonic epithelium [263]. In 
contrast, the primary product of Nox4 activity is H2O2 and it appears to be 
constitutively active [262]. Although Nox5 has demonstrable expression in human 
vasculature, it does not appear to be present in rodents [264].  
 
1.4.3.5.3 Redox signalling 
All NOX isoforms produce ROS by transferring electrons from NADPH to molecular 
oxygen, a phenomenon termed ‘electron transfer’ [265]. O2- and H2O2 are relatively 
mild oxidants in comparison with other ROS, and this enables relative selectivity in the 
reversible modification of proteins. As with other intracellular signalling 
intermediates, specificity is also enabled by spatial orchestration through discrete 
compartmentalisation of NOX enzymes. The primary targets for redox regulation are 
kinases, including receptor tyrosine kinases such as the insulin receptor in addition to 
AKT and MAPK [266] [267]. Indirect regulation may also occur through inhibitory 
oxidation of protein tyrosine phosphatases (PTP), which usually reverse kinase activity 
[268]. Beyond kinases, proteinases such as MMP’s have also shown redox sensitivity 






1.4.3.5.4 Linkage with the insulin resistance syndrome 
Genetic and pharmacological manipulation of ROS-producing enzymes has shown 
oxidative stress to play a causal role in multiple forms of insulin resistance [269]. It can 
increase expression of pro-inflammatory cytokines, such as TNF-α and IL-6, which 
inhibit transcription of intermediates such as IRS-1 and GLUT-4 to attenuate 
downstream signalling [270]. Additionally, it results in activation of a specific subtype 
of MAPK, termed ‘stress-activated protein kinases’ (SAPK) [269]. Examples include IĸB 
kinase (IKK) and c-Jun-N-terminal kinase (JNK), which suppress MAPK phosphatases 
and also interfere with PI3K/AKT signalling to potentiate resistance.  
Mechanistic data has also been derived from in vivo manipulation of vascular insulin 
signalling. Mice with endothelium-targeted over-expression of a dominant-negative 
mutant human insulin receptor (ESMIRO), or with global haploinsufficiency of the 
insulin receptor (IRKO), have enhanced vascular superoxide production. This could be 
suppressed with a pharmacological Nox-2 inhibitor, and was associated with improved 
endothelium-mediated vasorelaxation [271]. Consistent with this notion, diabetic 
blood vessels in hamsters demonstrate improved endothelium-dependent relaxation 
when treated with superoxide dismutase (SOD), an anti-oxidant [272]. However, 
conflicting data has arisen from studying mice with endothelium-specific 
overexpression of the human insulin receptor (hIRECO), a model of increased 
endothelial insulin signalling, which also exhibited reduced NO bioavailability and 
superoxide-mediated oxidative stress [273]. 
It is clear that regulation of ROS abundance preserves a physiological balance in 





driving appropriate differentiation, mitogenesis and migration in cells and acting 
primarily as a reversible signalling mechanism [274]. Hence, the benefits of 
suppressing ROS production are disparate depending on the context, i.e. physiology or 
pathology. This notion is best supported by the ‘redox window’ hypothesis, as shown 
in Figure 1-9 [275]. In the context of health, excess reduction of ROS levels beyond a 
hypothetical cut-off is deleterious to function. However, in the context of underlying 
pathophysiology such as DM where the oxidative state is enhanced, suppression of 
ROS provides benefit by shifting levels into an optimal window. This nuanced response 
is likely to involve complex temporo-spatial orchestration of multiple signalling 
radicals. Indeed, this may provide a plausible explanation for the disappointing results 
from clinical trials that have sought to improve cardiovascular outcomes with broad-







Figure 1-9 – ‘Redox window’ hypothesis.  
Adapted from Yun et al. Antioxid Redox Signal 2009; 11(8):1961-74 [275].  
A hypothetical “redox window” exists in which vascular repair and regeneration is permitted 
and amplified. However, a shift to either an overly oxidative or reductive environment can be 
disruptive depending on clinical context.  
 
1.4.4 Cell-specific insulin resistance 
1.4.4.1 Vascular endothelial cells 
1.4.4.1.1 Reduced NO bioavailability 
Earlier sections have explored the sequence of pathological events implicated in 
progression of atherogenesis. However, the earliest alterations in endothelial cell 
phenotype occur before manifestation of structural abnormalities. One of the most 
important features is a subtle but crucial reduction in NO bioavailability in the insulin-
responsive endothelium. As described, NO has many anti-atherogenic and anti-
thrombotic properties required to preserve normal physiology. In the context of 
health, there is continuous, basal vascular synthesis of NO which is essential for 
vascular function, by promoting vasodilation, inhibiting platelet aggregation, 
suppressing inflammation and limiting leukocyte adhesion molecule expression. It is 
therefore apparent that this reduced bioavailability plays a pivotal role in coupling 
insulin resistance with vascular dysfunction. Indeed, eNOS knockout mice are 
hypertensive, insulin resistant and develop accelerated atherosclerosis [279] [280].  
Other facets of relevance are the existence of parallel signalling pathways in metabolic 
and vascular tissues, and the presence of shared stressors mediating dysfunction 





addition to the compounding effects of compensatory hyperinsulinaemia. These 
concepts are now explored in greater detail. 
 
1.4.4.1.2 Shared signalling cascades 
As outlined during discussion of the insulin signalling cascade, there exists parallel 
pathways in metabolic and vascular tissue using PI3K/AKT signalling to achieve distinct 
tissue-specific effects. In metabolic tissues such as skeletal muscle, downstream 
effectors result in glucose uptake into cells, whilst in vascular endothelium, activation 
of eNOS results in NO production. Subsequently, defects in the signalling cascade 
upstream of AKT activation result in co-existence of metabolic and endothelial 
dysfunction. Consistent with this notion, a homozygous mouse model with targeted 
disruption of the IRS-1 gene displayed metabolic insulin resistance and impaired 
endothelium-dependent vasorelaxation [282]. Furthermore, a genetic polymorphism 
of the IRS-1 gene, which is implicated in metabolic insulin resistance, is associated 
with reduced NO production in human umbilical vein endothelial cells (HUVECs) [283].  
 
1.4.4.1.3 Common stressors 
It is also apparent that there are shared stressors implicated in insulin resistance and 
vascular dysfunction (see Figure 1-10). In the context of ROS, increased superoxide 
degrades NO and forms the oxidant peroxynitrite [284]. This impairs NO bioavailability 
and perpetuates oxidative stress. Activation of pro-inflammatory signalling cascades 
play a critical role in modulation and propagation of the atherogenic response. This 





response to insulin [285]. Further, it has been shown that hyperglycaemia has direct 
pro-apoptotic effects on endothelial cells and can promote leucocyte recruitment 
through upregulation of cell surface adhesion markers such as ICAM and VCAM [286]. 
AGE formation is additionally implicated in structural modifications of ECM proteins, 
such as collagen and laminin, which contributes to interactions between different cell 
types and progression of the atherosclerotic plaque [287]. The inflammatory marker 
CRP has also been shown to suppress eNOS expression [288] and enhance surface 
leukocyte adhesion molecule expression [289], thus contributing to pathogenesis in 




Figure 1-10 – Shared stressors contributing to insulin resistance and vascular  
dysfunction.  
Adapted from Kim et al. Circulation 2006; 113:1888-1904 [281]. 
Glucotoxicity, lipotoxicity and chronic inflammation underpin reciprocal relationships that 
contribute to the linkage between metabolic and vascular disorders. 
 





The concept of ‘pathway-specific insulin resistance’ is of particular relevance in 
appreciating the intricate cross-talk between different tissues in the context of DM 
(see Figure 1-11). A key feature of the signalling perturbations that underpin insulin 
resistance is that aside from reduced PI3K/AKT pathway signalling, other branches 
such as that of the mitogenic Grb2/MAPK pathway are unaffected [290]. This concept 
becomes increasingly relevant because during the initial phase of metabolic 
resistance, there is compensatory hyperinsulinaemia to preserve glucose homeostasis 
[291]. This adaptive response can, however, result in overdrive signalling through the 
Grb2/MAPK pathway [292]. Hence, there will be a hyperglycaemic state with reduced 
NO bioavailability but with augmented pro-atherogenic sequelae via increased 
endothelial cell leukocyte adhesion molecule expression and vasoconstriction 
mediated by ET-1 release. This has been corroborated in human subjects with DM, 
who have elevated baseline levels of ET-1 [293] and improved endothelial function 
when treated with a pharmacological antagonist [294].  
Insulin also plays a vital role in regulation of sympathetic nervous system (SNS) activity 
by acting on the arcuate nucleus of the hypothalamus [295]. In the context of obesity, 
there is SNS hyperactivity arising from chronic hyperinsulinaemia. This promotes 
vasoconstriction and can secondarily activate the renin-angiotensin-aldosterone 
system (RAAS), resulting in systemic hypertension [296]. This is an independent risk 








Figure 1-11 – Pathway-specific insulin resistance. 
Reduced PI3K/AKT signalling in the context of insulin resistance is accompanied by unopposed 
Grb2/MAPK pathways. This can be exaggerated by compensatory hyperinsulinaemia that 
occurs in the initial stages. 
 
1.4.4.1.5 Murine models of insulin resistance 
Mice with diet-induced obesity exhibit vascular insulin resistance associated with 
reduced expression of the insulin receptor [297]. However, this insulin-resistant 
phenotype is complex, due to the presence of multiple contributory factors such as 
hyperglycaemia, dyslipidaemia and obesity that co-exist and provide confounding 
effects. It is therefore challenging to dissect the mechanistic contribution of insulin 





causation and association. Consequently, our laboratory has performed considerable 
work using in vivo murine models of isolated insulin resistance.  
Mice with homozygous knockdown of the insulin receptor are non-viable, developing 
profound hyperglycaemia and early neonatal mortality [298]. However, mice with 
whole body haploinsufficiency for the insulin receptor (IRKO) demonstrated a mild 
perturbation of insulin signalling (approximately 30%), and provided a useful non-
obese, non-diabetic model for further studies on vascular function [299]. IRKO mice 
have been studied extensively by our laboratory. They have been shown to maintain 
normoglycaemia through compensatory hyperinsulinaemia, but this is associated with 
extensive vascular dysregulation with reduced NO bioavailability, oxidative stress, 
impaired endothelium-dependent vasorelaxation and raised blood pressure.  
A complementary model with endothelium-specific mutant dominant negative insulin 
receptor overexpression (ESMIRO) has been subsequently generated, under control of 
the Tie-2 promoter. The mutant receptor incorporates the substitution of alanine with 
threonine at the 1134 position in the tyrosine kinase domain, and although ligand 
binding is preserved, no downstream signalling occurs [300]. These mice had 
comparable glucoregulation to control littermates, but endothelium-specific insulin 
resistance was still sufficient to reduce NO bioavailability, cause vascular oxidative 
stress and impair endothelial function [301]. When crossed with atherosclerosis-prone 
Apolipoprotein E (ApoE) knockout mice, they develop accelerated atherosclerosis. This 
appeared independent of systemic metabolic perturbations, but was associated with 





endothelial insulin receptors has also been shown to induce expression of the 
leukocyte adhesion molecule VCAM-1 and increase atherosclerotic lesion area [303]. 
The emerging theme from the work performed using IRKO and ESMIRO models is that 
there may be a rationale for early intervention in insulin resistance, where 
glucoregulation is preserved but vascular phenotypic abnormalities have already 
manifest. However, as highlighted previously, murine models of increased endothelial 
insulin signalling also paradoxically exhibit enhanced superoxide abundance and 
oxidative stress-induced endothelial dysfunction. This highlights the complexity in 
interplay between metabolic and vascular function, and the narrow ideal range of 
vascular insulin signalling.  
 
1.4.4.2 Macrophages 
There is also some evidence that myeloid-specific insulin resistance can accelerate 
atherogenesis. Macrophages from obese mice have reduced insulin receptor 
expression, alongside increased expression of surface receptors such as scavenger 
receptor A (SRA) and CD36 [304]. These are implicated in the internalisation and 
cytoplasmic storage of oxidised LDL. Using murine bone marrow transplantation 
studies, it has been shown that macrophage insulin receptor deficiency increases 
endoplasmic reticulum (ER) stress-induced apoptosis and necrotic core formation in 
advanced atherosclerotic lesions [305]. However, conflicting data also exists, 
indicating that myeloid lineage-specific insulin resistance can protect atherosclerosis-





This may relate to insulin receptor-deficient macrophages having impaired capacity to 
produce pro-inflammatory cytokines, such as IL-1β and IL-6. 
 
1.4.5 Defects in vascular repair and regeneration 
As highlighted, vascular repair and regeneration are of crucial relevance in the 
response to vessel and tissue injury. However, these processes themselves may be 
retarded in patients with DM. Although the benefits of percutaneous coronary 
intervention (PCI) for functionally significant angiographic lesions are undisputed, 
numerous clinical studies have convincingly shown that patients with DM have higher 
rates of re-stenosis and late vessel occlusion after intervention [307, 308]. Collateral 
vessel formation also appears to be poorer in comparison with patients without DM 
[309].  
 
1.4.5.1 Systemic insulin resistance 
Systemic components of the metabolic syndrome are causally linked with vascular 
complications of insulin resistance, as already discussed. It is therefore reasonable to 
conceive that these same stressors may be linked with abnormalities in vascular 
reparative and regenerative strategies. Though relative contributions are difficult to 
dissect, studies have elucidated potential mechanisms. 
Hyperglycaemia appears to have detrimental effects on vascular repair. This may 
relate to EPC downregulation, either via reduction in their NO production [310] or 
through excessive activation of the Grb2/MAPK cascade [311]. In a chicken 





induction of apoptosis in endothelial cells and pericytes, and suppression of 
endothelial cell proliferation. This occurred without altered expression of VEGF [312]. 
In vitro injection of remnant-like particles (RLPs) derived from hypertriglyceridaemic 
patients appears to accelerate EPC senescence and functional capacity by increasing 
oxidative stress [313]. Elevated FFAs, namely palmitic and linoleic acids, appear to 
downregulate PI3K signalling and result in suppressed proliferation of EPCs [314]. 
Reduced HDL cholesterol is a core component of the dyslipidaemic profile associated 
with the metabolic syndrome. In vivo studies in mice have shown that HDL stimulates 
endothelial cell migration in a NO-independent manner, via activation of Rac GTPase, 
and augments carotid artery re-endothelialisation after perivascular electric injury 
[315]. In human subjects with low HDL, EPC abundance and migratory potential was 
reduced [316]. Though not strictly part of the diagnostic criteria for metabolic 
syndrome, DM is also associated with elevated levels of oxidised LDL cholesterol. In 
HUVECs, this appears to induce endothelial cell apoptosis through enhancement of 
caspase 3 activity via excess ROS production [317]. Furthermore, it appears to severely 
impair monocyte chemotaxis in response to VEGF in human patients and this may be 
implicated in suppressing regenerative potential [318].  
Adipocytokines also appear to influence vascular reparative capacity. Chronic 
exposure of both TNF-α and CRP has negative effects on EPC abundance and function, 
explained in part by reduction in eNOS expression [319]. However, the inflammatory 
response has been determined to be a crucial mediator of angiogenesis and 
atherogenesis, corroborated by similarities in transcriptional responses to VEGF and 





characteristics are likely to be critical in determining overall outcome. Adiponectin 
levels are reduced in states of insulin resistance, and has been associated with EPC 
senescence through enhanced Grb2/MAPK signalling [321], and with diminished 
angiogenesis in vitro and in vivo [322]. Lastly, leptin levels are raised in the context of 
insulin resistance. Its effects on EPC function are more ambiguous, enhancing at 
physiological concentrations but inhibiting when levels are higher [323]. 
A converging theme from the above discussion relates to an unifying role for oxidative 
stress, which is associated with glucotoxicity, lipotoxicity and states of chronic 
inflammation. As established, however, ROS also confers important roles in cell 
physiology that are critical for function and this extends to reparative strategies. For 
instance, generation of superoxide by Nox2 is vital for EPC mobilisation and 
proliferation in the context of carotid artery re-endothelialisation in vivo [324]. The 
pro-angiogenic effects of VEGF also appear to be promoted in part by Nox2 mediated 
superoxide production [325]. This is consistent with the perceived hypothesis of a 
‘redox window’ discussed earlier, where maintenance of ROS within a critical zone is 
essential for normal physiology but with the caveat that excess production can cause 
pathology.  
 
1.4.5.2 Cellular insulin resistance 
The effects of insulin resistance on repair and regeneration at a cellular level has not 
been extensively explored. Initial studies were performed using murine models that 
were genetically diabetic (db/db) and were compared with heterozygous controls. EPC 





with reduced re-endothelialisation [326]. Although providing useful insights, the 
model was unable to account for confounding effects of hyperglycaemia. 
To address this, our laboratory studied the effects of insulin resistance per se on EPC 
biology using the IRKO mouse model. IRKO mice are hypertensive but with broadly 
preserved metabolic sensitivity to insulin. Notably, they demonstrated marked 
impairment in re-endothelialisation of the femoral artery after denuding wire injury 
[327]. This was associated with reduced abundance of EPCs in peripheral blood but 
preserved levels in bone marrow and spleen, suggesting a mobilisation defect. 
Importantly, infusion of wild-type littermate bone marrow-derived c-Kit expressing 
progenitors could rescue vascular repair in IRKO mice. Outgrowth endothelial cells 
derived from South Asian men, who are insulin-resistant and have increased risk of 
cardiovascular sequelae, also exhibit impaired vascular reparative capacity due to 
suppression of AKT signalling [328]. 
As alluded to, the reduction in NO bioavailability associated with insulin resistance is 
also strongly implicated in hindering the reparative response. There is convincing 
evidence to indicate that NO is vital in initiating the angiogenic response that occurs 
secondary to hypoxia and inflammation [329]. eNOS expression appears reduced in 
diabetic EPCs, and associated with impaired migration and adhesion capacity [326]. 
Reduced endothelial NO bioavailability in the context of insulin resistant states may be 
pertinent in promoting cell senescence and impairing migration in response to 
chemotactic stimuli, factors likely to be relevant in promoting conduit repair [330]. 
Indeed, NO has more potent inhibitory effects on neointimal hyperplasia after arterial 





normoglycaemic controls [331]. VENIRKO mice with endothelium-specific deletion of 
the insulin receptor have impaired retinal neovascularisation in response to hypoxia, 
which is associated with reduced expression of vascular mediators such as VEGF and 
eNOS [332]. Genetic knockdown of AKT1, which results in reduced downstream eNOS 
activation, has been shown in vivo to impede VEGF-induced angiogenesis concurrent 
with reductions in EPC mobilisation [333].  
As highlighted, pathway-specific insulin resistance and compensatory 
hyperinsulinaemia results in overdrive signalling in the Grb2/MAPK pathways. Its 
consequences are more debatable, with separate studies demonstrating stimulatory 
[334] and inhibitory effects on angiogenesis [217]. 
 
1.5   Shc homology 2-containing inositol 5’ phosphatase 2  
1.5.1 Overview        
A range of complementary systems exist to suppress excess insulin signalling during 
periods of cellular stress. Shc homology 2-containing inositol 5’ phosphatase 2 (SHIP2) 
is a 5’ phosphatase that tightly regulates membrane PIP3 abundance and therefore 
downstream signalling. In addition to its catalytic activity, it also acts as a docking site 
for a large number of proteins implicated in insulin signalling and cytoskeletal 
dynamics. PtdIns(3,4)P2 is the product of SHIP2 activity, and accumulating evidence 
indicates that it is not inert but instead exerts influence over a variety of cellular 
processes. In vitro and in vivo studies have broadly demonstrated SHIP2 to be a 
negative regulator of insulin signalling, which is quiescent in basal states but rapidly 





delineate the role of SHIP2 in vascular function are rather sparse, though some 
mechanistic insights have emerged from contemporary research. 
                         
1.5.2 Inositol polyphosphate 5-phosphatases 
The family of inositol polyphosphate 5-phosphatases is comprised of ten mammalian 
isoenzymes and four derived from the yeast Saccharomyces cerevisiae [335]. Each 5-
phosphatase has a conserved catalytic domain, consisting of 300 amino acids, which 
removes the phosphate from the 5-position of the inositol ring on phosphoinositides. 
The first family member identified was 5-phosphatase-I, which is involved in the 
regulation of intracellular calcium signalling [336]. Skeletal muscle and kidney 
enriched inositol phosphatase (SKIP) has not been extensively characterised but 
appears to have selective expression in the heart, kidneys and skeletal muscle [337]. 
Proline-rich inositol polyphosphate 5-phosphatase (PIPP) also shows differential 
expression that is higher in brain, heart, kidneys, lungs and gastrointestinal tract [338]. 
The activities of synaptojanin 1 and 2 are PI3K-independent, and they are thought to 
play a particular role in synaptic vesicular trafficking which is relevant in the process of 
phagocytosis [339]. 
In broad terms, the 5-phosphatase family modify membrane concentrations of 
phosphoinositides to regulate a plethora of cellular functions including insulin 
signalling, cell survival and proliferation, vesicular trafficking, endocytosis and 












5-phosphatase-1 72-5ptase/Type IV/Inpp5e 
 
Table 1-1 – Family of mammalian 5-phosphatases. 
 
1.5.3 Expression and structure of SHIP proteins 
The Shc homology 2-containing inositol 5’ phosphatase (SHIP) proteins were first 
observed in blood cells where their activation occurred via tyrosine phosphorylation in 
response to growth factors [341]. Both SHIP1 and 2 are the products of distinct genes. 
The expression of SHIP1 is restricted to cells of haematopoietic and spermatogenic 
origin [342], whilst the isoenzyme SHIP2 is more widely distributed. It is encoded by 
the inositol polyphosphate phosphatase like 1 (INPPL1) gene on chromosome 11 
[343]. It is ubiquitous in mice, and highly expressed in human heart, skeletal muscle, 
brain, placenta and pancreas [344]. SHIP2 was originally cloned as a product named 
51C, which potentially complemented the gene defect observed in Fanconi anaemia 
[345]. Subsequent work with myeloid cells renamed the product to SHIP2 [344]. It is 
observed as a 139kDa protein consisting of 1258 amino acids, and exhibits 
approximately 38% homology with SHIP1 [346]. Both contain specific, identifiable 








Figure 1-12 – Structural homology of SHIP1 and SHIP2 proteins.  
Adapted from Suwa et al. Expert Opin Ther Targets 2010; 14(7):727-37 [347]. 
SHIP2 is composed of 1258 amino acids, with SH2, 5-phosphatase and proline-rich regions 
that are structurally analogous to SHIP1. However, there is an additional SAM at the C-
terminal end. 
 
The SH2 domain at the N-terminus is vital in mediating the interactions of SHIP2 with 
a number of other activated intracellular signalling proteins, such as Shc, Gab, p130Cas, 
the FcγRIIB receptor in B cells and the hepatocyte growth factor receptor c-Met. The 
central portion incorporates the inositol phosphatidyl phosphatase (IPP) region, with 
an undefined ~ 300 amino acid segment separating the two.  
At the C-terminal end, there is a distinct proline-rich region of ~ 350 amino acids 
which differs most significantly with the structure of SHIP1. It provides a single NPXY 
motif, which undergoes activation through reversible tyrosine phosphorylation at 
residues 986 and 1125 [348]. This has been shown to occur in response to a range of 
growth factors, including EGF, PDGF, IGF-1 and insulin [349]. Once activated, the motif 
has the potential to bind a range of proteins bearing a PTB domain, including Shc, 





of SHIP2 with c-Cbl and CAP has been implicated in mediating multi-ubiquitination of 
epidermal growth factor receptor (EGFR) and subsequent endocytosis [350]. The 
remainder of this region has numerous PxxP motifs, possibly eight, which can bind to 
proteins bearing SH3 domains such as the protein kinase Abl. Lastly, a ubiquitin 
interacting motif (UIM) has also been reported in the SHIP2 protein, which appears to 
enable ubiquitin-binding capacity [351]. 
In comparison with SHIP1, there is an additional sterile alpha motif (SAM) of ~ 50 
amino acids at the C-terminus of SHIP2. This motif is widespread in many proteins, 
and is implicated putatively in protein-protein interactions [352]. Hence, through its 
various domains, SHIP2 is able to interact with a wide spectrum of protein partners 
including receptors, adaptors, kinases, phosphatases and cytoskeletal proteins (see 
Figure 1-13). A broad inference from this understanding is that SHIP2 is likely to have 
effector function via scaffolding properties and through its enzymatic capacity. A 







Figure 1-13 – SHIP2 effector proteins. 
SHIP2 is able to interact with a wide range of protein partners including receptors, adaptors, 
kinases, phosphatases and cytoskeletal proteins. 
 
1.5.4 Enzymatic activity of SHIP2 
The central, enzymatic domain of SHIP2 is closely conserved between murine and 
human forms, and folds in a similar manner to that of the endonuclease family of 
DNA-modifying enzymes [353]. It has approximately 65% amino acid homology with 
SHIP1 [344]. Its activity as a 5-phosphatase primarily removes the phosphate group 
from the 5’ position of PIP3 to produce phosphatidylinositol 3,4-bisphosphate 
(PtdIns(3,4)P2) [354]. In other words, it acts as a negative regulator in the insulin 
signalling cascade (see Figure 1-14). The 3’ position of the inositol phospholipid must 
be phosphorylated before this process can occur, implying that SHIP2 acts sequentially 
with PI3K [341]. PIP3 is the primary substrate. However, it can also dephosphorylate 
PtdIns(4,5)P2 to produce phosphatidylinositol 4-phoshate (PI4P) [355], though this has 
been observed in fewer models. 
Enzymatic activity is not mediated by SHIP2 tyrosine phosphorylation or direct 
interaction with adapter proteins in isolation. Instead, cellular localisation is deemed 
to be a key determinant of effector function [356]. In serum-starved conditions, SHIP2 
is localised to peri-nuclear regions and likely associates to nuclear proteins such as 
lamin A/C [357]. It could also potentially control nuclear PtdIns(3,4)P2. However, 
translocation to the cell membrane appears to occur in response to stimulation, i.e. at 





The interplay between tyrosine phosphorylation of SHIP2 and phosphatase activity 
has not been fully elucidated. However, a recent study has demonstrated 
enhancement of phosphorylation in response to EGF stimulation, which subsequently 
augmented its phosphatase activity [359]. Indeed, it was also implied that the SH2 
domain of SHIP2, in conjunction with the C-terminus, may confer inhibitory effects to 
suppress activity under basal conditions, which can be overcome via activatory 
phosphorylation.  
Aside from SHIP2, PIP3 degradation is also mediated through the separate actions of 
the tumour suppressor, phosphate and tensin homolog (PTEN). This acts as a 3-
phosphatase and hydrolyses the 3-position phosphate from PIP3 to form PtdIns(4,5)P2 
[360]. In vitro studies have also shown that PTEN hydrolyses the 3-position phosphate 
from PtdIns(3,4)P2 to produce phosphatidylinositol 4-phosphate (PtdIns4P), but this 
does not appear to be replicable in vivo [361]. Despite SHIP2 and PTEN metabolising 
the same target, i.e. PIP3, modulation has differing effects as a consequence of cell 
localisation, cell-specific factors and variations in reaction products resulting in 
disparate secondary messenger effects. Cellular levels of PIP3 are generally 
maintained at low levels due to basal inhibitory effects of PTEN, but a rapid increase 
occurs upon PI3K activation in response to insulin and growth factors.  
A discussion of in vitro and in vivo studies that have explored the role of SHIP2 in 








Figure 1-14 – Key pathways in phosphoinositide metabolism. 
SHIP2 acts as a negative regulator of insulin signalling, mediated via 5-phosphatase activity on 
PIP3. PTEN is also able to metabolise the same target, with effects dependent upon cell 
localisation and secondary messenger effects.  
 
1.5.5 SHIP2 and insulin signalling 
1.5.5.1 In vitro studies 
Consistent with the role of SHIP2 as a negative regulator of insulin signalling, over-
expression has been demonstrated to inhibit insulin-mediated PI3K signalling and AKT 
activation in various cell types, including 3T3-L1 adipocytes [362], B lymphocytes [363] 
and Chinese Hamster Ovary (CHO) cells [364]. However, conflicting results have been 
suggested using RNA interference of SHIP2 in adipocytes, where no modulatory 
effects on insulin signalling were detectable [365]. SHIP2 has also been shown to form 
complexes with CAP in the vicinity of the insulin receptor, with CAP directly implicated 
in the process of transmembrane glucose transport [366]. Additionally, in response to 





protein, filamin [367]. This interaction may enable spatial localisation of SHIP2 to 
submembranous PIP3, allowing regulation through its phosphatase activity. In VSMCs, 
SHIP2 has additionally been shown to play a negative regulatory role in MAPK 
pathway activation in response to PDGF and IGF-1, by competing with Grb2 for Shc 
phosphorylation at its Tyr (317) residue [368]. In the context of SHIP2 inhibition, there 
is amelioration of high glucose-induced lipogenesis and VLDL production by HepG2 
hepatocytes which was contributed by regulation of ROS production [369]. This 
suggests its role as an important regulator of hepatic de novo lipogenesis and 
lipoprotein secretion in insulin-resistant states.  
Most recently, studies have been performed in the context of a small molecule 
inhibitor (SMI), obtained via high-throughput screening based on mass spectrometry 
[370]. These function by competing with SHIP2 for target substrates at the catalytic 
site. Treatment with AS1949490 (IC50 for SHIP2 = 0.62µM) augmented insulin-
mediated AKT phosphorylation and glucose uptake in L6 myotubes. It appeared to be 
a potent and selective inhibitor, with no exerted effects on other intracellular 
phosphatases such as SHIP1, PTEN and synaptojanin. Other SMI have also been 
reported in the literature with comparable inhibitory activity to AS1949490 [371], but 
their selectivity and effects, both in vitro and in vivo, have not been investigated to 
any extent.  
 
1.5.5.2 In vivo studies 
Most in vivo studies assessing the role of SHIP2 on insulin signalling have been 





been found to be elevated in the skeletal muscle and adipose tissue of diabetic db/db 
mice [372]. In transgenic mice over-expressing SHIP2 under the control of a modified 
chicken β-actin promoter with cytomegalovirus immediate-early (CMV-IE) enhancer, 
insulin-stimulated AKT activation was reduced in various tissues including skeletal 
muscle, adipose tissue and liver [373]. Expression of UCP1 in adipocytes was also 
reduced, implying reduced browning.  
Homozygous deletion of exons 19-29 of the SHIP2 gene to produce a truncated 
protein induced early cyanosis and lethargy in the first 24 hours of life. This was 
associated with significant hypoglycaemia and rapid mortality. Littermates with 
heterozygous deletion were viable littermates. However, they demonstrated 
enhanced insulin sensitivity and glycogen synthesis in skeletal muscle, associated with 
reduced serum insulin concentrations [374]. However, there was controversy 
surrounding the gene modification of these mice, as it later became apparent that the 
strategy had inadvertently resulted in accompanying partial deletion of the Phox2a 
gene, which would result in non-functionality. Phox2a is a homeo-domain containing 
transcription factor that is implicated in neuronal development and differentiation 
[375]. The exact consequences of Phox2a loss-of-function are not fully comprehended 
but it is reasonable to speculate that the severe hypoglycaemic phenotype observed 
could be the result of truncated SHIP2, Phox2a or a combination of both. 
A later strategy circumvented this limitation by producing mice with targeted deletion 
of exons 1-18 of the SHIP2 gene, commencing at the translation-initiating ATG codon 
[376]. This segment discretely encodes the SH2 and 5-phosphatase catalytic domains. 





protein. It was surprisingly non-lethal, although mice demonstrated characteristic 
abnormalities in facial development. AKT activation was enhanced though this was not 
associated with detectable abnormalities in glucose and insulin tolerance. Knockout 
mice fed with a high-fat diet appeared to be resistant to weight gain and had higher 
uncoupling protein 03 (UCP3) mRNA levels in skeletal muscle, a correlate of basal 
metabolic rate. However, they too did not become insulin resistant.  
Most recently, a third mouse model has been generated in which the SHIP2 protein is 
expressed but has germline catalytic inactivity [377]. This was achieved by inserting 
DNA recognition sites (loxP) in the introns surrounding exons 18 and 19 of the INPPL1 
gene to enable specific, Cre-mediated recombination. These form the basis of one of 
the murine models utilised in this project, and will therefore be elaborated upon in a 
subsequent section. The formation of a mutant mouse line with systemic SHIP2 
catalytic domain haploinsufficiency resulted in significant, multi-organ developmental 
defects. Perturbations in lipid metabolism and insulin secretion were observed, but 
glucose tolerance and insulin-induced AKT phosphorylation were not affected. 
However, these developmental confounders made it difficult to dissect the relative 
role of altered SHIP2 activity per se to systemic insulin sensitivity. 
 
1.5.5.3 Human studies 
INPPL1 polymorphisms have been implicated in human disease states. A 16 base pair 
deletion in the 3’-untranslated region occurred more frequently amongst patients 
with DM, compared to healthy controls, in Caucasian populations from the United 





metabolic syndromes, including DM, in British and French cohorts [379]. In a Japanese 
population, several gene polymorphisms located in the 5-phosphatase domain of 
SHIP2 appeared more commonly in controls than in patients with DM [380]. In the 
context of CHO cells expressing human insulin receptor (CHO-IR), expression of these 
SHIP2 mutants appeared to afford protection against insulin resistance by enhancing 
PIP3 levels and AKT phosphorylation. Additionally, in a study of British patients with 
DM, a significant association with SHIP2 single nucleotide polymorphisms (SNPs) was 
found [379]. Most recently, a study in a Japanese cohort has found SNPs in the 
promoter and 5’-untranslated region (UTR) segments of the SHIP2 gene to be strongly 
associated with impaired fasting glycaemia [381].  
 
1.5.5.4 PtdIns(3,4)P2 and effector proteins 
Importantly, the negative regulatory role of SHIP2 in the insulin signalling cascade 
extends beyond the effects mediated through reductions in PIP3. As described, SHIP2 
activity also results in enhanced formation of PtdIns(3,4)P2. It is found mostly at the 
plasma membrane but also in early endocytic vesicles [382]. It is not functionally 
redundant, but instead is thought to be relevant in exerting critical secondary 
messenger effects, such as lamellipodial dynamics implicated in cell migration, 
endocytosis and insulin signalling [90]. 
PtdIns(3,4)P2 has been shown to bind directly to lamellipodin, and this enables 
recruitment of the Ena/VASP complex to mediate assembly of actin filaments. This has 
been shown convincingly in the process of neuronal migration [383]. The influence on 





of tandem pleckstrin homology domain containing protein-1 (TAPP1) and TAPP2 
adapters [384]. Studies using knock-in mice expressing mutant TAPP1/2 that are 
incapable of binding PtdIns(3,4)P2 have shown enhanced AKT activation and whole 
body insulin sensitivity. 
Collectively, these observations provide support for the suggestion that PtdIns(3,4)P2, 
a product of SHIP2 activity, may itself act as a negative regulator of insulin signalling 
pathways. Regulation is also likely to be achieved through feedback loops which may 
potentially downregulate the components of the PI3K network. Indeed, in the 
catalytically inactive murine model described above, the observed phenotype was 
postulated not to depend upon an overstimulated PI3K/AKT pathway but instead on 
reductions in SHIP2-produced PtdIns(3,4)P2 and its derivative, PtdIns(3)P [377]. The 
data remains somewhat conflicting, however, as PtdIns(3,4)P2 has also been shown to 

















Table 1-2 – Identified PtdIns(3,4)P2 interactors. 
 
1.5.6 SHIP2 in atherogenesis 
As outlined above in the description of stages involved in atherogenesis, VSMCs 
mediate vascular remodelling and plaque stabilisation. Indeed, their apoptosis has 
been implicated in the process of fibrous cap rupture [36]. In studies of rat VSMCs, 
SHIP2 inhibited AKT phosphorylation in response to PDGF and IGF-1 in a phosphatase-
dependent manner as predicted [368]. Interestingly, SHIP2 overexpression also had a 
negative influence on the mitogenic and anti-apoptotic Grb2/MAPK pathway. This 
occurred via SHIP2 competing with Grb2 to bind to Shc, i.e. a phosphatase-
independent mechanism. Chronic treatment of VSMCs with insulin appeared to 
reduce SHIP2 expression. Overall, it can be surmised that SHIP2 may regulate PDGF 
and IGF-1 signalling in VSMCs by both phosphatase-dependent and -independent 
mechanisms. It may therefore be a modulator of the atherogenic process.  
A more recent study has proposed a novel regulatory role for SHIP2 in atherosclerosis. 
Polymorphisms of the ApoE4 allele are established as risk factors for DM, Alzheimer’s 
disease and cardiovascular disease [386]. This are thought to be through modulatory 
effects on lipoproteins, such as reductions in circulating HDL cholesterol. In 
endothelial cells, it has been shown that ApoE4-very low-density lipoproteins (VLDLs) 
suppress PIP3-mediated AKT signalling and inhibit the anti-apoptotic pathways 
activated by HDL [387]. Interestingly, this appears to occur by recruitment of SHIP2 






1.5.7 SHIP2 in oncogenesis 
The predominant work assessing the role of SHIP2 on the processes of cell migration 
and proliferation has been in the field of oncogenesis, though primarily in the context 
of non-endothelial cells.  
SHIP2 protein expression has been shown to be elevated in several malignant breast 
cancer lines compared to non-transformed cells [388]. These cells had higher 
migratory and proliferative capacity, which can be profoundly pro-oncogenic and 
augment metastastic spread. SHIP2 may act as a scaffolding protein to mediate 
interactions with proteins involved in cell adhesion and spread, such as talin and 
p130Cas [348]. Effects on cell proliferation may be via regulation of EGF receptor 
signalling which is known to mediate multiple cellular events. Both vinexin and C-Cbl 
are focal adhesion proteins which can bind to SHIP2 but also regulate the 
ubiquitination of EGF receptor [389]. 
However, there also exists conflicting data which supports SHIP2 having anti-
oncogenic effects. In glioblastoma tumour cells, SHIP2 overexpression resulted in 
potent cell cycle arrest [390]. A similar effect has also been observed in cells derived 
from squamous cell carcinoma (SCC) [391]. Additionally, SHIP2 expression has not 
been shown to affect cell growth or apoptotic potential in a multiple myeloma cell line 
[392]. Overall, it is credible to postulate that SHIP2 is likely to exert differing effects in 
different contexts depending on cell type and milieu. The complexity is likely to be 
further compounded by potentially distinct effects of PtdIns(4,5)P2, which is also a 





myosin 1c in forming focal adhesions to regulate cell migration of glioblastoma cells 
[393].  
 
1.5.8 SHIP2 in lymphangiogenesis 
The effects of SHIP2 on endothelial function per se has been documented in the 
context of in vitro lymphangiogenesis studies, prompted by familial defects of 
lymphatic function associated with SHIP2 mutations [394]. In human lymphatic 
endothelial cells with SHIP2 knockdown, with small interfering RNA (siRNA) or 
inhibition with SMI, there was reduced migration, proliferation and adherence to ECM 
proteins [394]. This was observed in basal conditions and following stimulation with 
growth factors. The increase in Grb2/MAPK signalling was more significant than that 
of PI3K/AKT, and it was therefore speculated whether sustained signalling may be 
paradoxically detrimental to cell survival through activation of caspases [395].  
 
1.5.9 SHIP2 and cell motility 
Further studies have attempted to provide a mechanistic insight into interactions 
between SHIP2 and its binding partners which may mediate the observed effects on 
cell motility. It has already been conveyed that PIP3 accumulation occurs at the 
leading edge of migrating cells, where polymerisation of actin filaments, filamin-
mediated cross-linking into networks and lamellipodium formation occurs. In COS-7 
cells, LL5β appears to be recruited to this submembranous region by PIP3, enabled by 
its PH domain [396]. This in turn mediates binding of filamin which has affinity for 





response to EGF stimulation. Consistent with this, the expression of SHIP2 in filamin-
deficient cells is exclusively cytosolic [367]. This machinery complex involving LL5β, 
SHIP2 and filamin with precise regulation of PIP3 levels may assist in driving the cell to 
mobilise precisely and dynamically to external signals.  
The notion of spatial orchestration is consistent with that seen in other cell types. For 
instance, in human astrocytoma cells, SHIP2 appeared to localise to the cell periphery 
in response to serum and could be detected at the leading edge of polarised cells 
[357]. Additionally, in HeLa cells, SHIP2 has been demonstrated to associate with 
p130Cas at sites of focal adhesions [397]. Of further note, in glioma cells, SHIP2 has 
been shown to associate with active Rho GTPases via PxxP motifs in the SH2 domain 
[398], which has already been defined as a key effector of front-rear cell polarity and 
migration.  
 
1.6   Treatment strategies  
1.6.1 Overview        
Current recommendations to manage patients with type II DM rely upon lifestyle 
modifications and pharmacotherapies to improve glycaemic control (see Figure 1-15). 
However, although improvements have occurred in prevention of microvascular 
sequelae, such as nephropathy and retinopathy, improvements in macrovascular 
outcomes have been much less marked. Contemporary research is using murine 





these may be exploited in the future to modulate the macrovascular complications 
associated with DM.  
 
1.6.2 Lifestyle modifications 
A conceptual understanding of the metabolic syndrome has provided clear rationale 
for recommended lifestyle modifications, including regulation of diet, weight and 
physical exercise [399]. This has been associated with reductions in insulin resistance 
[400] and concurrent improvements in endothelial function [401]. Restriction of 
calorific intake appears to improve NO-mediated vasodilatation in obese and 
hypertensive cohorts [402]. Furthermore, a two month regimen of regulated dietary 
intake correlates with increased adiponectin levels and reductions in insulin resistance 
in patients with and without DM [403]. However, intensive lifestyle intervention 
achieving sustained moderate weight loss has surprisingly been shown not to reduce 
cardiovascular morbidity and mortality in adults with type II DM [404].  
 
1.6.3 Pharmacotherapies 
In view of shared signalling cascades, common stressors and coupling of metabolic 
and haemodynamic physiology, pharmacotherapies that target insulin resistance or 
endothelial dysfunction may have concurrent beneficial effects.  
Conventional therapies for hypertension, such as ACE inhibitors, have adjunct benefits 
on vascular profile by suppressing angiotensin II levels which lowers blood pressure 
and enhances endothelial function [405]. They have also been shown to augment 





Statins operate as 3-hydroxyl-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors and reduce endogenous cholesterol synthesis [407]. They have similarly 
been shown to reduce inflammation, ET-1 levels and improve endothelial dysfunction 
in patients with DM [408]. 
Metformin is in the biguanide class and is a first-line treatment of hyperglycaemia. It 
enhances insulin sensitivity and decreases hepatic gluconeogenesis [409]. Therapy has 
also been shown to enhance endothelial NO production by increasing AMP-activated 
protein kinase (AMPK)-mediated phosphorylation of eNOS [410]. It also reduces 
circulating ET-1 levels in the context of insulin resistance [411]. Treatment with PPAR-
α agonists such as fenofibrate reduce inflammatory markers and concomitantly 
enhance insulin sensitivity in patients with hypertriglyceridaemia [412].  
Thiazolidinediones, such as rosiglitazone and pioglitazone, are peroxisome 
proliferator-activated receptor (PPAR)-γ ligands that primarily enhance insulin 
sensitivity in adipose tissue [413]. They also appear to improve endothelium-
dependent vasomotor function in response to insulin [414]. In addition, they 
demonstrate anti-atherogenic properties by inhibiting VSMC proliferation and lipid 
accumulation in macrophages [415]. However, preliminary analyses showed 
rosiglitazone to be associated with a paradoxical rise in MI and cardiovascular 
mortality [416], necessitating temporary withdrawal from the market until more 
robust studies suggested a neutral association [417].  
Glucagon-like peptide (GLP)-1 is released into the circulation in response to feeding 





exenatide and liraglutide are incretin mimetics in clinical use, with some evidence 
suggesting beneficial effects on cardiovascular outcomes in those with type 2 DM 
when added to standard care [418]. However, therapy with dipeptidyl peptidase-4 
(DPP-4) inhibitors such as sitagliptin, which prevent GLP-1 breakdown, does not 
demonstrate superiority over placebo with regards to cardiovascular outcomes [419]. 
Empagliflozin is a recent addition to the portfolio of oral hypoglycaemics, and 
operates as a sodium-glucose co-transporter-2 (SGLT2) inhibitor to increase glucose 
excretion in the urine [420]. A randomised controlled trial (RCT) has shown that 
adjunct therapy with empagliflozin reduced cardiovascular mortality [421], which may 









Figure 1-15 – Pharmacotherapies for insulin resistance. 
Evolution of pharmacological therapies that may have concurrent benefits on insulin resistance and endothelial dysfunction. Broad classes include biguianides, 






1.6.4 Contemporary research 
Despite established evidence-based treatment strategies, DM continues to be 
associated with persistently adverse cardiovascular outcomes. Some contemporary 
research has therefore shifted focus to the promotion of vascular renewal. This goal 
remains speculative, however, and there have been inevitable challenges in 
translating effects from pre-clinical models to the complex abnormalities occurring in 
people with DM.  
Murine studies support the potential for acute insulin treatment in augmenting 
angiogenesis [423] and vascular repair after injury [424]. Gene-based delivery of 
therapies such as Ang1 [425] and HIF-1α have shown some promising findings by 
normalising immature vasculature in diabetic db/db mice [426]. VEGF gene therapy 
with concurrent administration of a Notch inhibitor (DAPT) appears to enhance 
neovascularisation and perfusion recovery in diabetic mice in the setting of hindlimb 
ischaemia [427]. However, the interference of Notch signalling concurrently leads to 
poor neovessel quality with leaky, fragile vasculature [428]. Our own laboratory has 
shown that EPCs derived from South Asian men, who are insulin resistant and at 
increased risk of cardiovascular sequelae, exhibit impaired vascular repair and 
angiogenesis which can be rescued with expression of constitutively active AKT1 [328]. 
In addition to SHIP2, PTEN is an established negative regulator of insulin signalling. 
However, it is also clearly defined as a tumour suppressor and consistent with this, 
mice deficient in PTEN have a strong propensity for development of malignancy [429]. 





have translational capacity. Modulation of SHIP2 has already been explored in murine 
models, as described. Heterozygous deletion has shown enhanced insulin sensitivity, 
and knockout mice fed a high-fat diet appeared resistance to weight gain and also did 
not become insulin resistant. It can therefore be reasonably postulated that rescuing 
diminished PI3K/AKT signalling via SHIP2 inhibition may be beneficial in promoting 
vascular endothelial function and repair along with improving metabolic control. As 
outlined earlier, mice with SHIP2 catalytic inactivity have been generated but whole-
body haploinsufficiency resulted in impaired growth and developmental defects that 
impeded clarity [377]. In order to circumvent this limitation, our laboratory has 
created mice with germline endothelium-specific SHIP2 catalytic domain 
haploinsufficiency (ECSHIP2Δ/+). Moreover, we have created mice with whole-body 
inducible SHIP2 catalytic domain haploinsufficiency (SHIP2iΔ/+) to assess the potential 
benefits of transient SHIP2 inhibition. This may define the value of pursuing 
pharmacological inhibitors for therapeutic purposes. In vivo data generated from 










































The broad aim of this project was to assess the effects of SHIP2 modulation on 
metabolic and vascular function.  
To address these goals, in vivo studies were performed on 10 month aged mice with 
germline endothelium-specific SHIP2 catalytic domain haploinsufficiency (ECSHIP2Δ/+),  
and on younger mice (2-3 months) with whole body inducible SHIP2 catalytic domain 
haploinsufficiency (SHIP2iΔ/+). Studies were extended in vitro through use of HUVECs 
after SHIP2 silencing using lentiviral shRNA transduction or pharmacological inhibition. 
This exploration highlighted the relevance of observations to human pathophysiology, 
and potential benefits of clinical translation. 
Specifically, the effects of SHIP2 manipulation were explored in the following ways: 
1. Vascular formation (developmental angiogenesis in retinas)  
2. Vascular regeneration (using model of hindlimb ischaemia) 
3. Vascular repair (after injury to femoral artery) 
4. Studies of downstream endothelial cell signalling 
5. Studies of endothelial cell biology (including migration, proliferation, 
morphology and polarisation) 
6. Metabolic profiling 
The primary hypothesis for this project is that SHIP2 inhibition has favourable effects 






































3.1   Animal husbandry 
Chow feed           B&K Universal Ltd 
 
SHIP2(18-19lox/+) mice         Stephane Schurmans 
 
CreER+/0 mice           Jax strain 004453 
 
Tie2-Cre+/0 mice           Jax Labs Bar Harbor 
 
CO2 chamber           Vet Tech Solutions 
 
Isoflurane            Abbott Logistics BV 
 
Dry ice            BOC 
 
Liquid nitrogen           Statebourne Cryogenics 
 
27G needle           BD Microlance 
 
Pierse Fixation forceps         Fine Science Tools 
 
3.2   Genotyping 
1.5mL microcentrifuge tubes       Eppendorf   
     
Sodium hydroxide          Thermo Fisher Scientfic 
 
Ethylenediaminetetraacetic acid (EDTA)     Sigma-Aldrich 
 
Tris-HCl            Thermo Fisher Scientfic 
 
TaqMan Master mix         Bioline 
  
Forward and reverse primers       Invitrogen 
 
Distilled water          BD Biosciences 
 
Laminar flow hood         LabCaire 
 
PCR reaction tubes         Thermo Fisher Scientific 
 






Agarose gel           Bioline    
      
Ethidium bromide          Sigma-Aldrich 
 
Fume cupboard          Mach-Aire Criterion 
 
Gel tray            Invitrogen 
 
100 base pair ladder         Thermo Fisher Scientific 
 
Chemi XT4 illuminator         Syngene  
 
Gene Sys V1.4.0.0          Syngene 
 
 
3.3   Pulmonary endothelial cell (PEC) isolation 
MV2 basal media          PromoCell 
 
Foetal bovine serum (FBS)        Biosera 
 
Endothelial cell growth supplement (ECGS)    PromoCell 
 
Antibiotic-antimycotic solution (AAS)      Invitrogen 
 
Bovine skin gelatin powder        Sigma-Aldrich 
 
Siliconized glass bottle         Sigma-Aldrich 
 
Bovine serum albumin (BSA) solution      Sigma-Aldrich 
 
Phosphate buffered saline (PBS)       Sigma-Aldrich 
 
Bonn scissor           Fine Science Tools 
 
15mL Falcon           Sarstedt 
  
Dulbecco’s Modified Eagle’s Medium (DMEM)    Life Technologies 
 
Laminar flow hood         Envair Bio2+ 
 
Type II collagenase (#11097113001)      Roche 
 
Water bath           Grant 





5cm petri dish          Thermo Fisher Scientific 
 
Size 22 scalpel blade         Swann-Morton 
 
5mL stripette           Corning 
 
MACSMix rotator          Miltenyi Biotec 
 
Incubator           Sanyo 
 
10mL syringe           BD Biosciences 
 
50mL Falcon           Sarstedt 
 
14G orange cannula         BD Biosciences 
 
70µm cell sieve          Greiner Bio-One 
 
Centrifuge           Eppendorf 
 
CD146 antibody-coated magnetic beads     Miltenyi Biotec 
 
Magnetic particle concentrator       BD Biosciences 
 
MiniMACS column         Miltenyi Biotec 
 
6-well plate           Corning 
 
3.4   SHIP2 activity assay 
5’ phosphatase fluorescence polarisation activity assay   Echelon 
(K-1400) 
 
Reaction buffer (cat# K-S2RB)       Echelon  
             
POLARstar Omega platereader       BMG Labtech 
 
3.5   Vascular formation in retinas 
Dumont micro-blunted tip forcep      Fine Science Tools 
  






24-well plate           Falcon 
 
Paraformaldehyde (PFA)        Thermo Fisher Scientific 
 
KL1500 LCD dissection microscope       Meyer Instruments 
 
Triton X-100           Sigma-Aldrich 
 
Sodium deoxycholate         Sigma-Aldrich    
 
Bovine serum albumin (BSA) powder      Sigma-Aldrich 
 
Sodium azide           Sigma-Aldrich 
 
Calcium chloride          Sigma-Aldrich 
 
Magnesium chloride         Sigma-Aldrich 
 
Manganese chloride         Sigma-Aldrich 
 
Microtitre plate shaker         Stuart 
 
Isolectin B4 pre-conjugated to Alexa Fluor 488    Life Technologies 
 
Vannas spring scissors         Fine Science Tools 
 
Poly-L-lysine coated glass slide       Sigma-Aldrich 
 
22 x 22mm coverslip         VWR 
 
Prolong Gold           Invitrogen   
  
LSM880 confocal microscope       Zeiss 
 
Image J software (v1.46r)        National Institutes of  
             Health 
 
3.6   HUVEC culture and manipulation 
Pooled human umbilical vein endothelial cells (HUVECs) Promo-Cell 
 
M199 basal media          Sigma-Aldrich 
 
HEPES solution          Thermo Fisher Scientific 





Sodium pyruvate          Sigma-Aldrich 
 
Heparin            Wockhardt 
 
Endothelial cell growth supplement (ECGS)    Sigma-Aldrich 
 
10cm petri dishes          Corning 
 
Trypsin-EDTA           Sigma-Aldrich 
 
Haemocytometer          Hawksley 
 
Trypan blue           Sigma-Aldrich 
 
SHIP2-targeting short hairpin RNA (shRNA) lentivirus  Sigma-Aldrich 
(SHCLNV-NM001567)   
 
GFP-targeting short hairpin RNA (shRNA) lentivirus   Sigma-Aldrich  
(SHC002H) Sigma-Aldrich 
 
AS1938909           Merck 
 
AS1949490           Cambridge Bioscience 
 
Dimethylsulfoxide          Sigma-Aldrich 
  
Gp91ds-tat           Genscript 
 
Gp91ds-tat scrambled peptide       Genscript 
 
Wortmannin (ab120148)        Abcam 
 
LY294002 (ab120243)         Abcam 
 
3.7   Endothelial cell functional assays 
3.7.1   Scratch wound  
ImageLock 96-well plate        Essen Biosciences 
 
IncuCyte woundmaker 96-pin device      Essen Biosciences 
 
CKX-41 light microscope        Olympus 
 






3.7.2   Boyden chamber  
Vascular endothelial growth factor (VEGF)    BD Biosciences 
 
8µM polycarbonate inserts        Falcon 
 
Ethanol            Thermo Fisher Scientific 
 
Cotton bud           Johnson+Johnson 
 
Haematoxylin          Sigma-Aldrich 
 
Eosin            Sigma-Aldrich  
 
3.7.3   5-ethynyl-2’-deoxyuridine (EdU) incorporation 
Click-iT EdU Alexa Fluor 647 imaging kit     Life Technologies 
 
Fluorescence-activated cell sorting (FACS) tubes   Fisher  
 
BD-LSR Fortessa flow cytometer       BD Biosciences 
 
FACSDiva (v6.2)          BD Biosciences 
 
3.7.4   Bead sprouting 
EGM-2 basal media         Lonza 
 
Bulletkit            Lonza 
 
Cytodex-3 beads          Amersham 
 
T25 cell culture flask         Corning 
 
Fibrinogen           Sigma-Aldrich 
 
Aprotinin           Sigma-Aldrich 
 






3.8  Immunofluorescence 
3.8.1   Lamellipodial staining  
35mm imaging dish         Ibidi 
 
Phalloidin pre-conjugated to Alexa Fluor 647 (A22287)  Life Technologies 
 
3.8.2   GM130 staining 
24-well imaging plate         Ibidi 
 
Goat serum           Sigma-Aldrich 
 
Mouse anti-GM130 antibody pre-conjugated to     BD Pharmingen 
to Alexa Fluor 488 (#560257)     
 
Hoescht 33342 (#561908)        BD Sciences 
 
3.8.3   SHIP2 staining 
Rabbit anti-SHIP2 primary antibody (ab166916)   Abcam 
 
Goat anti-rabbit secondary antibody pre-conjugated  Invitrogen 
to Alexa Fluor 647 (#A-21245)    
 
Ulex Europaeus pre-conjugated with fluorescein    BD Sciences 
isothiocyanate (FITC) (#553929) 
 
3.9  Dihydroethidium (DHE) assay 
96-well plate           Thermo Scientific 
 
Dihydroethidium          Life Technologies 
 
Krebs-HEPES buffer         Sigma-Aldrich 
 
Flex Station 3 microplate reader       Sunnyvale 
 






3.10  Western blotting 
Cell extraction buffer         Sigma-Aldrich 
 
Protease inhibitor          Santa Cruz Biotechnology 
 
Phosphatase inhibitor         Santa Cruz Biotechnology 
 
1.8cm blade cell scraper        Corning 
 
-40°C freezer           Sanyo 
 
6mm cone ball          Retsch 
 
Tissue lyser           Qiagen 
 
Bicinchoninic acid (BCA) assay kit      Thermo Fisher Scientific 
 
DMX TC microplate reader        Dynex Technologies 
 
Revelation software (v4.21)        Dynex Technologies 
 
Sample buffer          Invitrogen 
 
Reducing buffer          Invitrogen 
 
Heating block           Fisher-Scientific 
 
Bis-Tris polyacrylamide gel        Bio-Rad 
 
Marker            Bio-Rad 
 
Criterion cell tank          Bio-Rad 
 
2-(N-morpholino)ethanesulfonic acid/sodium dodecyl   Invitrogen 
sulphate (MES SDS) 
 
Polyvinylidene fluoride (PVDF) membrane    Merck Millipore 
 
Metal stirrer           Stur Lab 
 
Methanol           Fisher Scientific 
 
Magnetic rotary plate          Heidolph 
 






Primary antibodies (see Table 4-5)      Cell Signalling 
 
Secondary antibodies (see Table 4-5)      Dako 
 
Cling film           Viking Direct 
 
Immobilon western chemiluminescent horseradish   Merck Millipore 
peroxidase (HRP) substrate   
 
Camera scanner (Image Station 2000R)     Kodak 
 
Restore PLUS stripping buffer       Thermo Scientific 
 
GeneTools (v1.6.1)         Syngene 
 
3.11  Tamoxifen induction 
Tamoxifen (#T5648)         Sigma-Aldrich 
 
Corn oil            Sigma-Aldrich 
 
3.12  Metabolic profiling 
3.12.1  Gross body weights 
Electronic scales          Kern 
 
3.12.2  Glucose tolerance testing (GTT) 
Glucose            Sigma-Aldrich 
 
Glucometer           Aviva 
 
Accu-Chek testing strips        Aviva 
 
3.12.3  Insulin tolerance testing (ITT) 






3.12.4  Plasma insulin measurement (ELISA) 
1mL syringe           Terumo 
 
-80°C freezer           Panasonic 
 
Ultra-sensitive mouse insulin ELISA kit     Crystal Chem 
 
3.13  Angiogenesis after hindlimb ischaemia 
Electric razor           Contura 
 
Veet cream           Reckitt Benckiser 
         
Oxygen            BOC Medical 
  
Microporous surgical tape        Jax First AId 
 
Buprenorphine          Alsatoe Animal Health 
 
Povidone-iodine solution        Sigma-Aldrich 
 
Vicryl suture           Ethicon 
 
Optimal cutting temperature (OCT) compound   CellPath 
 
2-methylbutane (isopentane)       VWR Chemicals 
 
Long forceps           Agar Scientific 
 
20mm cork plates          Fisher Scientific 
 
CM1900 cryostat          Leica 
 
Stainless steel S35 microtome blade      Feather 
 
Superfrost Plus slides         Thermo Fisher Scientific 
 
PAP pen            Kisker Biotech MKP-1 
 






3.14  Vascular repair after denuding injury 
OPMI 1-FC dissecting microscope      Zeiss 
 
Iris scissors           World Precision   
             Instruments 
 
Lignol (1% lignocaine and adrenaline)     Arnolds 
 
0.014 inch angioplasty guide wire      Abbott Vascular 
 
Irripod (sterile sodium chloride (NaCl))     Unither 
 
Evans blue solution         Acros Organics 
 
Dissecting Stereo microscope       Olympus 
 
QiCam digital camera         Olympus 
 































































4.1   Animal husbandry 
4.1.1 General housing  
All murine work was performed in accordance with accepted standards of care as per 
the Experimental Animals (Scientific Procedures) Act 1998, and with UK Home Office 
approval (project licence 40/3523 and P144DD0D6, personal licence IB8837F68). Mice 
were housed in a designated facility at University of Leeds. Environment was 
maintained at a fixed temperature and humidity, and with the use of a 12 hour 
light/dark cycle. Unless deliberately specified, mice were fed with a standard chow 
diet and provided with unrestricted access to water. All littermates were maintained 
with parents until 3 weeks of age, at which point they were weaned and ear notches 
obtained for genotyping. Littermates were grouped into cages containing a maximum 
of 5 mice. Every effort was made to utilise mice promptly for experimental purposes, 
once sufficiently mature to tolerate procedural testing.  
 
4.1.2 Breeding 
All mice were bred onto a C57 black 6 (C57BL/6J) background for at least 10 successive 
generations. This was performed in a conventional animal facility using general 
housing conditions as described above. Initially, Cre-recombinase specific loxP sites 
were inserted into introns surrounding exons 18 and 19 of the INPPL1 gene in a 
heterozygous fashion (SHIP2(18-19lox/+)) [377].  
For production of germline ECSHIP2Δ/+ mice, female SHIP2(18-19lox/+) mice were crossed 
with male Tie2-Cre+/0 mice. The Cre/lox system is particularly useful for lineage-





recombinase that excises DNA flanked by two correctly orientated loxP recognition 
sites [430]. Promoter and enhancer regions of the mouse Tie2 gene were used to drive 
Cre transgene expression specifically in endothelial cells [431]. Tie2 is an angiopoietin 
receptor, which remains expressed throughout development and adulthood and is 
detectable in the endothelial cells of virtually all quiescent and angiogenic mature 
adult tissues [432]. To produce the separate SHIP2iΔ/+  colony, female SHIP2(18-19lox/+)  
mice were crossed with male mice that expressed a mutated fusion protein of Cre 
recombinase and the human oestrogen receptor (CreERT2+/0) in all cell lineages. 
Expression of this fusion protein is driven by a CAG promoter (Cytomegalovirus (CMV) 
early enhancer element, chicken β-Actin gene and splice acceptor of the rabbit β-
Globin gene) to enable tamoxifen-inducible global SHIP2 haploinsufficiency [433]. The 
protocol used for tamoxifen induction is outlined in Section 4.11. 
Breeding cages consisted of one male and two female mice. As anticipated, progeny of 
various genotypes were born, the identities of which were confirmed using DNA from 
ear notches. Females were occasionally used to establish new breeding trios, but it 
was only males that were used for experimental purposes. This was to negate 
confounding effects pertaining to cyclical variations in reproductive hormones. 
Comparative controls (“WT”) were always littermates that expressed Cre recombinase 









Figure 4-1 – Breeding of ECSHIP2Δ/+ colony. “WT” represents controls mice. “SHIP2KD” represents mice with endothelium-specific germline SHIP2  
















Sacrifice of mice was performed using Home Office approved techniques at all times. 
This predominantly involved use of a chamber allowing exposure to rising 
concentrations of carbon dioxide (CO2) within a 12 minute cycle. Death was 
subsequently confirmed by a secondary means such as cervical dislocation. When 
blood sampling or organ harvesting was required, euthanasia was performed using 
terminal anaesthetic with isoflurane inhalation. Exsanguination via intra-cardiac 
puncture using a 27G needle was performed rapidly to derive whole blood, and 
organs were then harvested prior to transfer in ice or liquid nitrogen for immediate 
processing or storage. Sacrifice of pups prior to retinal harvesting was achieved by 
cervical dislocation using Pierse Fixation forceps followed by prompt decapitation. 
 
4.2   Genotyping 
4.2.1 DNA extraction 
Tissue samples were derived from ear notching, for the purpose of identification, at 
the time of weaning (3 weeks of age). Samples were kept in 0.5mL microcentrifuge 
tubes in a freezer at -20°C until required. At the time of genotyping, heat blocks were 
set to 95°C. 100µL of 25mM sodium hydroxide (NaOH) mixed with 0.2mM 
ethylenediaminetetraacetic acid (EDTA) was added to each tissue sample before 
placing in the heat block for a duration of 10 minutes. This enabled disruption of cell 
walls and the hydrogen bonds between DNA bases, converting double strands to 





base) was introduced for 10 minutes to decrease alkalinity of the mixture and allow 
hydrogen bonds to be re-established. All samples were subsequently vortexed. 
 
4.2.2 Polymerase chain reaction (PCR) 
Most of the reagents used for DNA PCR were stored in a -20°C freezer. Components 
included a pre-ordered ‘TaqMan Master mix’ stock solution, distilled water and 
specific primers (see Table 4-1). The ‘Master mix’ solution contained deoxynucleotide 
triphosphate (dNTP), thermostable Thermophilus aquaticus (Taq)-derived DNA 
polymerase, magnesium chloride (MgCl2) as a bivalent cation and a buffer solution to 
maintain an optimal chemical environment for enzymatic activity. Stocks of the 
forward and reverse primers were sourced commercially, and working solutions made 
by reconstitution in TE buffer (10mM Tris and 1mM EDTA) with a 1:10 dilution in 
distilled water. These short fragments were complementary to the 3’ ends of the 
sense and anti-sense strands of the respective DNA target (i.e. Cre or floxed SHIP2), 
with the following primer sequences: 
 
Cre – forward 5’ – GCA TTA CCG GTC GAT GCA ACG AGT GAT GAG – 3’ 
Cre – reverse 5’ – GAG TGA ACG AAC CTG GTC GAA ATC AGT GCG – 3’ 
SHIP2 – forward 5’ – GCT TAG ACA TGG ATA TCC AG – 3’ 
SHIP2 – reverse 5’ – CAG TTG GCT TCT GCT TGT GC – 3’ 
 
Table 4-1 – Cre and SHIP2 primers for DNA sequencing. These were used on tissue  







Samples were prepared in a laminar flow hood to reduce the risk of contamination. 
Individual reagents were kept on ice prior to use, and added in the volumes listed 
below (Table 4-2), to produce a final working solution of 24µL in individually labelled 
PCR tubes. These samples were vortexed prior to addition of 1µL of DNA using a 
designated Gilson pipette. Both negative and positive controls were also prepared, 
with tissue derived from mice that had been previously genotyped. A final vortex was 
performed to ensure adequate mixing. PTC thermal cyclers with pre-specified 
programmes were utilised to enable DNA amplification. This incorporated stages of 
initialisation, denaturation, annealing, elongation and a final hold (detailed in Table 4-
3). All products were subsequently refrigerated at 4°C until use for gel 
electrophoresis.  
 
Reagent Volume (µL) 
‘Master mix’ 10.0 
Forward primer 0.5 
Reverse primer 0.5 















95°C 1 min  
  







     35 cycles 
 
95°C 15 secs 94°C 30 secs 
51°C 30 secs 59°C 30 secs 





4°C Hold 4°C Hold 
 
Table 4-3 – Cre and SHIP2 DNA amplification cycles. 
 
4.2.3 Agarose gel electrophoresis 
This was performed using 1.5% agarose gel, which was made by mixing 1.8g of 
agarose using a spatula into 120mL of Tris-acetate-EDTA (TAE) buffer in a conical flask. 
This was heated in a microwave at 800W in two stages (60 secs and 30 secs) before 
addition of 3µL of ethidium bromide in a fume cupboard, which intercalates into DNA 
and fluoresces under ultraviolet (UV) light to allow visualisation. The agarose gel was 
subsequently poured into a gel tray and allowed to set for 30 minutes. The gel 
contained a plastic comb to form wells into which reaction samples could be loaded. 
The agarose gel was maintained in a tank containing 600mL of TAE buffer, derived 
from a 50X stock solution containing 242g Tris, 100mL of 0.5mM EDTA and 57mL of 
acetic acid diluted up to 1L using distilled water. 5µL of a 100 base pair ladder was 
loaded for reference purposes, with adjacent wells containing 20µL of each of the 





carbohydrates without cross-links, resulting in a gel with large pores. Application of an 
electric current at 110 V for 60 minutes enabled movement of negatively charged DNA 
from cathode to anode through these pores, with distance travelled being inversely 
related to molecular size. Imaging of produced bands was conducted in a Chemi XT4 
illuminator using Gene Sys software, with a single band at 408 base pairs for the Cre 
transgene and two bands at 411 and 500 base pairs for the SHIP2 transgene. 
 
4.3   Pulmonary endothelial cell (PEC) isolation 
4.3.1 Preparation of reagents 
Pulmonary endothelial cell (PEC) isolation was achieved using a modified technique 
derived from Sobczak et al [434]. Certain reagents were prepared in advance. 500mL 
basal endothelial medium MV2 was supplemented with 50mL batch-tested foetal 
bovine serum (FBS), 27.1mL endothelial cell growth supplement (ECGS) and 10mL 
antibiotic-antimycotic solution (AAS). This stock solution was divided into individual 
50mL aliquots and maintained in sterile conditions for up to 1 month. A stock solution 
of 2% gelatin was also prepared, derived from 2g of bovine skin gelatin powder mixed 
in 100mL of distilled water. This was placed in a siliconized glass bottle and autoclaved 
prior to use. Lastly, 666µL of 7.5% bovine serum albumin (BSA) was added to 50mL 
phosphate buffered saline (PBS) to produce 0.1% PBS/BSA stock solution. 
 
4.3.2 Lung harvest and single cell suspension 
ECSHIP2Δ/+ mice were euthanised in a CO2 chamber, followed by a midline sternotomy 





connective tissue or thrombi. This was placed in 15mL Falcon tubes containing 10mL 
of sterile Dulbecco’s Modified Eagle’s Medium (DMEM) and transferred on ice to a 
laminar flow hood in the tissue culture laboratory. Here, lungs were transferred to 
separate Falcons, containing 10mL of 1mg/mL type II collagenase mixed in DMEM, 
that were pre-warmed to 37°C in a water bath. Lung tissue derived from single mice 
was transferred onto a 5cm diameter petri dish and 500µL of type II collagenase 
solution added to aid enzymatic digestion. Specimens were minced thoroughly with 
two size 22 scalpel blades until a homogenous paste was formed and bubbles 
visualised. This was aspirated using a 5mL stripette into its original Falcon tubes 
before incubation on a MacsMix rotator in an incubator at 37°C for 45 minutes. Once 
the incubation period was complete, solutions were transferred to fresh 50 mL 
Falcons. A 10mL syringe was attached to the end of a 14G orange cannula, and the 
solution agitated 20 times gently to avoid bubble formation. 
 
4.3.3 Magnetic bead coating and cell isolation 
This single cell suspension was passed through 70µm cell sieves into separate 50mL 
Falcon tubes and neutralised with 5mL of MV2. The filtrate was centrifuged at 400g 
for 5 minutes before gentle aspiration of the supernatant. Cells were re-suspended in 
200µL PBS/BSA mixed with 20µL anti-CD146 antibody-coated magnetic beads and 
transferred to 1.5mL microcentrifuge tubes. CD146 is expressed in endothelial cells in 
vascular tissue throughout the body, and is involved in cell adhesion and cohesion of 
the endothelial monolayer at intercellular junctions [435]. Samples were spun on the 





centrifugation at 4000 revolutions per minute (rpm) for 5 minutes. During this phase, 
a magnetic particle concentrator was assembled in the hood and loaded with 
MiniMACS columns which had been primed with 500µL PBS/BSA. Each sample was 
applied to an individual column and once fully drained and washed through three 
times with 500µL PBS/BSA, 1mL of fresh PBS/BSA was added and a plunger used to 
mechanically expel the CD146+ cells into fresh 15mL Falcon tubes. After centrifugation 
at 400g for 2 minutes, this process was repeated three times over to wash debris from 
the selected cells. The final samples were re-suspended in 2mL of MV2 media and 
added to individual wells of a 6 well plate that had been pre-coated with 2% gelatin. A 
full media change was performed after 24 hours, followed by a half media change 
every 48 hours until confluence was reached. PECs were utilised for the SHIP2 activity 
and dihydroethidium (DHE) assays, and to assess protein expression of SHIP2 in the 
ECSHIP2Δ/+ colony. 
 
4.4  SHIP2 activity assay 
This was performed using both PECs and HUVECs. The purchased kit operates as a 5’ 
phosphatase fluorescence polarization activity assay using the following components: 
10µg PI(3,4,5)P3 substrate, 0.6µg PI(3,4)P2 standard, 10µg vials of PI(3,4)P2 detector, 
10µM probe, PBS tablet and a 384-well assay plate with acetate sealer. First, reagents 
were prepared. The PBS tablet was dissolved in 200mL distilled water and was used as 
the PBS buffer solution. A 40µM stock solution of PI(3,4,5)P3 substrate was produced 
by reconstituting 10µg in 255µL distilled water. A standard buffer containing 2µM of 





buffer (purchased separately). The PI(3,4)P2 standard was produced by reconstituting 
0.6µg in 350µL distilled water for a 2µM stock solution. 1mL PBS was added to 10µg of 
PI(3,4)P2 detector to produce a 10µg/mL working solution. The 10µM probe stock was 
diluted 200-fold for a working solution of 50nM.  
At commencement, 45µL of each sample was mixed with 45µL of 4µM PI(3,4,5)P3 
substrate, a 10-fold dilution of the original 40µM stock, and incubated at 37°C for 1 
hour. The reaction was then terminated by heating to 95°C for 3 minutes. Samples 
were allowed to cool and centrifuged at 5,000 rpm for 2 minutes. Five serial two-fold 
dilutions of the 2µM PI(3,4)P2 standard in standard buffer were made (i.e. 1.0µM, 
0.5µM, 0.25µM, 0.125µM and 0.0625µM). A 0µM control containing just standard 
buffer was also used. 40µL of these diluents were added to wells of the plate in 
duplicate, succeeded by addition of each sample as duplicates in separate wells. 
Subsequently, 40µL PI(3,4)P2 detector and 20µL probe was added to all wells.  
The plate was covered in foil to protect from light, and transferred to a POLARstar 
Omega platereader. This enabled fluorescence polarisation detection with use of 
appropriate filters (550nm excitation, 580nm emission). Values were expected to 
decrease as probe binding to the PI(3,4)P2 detector was displaced by PI(3,4)P2 
produced from SHIP2 enzymatic activity. Kinetic readings were obtained every 10 
minutes for a duration of 90 minutes. A PI(3,4)P2 standard curve was plotted using a 
non-linear regression curve fit. Polarisation values obtained from the enzymatic 
reactions were then used to interpolate PI(3,4)P2 values from the standard curve, 






4.5  Vascular formation in retinas 
4.5.1 Ocular harvesting 
Dissection and staining of retinas was performed on littermates derived from the 
ECSHIP2Δ/+ colony. These were harvested at 5 days of age to assess primitive vascular 
labyrinth formation during post-natal developmental angiogenesis, using an 
established and well-reported protocol [436]. Pups were first separated from their 
parents and weighed. Euthanasia was performed by cervical dislocation using Dumont 
micro-blunted tip forceps followed by decapitation, with the tail tip collected in 
individual wells of a tissue plate for genotyping purposes.  
A longitudinal incision was made on the upper and lower surfaces of the head with 
fine scissors. The head was turned to one side, to allow the subcutaneous tissue to be 
gently peeled forward. This extended beyond the nasal bridge to allow exposure of 
both orbits. Traction was placed on the large pedicle close to the orbit to enable 
removal of as much adherent tissue as possible from the eyeball. Subsequently, blunt 
curved forceps were placed in the inferior border of the orbit to allow the eyeball to 
be lifted out on its optic nerve pedicle. Both eyeballs were placed in individual wells of 
a 24-well plate containing 1mL of 4% paraformaldehyde (PFA) in PBS and uniquely 
labelled for subsequent identification purposes. Samples were stored at room 
temperature for 2 hours to enable a ‘strong fix’. After a wash in 1mL of PBS, they were 
maintained in 2mL of fresh PBS at 4°C until time of dissection.  
 





This was performed using a KL1500 LCD dissection microscope. First, eyeballs were 
carefully transferred into a petri dish filled with PBS to prevent drying. A needle was 
used to pierce the cornea, which enabled advancement of a scissor blade into the 
anterior chamber to remove all but a small rim of cornea. The cornea was carefully 
pulled apart, which advanced the tear into the sclera and choroid and facilitated 
gradual detachment from the iris. Using this technique, layers were removed to 
expose the retina. The lens was extracted with a forceps and a small volume of PBS 
added into the posterior chamber. This enhanced visualisation of hyaloid vessels, 
which could be circumferentially fractured from the posterior chamber by pulling 
gently at the ciliary shelf and removed in bulk from the region of the optic nerve. 
Great care was taken at this stage to avoid damage to the retinal surface itself. The 
retinas were subsequently returned to their original wells and maintained in PBS to 
enable staining. 
 
4.5.3 Isolectin B4 staining  
Permeabilisation and blocking buffer was made using the following constituents: 
50mL PBS (pH 6.8), 0.5% Triton X-100, 0.01% sodium deoxycholate, 1% BSA, 0.02% 
sodium azide and 1M each of calcium chloride (CaCl2), magnesium chloride (MgCl2) 
and manganese chloride (MnCl2). 2mL of this buffer was added to each well and 
retinas left overnight at 4°C on a microtitre plate shaker at 250 rpm. They were 
subsequently rinsed for 10 minutes in 2mL of PBLEC solution, which was made using 
49.5mL of PBS (pH 6.8), 1% Triton and 1M each of CaCl2, MgCl2 and MnCl2. Griffonia 





a 1:100 dilution, dissolved in PBLEC solution. This specifically binds terminal α-
galactosyl residues expressed by various cells including, but not limited to, endothelial 
cells [437]. 
Overnight labelling was performed at 4°C, covered in foil to protect from light. This 
was followed by three washes with 0.2% Triton mixed in PBS, each for 20 minutes at 
room temperature. After the completion of staining, liquid was carefully aspirated 
from wells using a 1mL pipette. The orbit was partially cut using spring scissors at 12, 
3, 6 and 9 o’clock positions, which enabled the retina to remain intact but capable of 
flat mounting. This was achieved on a poly-L-lysine coated glass slide and after 
placement of a 22 x 22mm coverslip preloaded with Prolong Gold, specimens were 
sealed with nail varnish. Samples were covered in foil prior to imaging using a LSM880 
confocal microscope. This final step was performed by Dr Richard Cubbon to allow 
blinded imaging. 
 
4.5.4 Analyses of vasculature 
Analyses were performed with Image J software using reported methodology [436]. 
Individual sections of retina were imaged at 10X magnification to assess the primitive 
plexus at P5. Radial outgrowth was defined as the distance from the centre of the 
optic disc to the peripheral vasculature (in µm). For quantification of vascular area and 
branch points, a subjective region of interest was first established to differentiate 
frontal from central regions within each quadrant based on vascular density and 
extent of remodelling. ‘Vascular area’ was subsequently quantified as the proportional 





Magnified 0.04mm2 (200 x 200µm) regions of interest, set back 200µm from the 
vascular front between arteries and veins, were used for quantification of ‘branching 
points’. These were deemed to be at junctions of capillary segments. Tip cells were 
quantified per mm of ‘vascular front’, defined as the line connecting the bases of the 
sprouting endothelial cells. There are no specific criteria available for defining tip cells, 
as there is no data available on endothelial markers that selectively label sprouting tip 
cells [436]. Filopodia were quantified per 100µm of ‘angiogenic front’, and this was 
defined as the line navigating to the tip of the sprouts. Images were collected at a 40X 
objective. The average of multiple regions (≥ 4) per pair of retinas for each mouse was 







Figure 4-3 – Mounted retinas were stained with isolectin B4 (green) and analysed for  
the following parameters: radial outgrowth (Panel A), frontal and central vascular  
area (Panel B), number of branch points as depicted by white circle (Panel C) and  





4.6   HUVEC culture and manipulation 
4.6.1 Cell culture 
Human umbilical vein endothelial cells (HUVECs), as the name suggests, line single 
umbilical cord veins. In foetal development, this carries oxygenated blood from the 
placenta into the growing foetus and thus provides an useful analogue for adult 
human macrovascular endothelial cells. HUVECs are relatively cost-effective and 
isolation from umbilical cords is reasonably simple. They proliferate rapidly in defined 
tissue culture conditions and are therefore of particular use when performing 
functional in vitro assays. 
Healthy pooled donor samples were obtained commercially and maintained as 
aliquots in liquid nitrogen. At time of use, P2 aliquots were removed from storage and 
transferred in ice. After prompt defrosting of the 1mL sample in a water bath at 37°C, 
it was added to 9mL of M199 media. This had been pre-prepared and contained 
380mL of M199 basal media, 100mL of FBS, 10mL of 1M HEPES buffer, 5mL of AAS, 
10mL of sodium pyruvate, 2500 IU of heparin and 2.5mL of ECGS. After thorough 
vortexing, cells were divided equally into three 10cm petri dishes which had been pre-
coated with 0.1% gelatin. 6.67mL of M199 media was added to produce a total 
solution of 10mL in each dish. They were incubated at 37°C, with a full media change 
every 48 hours. Subsequently, either shRNA lentiviral transduction (see Section 4.6.3) 
or small molecule inhibition (SMI) (see Section 4.6.4) was performed prior to use in 







4.6.2 Cell counting  
For all the functional assays conducted with HUVECs, it was necessary to count 
absolute numbers of cells so that the correct amounts were used in individual 
experiments. To achieve this, one of the three 10cm petri dishes was washed twice in 
warmed, sterile PBS to remove media and debris. Specific volumes of 0.25% trypsin-
EDTA were added depending on the size of well (3mL for a 10cm petri dish, 1mL for a 
6-well plate), and incubated at 37°C for 2 minutes. Visualisation under light 
microscopy confirmed adequate detachment of cells, which were then neutralised by 
the addition of M199 media (5mL in the petri dish, 2mL in the 6-well plate). Samples 
were thoroughly mixed with a 10mL stripette prior to transfer into a 10mL Falcon tube 
for centrifugation at 400g for 5 minutes. The supernatant was carefully discarded and 
the resultant pellet reconstituted in 1mL of M199 media. This was vortexed prior to 
mixing of 20µL with an equivalent volume of trypan blue solution. This diazo dye 
traverses the cell membrane of dead cells (i.e. necrotic or apoptotic), conferring a blue 
colour to distinguish them from live cells which remain white. The mixture was 
injected carefully into a haemocytometer and by visualising the number of white cells, 
an extrapolated value could be used to quantify number of live HUVECs in 1mL. This 
enabled calculations to vary seeding densities depending on the assay performed. 
 
4.6.3 SHIP2 lentiviral transduction 
All work that included lentiviral transduction was conducted in a designated viral 
laboratory (‘Category 2’) with appropriate precautions taken at every step. Once cells 





lentivirus was used to transduce SHIP2-targeting shRNA or control green fluorescent 
protein (GFP)-targeting shRNA. This modality was preferred to small interfering RNA 
(siRNA), which requires higher dosage, has a higher likelihood of ‘off target’ effects 
and allows only transient knockdown [438]. The shRNA is an artificial RNA molecule 
with a tight hairpin turn. Once it has integrated into the host genome through its 
expression vector, i.e. lentivirus, there is nuclear transcription mediated by 
promoters. The resulting pre-shRNA is exported out of the nucleus and processed into 
a RNA-induced silencing complex (RISC). The antisense strand directs RISC to mRNA 
that has a complementary sequence. There is subsequent cleavage or regression of 
translation of the mRNA, in this case SHIP2, resulting in targeted gene silencing. 
 
 
Figure 4-4 – Schematic of shRNA-mediated lentiviral transduction. TRBP = Tat-RNA  





complex. Rao et al. Adv Drug Deliv Rev 2009; 61(9):746-59 [438]. 
 
Prior laboratory experience of shRNA lentiviruses enabled clarification that addition of 
10µL of shRNA to 300,000 cells results in 10 multiplicity of infection (MOI), i.e. 10 
vector particles per cell. This was used to calculate respective volumes of SHIP2 shRNA 
and control lentivirus that needed to be added to generate 5, 10 and 20 MOI, 
respectively. This was introduced directly into the petri dishes seeded with HUVECs 
using a sterile 200µL pipette, with gentle mixing for 45 seconds to ensure spatial 
distribution. After 24 hours, a full media change was performed and a further 3 days 
were allowed to elapse before splitting of cells for their respective assays. This was to 









Figure 4-5 – Timeline for HUVEC culture, lentiviral transduction and splitting for assays. HUVEC = human umbilical vein endothelial cells; shRNA =  






4.6.4 SHIP2 small molecule inhibition (SMI) 
This was performed on plated HUVECs without lentiviral manipulation. Firstly, dose 
response was assessed in the context of a mechanical scratch assay. Cells were split 
and seeded at 50,000 cells/well, with a minimum of 4 replicates, and grown to 
confluence. They were serum depleted using 1% FBS-containing M199 media for a 
duration of 4 hours. A mechanical wound was made with the tip of a 1000µL pipette 
to generate longitudinal scratches, washed in 100µL PBS and replaced with 300µL of 
2% FBS-containing M199 media, mixed with differing concentrations (0-20µM) of 
commercially available SHIP2 SMI for 18 hours duration. Two different types were 
used, AS1949490 and AS1938909, pre-dissolved in dimethylsulfoxide (DMSO) to 
generate a stock solution of 5mM. Control cells were exposed to an equivalent volume 
of DMSO without SMI. 10µM corresponds to maximum inhibition of SHIP2 in activity 
assays [370, 439] and was therefore used for statistical analysis and further functional 
assays.  
Exposure to the inhibitor was for the duration of the assay, i.e. 18 hours for scratch 
wound, 4 hours for 5-ethynyl-2’-deoxyuridine (EdU) proliferation, 6 hours for bead 
sprouting and 30 mins for GM130 staining. 
 
4.6.5 Nox2 and PI3K peptide inhibition 
In the case of the DHE assay to measure superoxide abundance in PECs and HUVECs 
(see Section 4.9), the influence of Nox2 was determined by addition of gp91ds-tat. 





appropriate selectivity for Nox2 [440]. Initially, 29mg was dissolved in a 1mL solution 
composed of 100mL distilled water, 0.9g sodium chloride and 57.5µL acetic acid, to 
produce a 10mM stock. This was diluted in M199 media to produce a working solution 
of 50µM. An equivalent scrambled peptide reconstituted in a comparable fashion was 
used as a control. These were added to the 10cm petri dishes on day 3 after lentiviral 
transduction, with exposure for 24 hours in total. 
To assess the effects of PI3K signalling on oxidative stress, two potent and selective 
PI3K inhibitors were utilised: Wortmannin (IC50 of ~ 3nM) and LY294002 (IC50 of 
0.5µM). Both were dissolved in DMSO as 10mM stocks and diluted to working 
solutions of 50nM and 5µM, respectively. The equivalent volume of DMSO was used 
as controls. Incubation was for 30 minutes and immediately preceded the DHE assay 
for PECs and HUVECs. 
 
4.7  Endothelial cell functional assays 
4.7.1   Scratch wound  
This was performed on HUVECs in a 0.1% gelatin-coated 96-well plate. Cells were 
initially seeded at 50,000 per well in quadruplicate, and allowed to grow to full 
confluence in 100µL M199 media for 24 hours. Once this had been achieved, cells 
were serum deprived by washing in PBS and adding 1% FBS-containing M199 media 
for a duration of 4 hours. A mechanical Woundmaker 96-pin device was used to 
generate homogenous, longitudinal cell-free scratch wounds in the centre of each 
well. Visualisation using a CKX-41 light microscope was conducted to ensure adequate 





with 100µL of PBS to remove floating cells and debris, and replaced with 300µL of 2% 
FBS-containing M199 media.  
Imaging was performed on each of the wells individually to obtain baseline images 
(t0). Two images per scratch at 40X magnification were obtained using the light 
microscope and Olympus Cell F software (v3.4). All samples were incubated at 37°C 
for 18 hours, followed by repeat imaging (t18). Image J software was utilised to 
quantify wound area at each time point. Subtraction of t18 from t0 enabled 










4.7.2   Boyden chamber 
HUVECs were defrosted, plated and exposed to shRNA as outlined previously. 
50ng/mL VEGF was pre-prepared by adding 3mL basal media to 7.5µL 100µg/mL 
human VEGF. A non-coated 24-well plate was used, with addition of either 750µL 
basal media and VEGF (as experimental) or 750µL basal media and DMSO (as control). 
A sterile polycarbonate insert with 8µm pores was carefully placed into each well 
using sterile forceps. Cells were split and counted, and 50,000 HUVECs suspended in 
500µL basal media were added to each insert. The plate was gently rotated to ensure 
that inserts were adequately bathed in basal media. The bottom of the plate was 
assessed to confirm absence of air bubbles.  
Cells were incubated at 37°C for 6 hours, following which inserts were transferred 
using forceps into separate wells and fully submerged in 750µL of 70% ethanol. Each 
insert was subsequently rinsed briefly in a clean beaker of water before placement in 
separate wells containing 750µL of distilled water. 300µL was additionally added to 
each insert. These were then removed and a cotton bud used to thoroughly clear the 
inner surface and remove non-migrating cells. Inserts were re-rinsed in fresh water. 
Cells were sequentially stained with haematoxylin and eosin by placing for 30 seconds 
in wells containing 750µL of one then the other, with a wash in between, before 
rinsing and imaging.  
This was performed using the CKX-41 light microscope at 20X magnification, with data 
storage using Olympus Cell F software. Five images were obtained per well, with 
specific avoidance of peripheries where cells clump due to incomplete wiping of the 





cytoplasm. Abundance was determined using Image J software, and data expressed as 
net migration by subtracting mean number of visualised cells in the control wells from 
those containing VEGF. 
 
 
Figure 4-7 – Representative image from Boyden chamber assay with visualisation of  
circular pores and migrant HUVECs. 
  
4.7.3   5-ethynyl-2’-deoxyuridine (EdU) incorporation 
4.7.3.1 Click-iT kit 
This assay was performed with manipulated HUVECs (shRNA or SMI) on 0.1% gelatin-
coated 6-well plates. Cells were initially seeded at 100,000 cells/well in 1mL M199 
media, with 3-4 replicates, and incubated for 48 hours which ensured ~ 80% 
confluence (based on prior optimisation experiments in our laboratory). Reagents 
were obtained commercially from a Click-iT EdU Alexa Fluor 647 flow cytometry kit. 





fixative, saponin-based permeabilisation and wash reagent, EdU buffer additive and 
500µL of 100mM copper sulphate (CuSO4).  
Measurement of DNA synthesis provides a marker of active proliferation. EdU is a 
nucleoside analogue of thymidine and is incorporated into DNA during synthesis. 
Detection is based on a copper-catalysed covalent reaction between azide (Alexa Fluor 
647) and alkyne (EdU). Unlike older assays, there is no denaturation step and 
therefore, integrity of double-stranded DNA is not compromised to improve 
reproducibility. Moreover, EdU assays utilise biologically unique moieties which 
produce low background noise and high detection sensitivities. DMSO is a solvent 
used to facilitate the entry of organic molecules into cells. 
Prior to commencement, working solutions for some of these reagents were 
prepared. 4mL of DMSO was added to EdU to produce a 10mM stock solution which 
was stored at -20°C. Similarly, 130µL of DMSO was added to Alexa Fluor 647 azide and 
again stored in the freezer until use. A 10x stock solution of the EdU reaction buffer 
additive for freezer storage was made through addition of 2mL of deionised water. 
Lastly, the saponin-based permeabilisation and wash reagent was diluted 1:10 in 1% 
PBS/BSA and this was stored with the remainder of the reagents in a fridge set at 4°C. 
All experimentation from this point onwards was performed in a low light 
environment.  
Initially, 10µM EdU was added and mixed in each well with incubation at 37°C for a 
period of 4 hours. Media was aspirated and cells washed twice in PBS to remove 





cells. After direct visualisation under CKX-41 light microscopy to confirm cell 
detachment, the solution was neutralised with 2mL M199 media and centrifuged at 
400g for 1 minute to discard the supernatant from the cell pellet. There was a further 
wash step with 3mL of 1% PBS/BSA with repeat centrifuging to enhance purity of 
isolated samples.  
100µL of the PFA-based fixative was added and mixed for 15 minutes at room 
temperature. After a further wash and centrifuge, the pellet was re-suspended for 15 
minutes in 100µL of saponin-based permeabilisation and wash reagent which 
contained 0.5% Triton X-100 (sodium azide in BSA). During this incubation period, the 
Click-iT reaction cocktail was produced, as outlined in Table 4-4. A working solution of 
EdU reaction buffer additive was generated by diluting the original 10x stock using a 
1:10 ratio in deionised water. 500µL of this reaction mix was added to each sample 
with a further incubation for 30 minutes. On completion, there was one last wash with 
3mL of saponin reagent and after a final centrifuge, samples were re-suspended in 









Reagents Number of reactions 
2 5 10 
PBS 875µL 2.19mL 4.38mL 
Copper sulphate 20µL 50µL 100µL 
Alexa Fluor 647 azide 5µL 12.5µL 25µL 
Reaction buffer additive 100µL 250µL 500µL 





Table 4-4 – Components of Click-iT reaction cocktail. PBS = phosphate buffered  
saline. 
 
4.7.3.2 Flow cytometry 
This was performed using a BD-LSR Fortessa flow cytometer, with analysis using 
FACSDiva software to quantify the proportion of proliferating cells in each sample (i.e. 
those that had incorporated EdU). All samples were thoroughly mixed prior to loading 
into fluorescence-activated cell sorting (FACS) tubes. The flow cytometer is able to 
generate a column of fluid, which is converted into single cell droplets via 
hydrodynamic focusing. A laser beam is used to excite cells with specific fluorochrome 
labelling with quantification of emitted light from each cell. Alexa Fluor 647 was 
utilised as it has photostability, a high Stokes shift (excitation 634nm, emission 
660nm) and distinct profile for ease of identification. Prior to formal analysis, a plot of 
side scatter area (SSC-A) versus forward scatter area (FSC-A) was visualised to identify 
the homogenous cell population of interest, and to exclude the remainder which are 
likely to constitute dead cells (low FSC, low SSC) and clumped cells (non-proportional 
FSC-A [area] and FSC-H [height]). The first 10,000 cells in the sample mixture were 
used for analysis purposes. Gating criteria were used to differentiate proliferating cells 







   
          
Figure 4-8 – Flow cytometer analysis. Homogenous HUVEC population of interest  
identified, depicted by gating as P1 (Panel A). Linearity of distribution established  
based upon area and height to ensure elimination of clumped cells (Panel B). Cell  
count histogram used to establish proliferating cells (P2) which could be quantified as  
proportion of total (Panel C). FSC = forward scatter; SSC = side scatter; APC =  
allophycocyanin. 
 
4.7.4  Bead sprouting 
4.7.4.1 Coating with HUVECs 
To allow greater control of media composition, EGM-2 basal media was used rather 





hydrocortisone, 2mL human FGF, 0.5mL VEGF, 0.5mL IGF-1, 0.5mL ascorbic acid, 
0.5mL human EGF, 0.5mL GA-1000 and 0.5mL heparin. Cells were trypsinised and 
quantified using the haemocytometer. 10 wells of a 24-well plate were used per 
condition, with 100,000 cells per well. The desired number was reconstituted in 1.5mL 
EGM-2 media for later use.  
Commercially-obtained cytodex-3 polystyrene beads were utilised. These were 
sourced as 0.5g dry aliquots which were reconstituted in a Falcon tube with 50mL PBS 
and mixed on a rocker at room temperature for 3 hours. Following this, the beads 
were allowed to settle for 15 minutes. The supernatant was discarded and the beads 
washed in 50mL of fresh PBS. They were then re-suspended in 25mL PBS to produce a 
20mg/mL working solution containing 60,000 beads/mL. This was placed in a 
siliconized glass bottle and autoclaved prior to storage at 4°C. 
At time of use, cytodex-3 beads were agitated and the desired volume pipetted 
carefully into a 1.5mL microcentrifuge tube. For use of 20 wells (10 per condition), this 
equated to 84µL with approximately 400 cells/bead. They were allowed to settle for 5 
minutes, with the supernatant subsequently discarded. Beads were re-suspended in 
1mL EGM-2 media, and left to settle for 5 minutes prior to aspiration. The aliquoted 
cell suspension was added to the beads and the resultant solution carefully pipetted 
into an autoclaved FACS tube. It was placed in an incubator at 37°C for 4 hours, with 
gentle mechanical agitation of the base every 20 minutes. Once complete, the 
solution was carefully transferred into a T25 cell culture flask. Further EGM-2 media 






4.7.4.2 Embedding in fibrin gel 
First, 2mg/mL fibrinogen was made by reconstitution in distilled PBS and maintenance 
in a water bath at 37°C for 5 minutes. A 0.2µm filter was used to sterilise the solution. 
6mL of fibrinogen solution was used for 10 wells, corresponding to approximately 
500µL per well after accounting for loss during filter sterilisation. 4U/mL aprotinin was 
produced by reconstituting 10mg in 10mL distilled water and passing through a 
sterilisation filter. 0.15U/mL was added to the fibrinogen solution and set aside. The 
T25 flask was gently tapped to dislodge the coated beads, which were gently aspirated 
into a 15mL Falcon tube using a stripette. The flask was washed twice with 3mL EGM-
2 media to enable transfer of any residual beads. Beads were allowed to settle for 5 
minutes, with the media subsequently aspirated and re-suspended in 1mL EGM-2 
media. 3 subsequent washes with 1mL media was performed. 
At this point, wells were prepared by adding 12.5µL of 50U/mL thrombin to the centre 
of each well. After the final wash, coated beads were re-suspended gently in the 
fibrinogen/aprotinin solution and transferred to a 15mL Falcon tube. The solution was 
gently pipetted to ensure adequate mixing, followed by addition of 500µL to each well 
directly onto the pre-deposited thrombin. The suspension was spread evenly with a 
cautious approach to avoid introducing air bubbles. The thrombin converts fibrinogen 
into fibrin, which produces a solidified matrix which the beads are embedded in. To 
facilitate this, the plate was left undisturbed for 5 minutes followed by cautious 
transfer to an incubator for 15 minutes. 1mL of EGM-2 media was then added to each 






4.7.4.3 Imaging of sprouts 
After a period of 24 hours, imaging was performed using a Olympus CKX-41 light 
microscope, with storage of data using Olympus Cell F software. 10 individual beads 
were imaged per condition. Analysis was conducted using Image J software, with 
calculations of mean number of sprouts per bead and sprout length. Divergent sprouts 
were considered as separate if the length distal to their branch point was > 50% of the 
total sprout length.  
 
 
Figure 4-9 – Representative image of cytodex-3 bead with cell sprouting.  
Measurement of sprout length depicted (black arrow).  
 
4.8  Immunofluorescence 
4.8.1 Lamellipodial staining 
Cells were defrosted and plated, before being exposed to control or SHIP2 shRNA 
lentivirus (as described in Section 4.6.3). Cells were subsequently split onto pre-coated 
35mm imaging dishes at a density of 15,000 per dish, and maintained in 1% FBS-





vehicle control, was added to each sample for 30 minutes, followed by fixation with 
PFA. Permeabilisation was performed with 0.25% Triton X-100 in PBS for 30 minutes, 
followed by 3 wash steps in PBS. Lamellipodial staining was achieved by the addition 
of phalloidin at a 1:50 dilution, mixed in 1% PBS/BSA, that had been commercially 
purchased in a pre-conjugated form bound to Alexa Fluor 647. Phalloidin binds 
filamentous actin at the interface between subunits and prevents filament 
depolymerisation [441]. Samples were kept overnight at 4°C covered in foil, followed 
by further washes and maintenance in fresh PBS until imaging of single cells with 
LSM880 confocal microscopy. This step was performed by Dr Richard Cubbon. Analysis 
was conducted using Image J software, with assessment of cell parameters including 
total area and perimeter, lamellipodial area and perimeter, and a crude assessment of 
lamellipodial distribution based on arbitrary quadrants (with Q1 designated as the one 
with the greatest proportion of lamellipodia and Q4 with the least). This was 
performed in a fashion broadly consistent with published techniques [442]. 






Figure 4-10 – Representative image of single HUVEC stained with phalloidin (red).  
Whole perimeter of cell depicted (white) with concentrated region of phalloidin  
representing lamellipodia (example shown in yellow). Cell was split into quadrants  
(Q1-Q4) to quantify lamellipodial distribution.  
 
4.8.2 GM130 staining 
HUVECs were plated in triplicate in imaging 24-well plates for 24 hours to achieve 
confluence. On the day of assessment, serum starvation was performed in 1% FBS-
containing M199 media for 4 hours, proceeded by a mechanical scratch using the tip 
of a 1000µL pipette. After incubation for 30 minutes, cells were fixed in 4% PFA at 
37°C for 10 minutes and stored in PBS. At time of staining, initial permeabilisation was 





conducted at 4°C for 1 hour. Cells were subsequently incubated with mouse anti-
GM130 antibody pre-conjugated to Alexa Fluor 488 at 5 µg/mL (1:200 dilution) and 
left overnight wrapped in foil on a microtitre plate shaker in the cold room. GM130 is 
homologous to the Golgi autoantigen golgin-95 and operates as a structural element 
of the Golgi apparatus, in addition to providing attachment sites for membranes and 
other proteins. Notably, the monoclonal anti-GM130 antibody interacts regardless of 
phosphorylation status. 
After three 5 min washes in PBS, phalloidin pre-conjugated to Alexa Fluor 647 was 
added at a 1:50 dilution in 1% PBS/BSA and kept for 24 hours on the shaker. After 
three subsequent washes, Hoescht 33342 was used for nuclear staining at a 1:2000 
dilution in PBS, added for 15 minutes at room temperature. After one last set of 
washes in PBS, the samples were stored in PBS at 4°C until time of confocal imaging. 
This final step was performed by Dr Richard Cubbon. 
Each cell on stored images was analysed using Image J software. Specifically, the 
angulation of the Golgi apparatus relative to the nucleus was determined                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
to establish overall direction of cell polarity, with a horizontal direction towards the 
scratch being considered as 0°C. This was repeated for each individual cell, both in 
images obtained at the site of scratch and also in remote areas that were fully 
confluent. Cells were determined to be forward facing (i.e. towards the site of scratch) 







Figure 4-11 – Confluent HUVECs adjacent to site of mechanical scratch, with staining  
of filamentous actin (red), Golgi apparatus (green) and nuclei (blue). The relative  
position of the Golgi apparatus to the nucleus was used to establish cell directionality,  
and this was repeated for individual cells to quantify proportion that were forward  
facing. 
 
4.8.3 SHIP2 staining 
HUVECs were defrosted and plated as described, but without exposure to lentivirus or 
SMI. Once culture dishes were 80% confluent, cells were trypsinised and counted. 
100,000 cells were plated onto pre-coated 35mm imaging dishes, with repeated 
pipetting performed prior to extraction to avoid clumping. Cells were subsequently 
serum starved in 1% FBS-containing M199 media for 4 hours. A longitudinal scratch 
was subsequently made mechanically using the tip of a 1000µL pipette, followed by 
incubation at 37°C in 2% FBS-containing M199 media for either 30 mins or 1 hour. 





500µL of pre-warmed 4% PFA for 10 minutes at 37°C. Samples were stored in a fridge 
at 4°C until time of staining. At this point, cells were permeabilised in 0.25% Triton-
X100 (made using 125µL Triton, 50mL PBS, 0.5g BSA and 250µL goat serum to block 
non-specific binding) and left at 4°C for 1 hour. Three washes in 1mL 0.1% PBS/BSA 
were conducted to remove debris and enhance image quality, with 5 minute durations 
between each.  
Rabbit anti-SHIP2 primary antibody (ab166916) was added at 1:100 dilution in the 
permeabilisation/blocking buffer. This was left overnight at 4°C prior to 3 washes in 
PBS adhering to the regimen above. Subsequently, goat anti-rabbit secondary 
antibody pre-conjugated to Alexa Fluor 647 was introduced as the secondary 
antibody, at a 1:200 dilution in the permeabilisation/blocking buffer, prior to 
incubation at room temperature for 1 hour whilst covered in foil. After 3 further 
washes in PBS, fluorescein isothiocyanate (FITC)-conjugated Ulex Europaeus was 
added at 10µg/mL (1:100 dilution), mixed in PBS, and incubated for 1 hour at room 
temperature to label the cell membrane. This is a glycoprotein known to interact with 
-L fucosyl residues in oligosaccharides on the membranes of human endothelial cells 
in addition to red blood cells (erythrocytes) and a variety of human and animal 
epithelial cells [443]. After three further washes, Hoescht 33342 at 1:2000 dilution 
mixed in PBS was added for 15 minutes at room temperature.  
After a final set of washes, samples were maintained in 2mL of fresh PBS to prevent 
drying of cells and left in a light-protective environment until time of confocal imaging 
using 80X magnification. This was performed by Dr Richard Cubbon no later than two 





case of negative controls, the above protocol was adhered to with precision but no 
primary antibody was included.   
 
4.9  Dihydroethidium (DHE) assay 
For this assay, cells were seeded onto a clear 96-well plate at a concentration of 
50,000 PECs or 30,000 HUVECs per well. No pre-coating with gelatin was performed 
based on prior optimisation experiments. 100µL of respective media (i.e. MV2 or 
M199) was added and cells incubated for 24 hours at 37°C to enable confluence to be 
reached. 4 unlabelled/control and 4 labelled wells were required for each sample, 2 of 
each receiving gp91ds-tat (or scrambled peptide), or one of the PI3K inhibitors in a 
separate experiment. All conditions also had 2 replicates, making use of 16 wells in 
total per experiment.  
The assay required use of DHE to quantify superoxide abundance. In its presence, DHE 
is oxidised into 2-hydroxy-ethidium. This integrates into cellular DNA and stains the 
nucleus red, which enables indirect superoxide quantification. DHE was purchased as 
a 5mM stock dissolved in DMSO, and diluted 1:200 in sterile Krebs-HEPES buffer to 
produce a working solution of 25µM. This buffer contained various constituents as 
outlined: sodium chloride (99mM), potassium chloride (5mM), dipotassium phosphate 
(1mM), sodium bicarbonate (25mM), magnesium sulphate (1mM), calcium chloride 
dehydrate (3mM), HEPES-sodium salt (20mM) and glucose (6mM).  
All wells were washed with 100µL of PBS. ‘Unlabelled’ control wells were replaced 





M199 media could not be utilised as a suitable vehicle because it generated 
autofluorescence in preliminary experiments due to the phenol red. After gentle 
mixing, the plate was incubated at 37°C for 20 minutes. This was followed by two 
washes in PBS, and replacement with 100µL of fresh Krebs-HEPES buffer. Transfer for 
analysis was in tin foil to protect from light.  
A Flex Station 3 microplate reader was used with processing in SoftMax Pro to enable 
quantification of fluorescence. This was performed at excitation of 500nm and 
emission of 600nm to capture 2-hydroxy-ethidium fluorescence. A run time of 3 
minutes was conducted for each well, with readings at 10 second intervals. Prior 
studies have confirmed that the fluorescent signal does not decay over this time 
period. A mean of all readings allowed calculation of an average value for each well, 
and ‘unlabelled’ values were subtracted from ‘labelled’ to obtain net fluorescence.  
 
4.10  Western blotting 
4.10.1 Preparation of lysates 
PECs were derived from 10 month old ECSHIP2Δ/+ mice to validate SHIP2 knockdown 
and measure basal Nox2 protein expression. These cells were initially grown to 
confluence in individual wells of a 6-well plate. At time of lysate preparation, they 
were washed in 2mL of PBS to remove excess media followed by two washes in ice-
cold PBS (containing calcium and magnesium), each for a duration for 5 minutes, to 
arrest cellular processes. 100µL of cell extraction buffer was added, made from 50mM 
stock, with the addition of 10µL each of 1% protease and phosphatase inhibitor 





scrapers. Samples were immediately transferred to 0.5mL microcentrifuge tubes and 
stored at -40°C until time of Western blotting.  
A similar approach was used for HUVECs, which had been transduced with 
appropriate shRNA viruses (see Section 4.6.3). These lysates derived from confluent 
wells were used to assess extent of SHIP2 knockdown at differing lentiviral MOI, basal 
Nox2 protein expression and downstream signalling intermediates such as total and 
phosphorylated AKT, eNOS and ERK. Lastly, organs were harvested from SHIP2iΔ/+ mice 
to confirm adequate knockdown of the SHIP2 catalytic domain. This was conducted 
once metabolic testing had been completed, and immediately subsequent to Sch1 
using the CO2 chamber as described. White adipose tissue (WAT) and tissue from liver, 
aorta and skeletal muscle (quadriceps) was harvested, prior to transfer into 1.5mL 
microcentrifuge tubes and storage at -40°C until time of requirement. 
 
4.10.2 Protein quantification 
PEC and HUVEC lysates were removed from storage and allowed to defrost on ice for 
30 minutes. In the case of tissue samples, they were kept in ice until thawed. Once 
achieved, 30mg was isolated and mixed with 400µL of cell extraction buffer mixed 
with both protease and phosphatase inhibitors. A 6mm cone ball was added to each 
sample and homogenised using a tissue lyser for 15 seconds at a frequency of 
30/second. This was repeated twice. The lysate was pipette transferred into fresh 
1.5mL microcentrifuge tubes and vortexed, prior to storage on ice for 30 minutes with 





rpm for 45 minutes at 4°C, with 100µL of the remaining supernatant transferred to 
fresh tubes.   
Protein quantification was achieved using a bicinchoninic acid (BCA) assay kit in a 96-
well plate format. Firstly, 8µL of each of the supernatant was mixed with 56µL of RIPA 
buffer (i.e. 1:8 ratio) and briefly vortexed. These were pipetted in duplicates as 25µL 
aliquots into individual wells. Nine standards of BSA at known concentrations were 
also loaded, again in duplicate. The assay kit relied on two reagents for colorimetric 
analysis: Reagent A (sodium carbonate, bicinchoninic acid and sodium tartrate in 0.1M 
sodium hydroxide) and Reagent B (4% cupric sulphate). These were mixed in a 50:1 
ratio and 200µL individually added to each well. The plate was covered with a lid and 
incubated at 37°C for 30 minutes. A Dynex MRX TC microplate reader with Revelation 
software was used for analytic purposes, at a wavelength of 562nm. Use of BSA 
standards enabled construction of a standard curve, which was appraised for linearity 
by quantification of the correlation coefficient (r2) and accepted when > 0.99. Protein 
concentrations were derived from use of this curve, with values only accepted when 
the coefficient of variation between duplicate samples was < 10%.  
 
4.10.3 SDS-polyacrylamide gel electrophoresis 
The calculated concentration (in µg/mL) was used to establish sample volumes 
equating to 30µg protein (cell samples) and 50µg protein (tissue samples), accounting 
for the 1:8 dilution during protein quantification. This was mixed with loading buffer 
(1:4 dilution) and reducing agent (1:10 dilution), and topped up with cell extraction 





a heating block set at 95°C for 5 minutes, prior to loading onto a 4-12% Bis-Tris 
polyacrylamide gel. 3.5µL of a marker was loaded for reference purposes. The gel was 
placed in a Criterion Cell tank. 500mL of running buffer was produced in a conical flask 
by mixing 25mL of 2-(N-morpholino)ethanesulfonic acid/sodium dodecyl sulphate 
(MES SDS) with 475mL of deionised water, and subsequently poured gently into the 
tank. Electrophoresis was conducted at 180V for 1.5 hours. The gels were visually 
checked every 30 minutes to ensure that samples were running correctly.  
 
4.10.4 Membrane transfer 
Once complete, the gel was briefly washed in deionised water. The iBlot system was 
used to transfer proteins onto a polyvinylidene fluoride (PVDF) membrane. First, 
transfer buffer was made from a 10X stock solution composed of 6.06g tris, 29g 
glycine, 400mL methanol and 1600mL distilled water. A transfer tank was set up with 
a metal stirrer. The transfer membrane was activated with sequential spraying of 
methanol and transfer buffer, with direct visualisation of air bubbles used for 
confirmatory purposes. The membrane was soaked in transfer buffer, as were the 
sponges and filter paper. The pack was assembled within the cassette so that the gel 
and membrane were flanked on each side by filter paper, which were themselves 
encompassed by sponges. A plastic roller was used to remove any air bubbles that 
may ordinarily prevent adequate transfer. The cassette was placed in the transfer tank 







4.10.5 Immunostaining for signalling components 
After transfer, the membrane was carefully removed from the cassette and allowed to 
dry on tissue paper. It was then washed in a blocking solution containing 5% BSA in 
0.1% Tween for 5 minutes, before being cut at appropriate regions to enable 
simultaneous staining for multiple signalling components of varying molecular 
weights. Membranes were then incubated at room temperature on a shaker in 15mL 
of Tween/BSA for 1 hour to prevent non-specific antibody binding.  
After discarding the solution, the relevant primary antibodies were prepared in 
Tween/BSA at the appropriate dilution (see Table 4-5). β-actin was used as a control. 
Incubation was overnight at 4°C. After washing the membrane three times in 0.1% 
TBST, each for 5 minutes, appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibodies were prepared. This was applied to the membrane for 1 hour at 
room temperature, prior to three subsequent washes in Tween of 15 minutes 
duration. The membrane was transferred onto cling film and carefully flattened. 
Visualisation of protein bands was achieved via enhanced chemiluminescence, 
through addition of 1mL of Immobilon Western Chemiluminescent HRP Substrate 
containing 500µL peroxide solution and 500µL enhancer solution. Imaging was 
performed using a camera scanner (Image Station 2000R) with densitometric analysis 
using Syngene GeneTools software. 
 
4.10.6 Stripping membrane 
Assessment of phosphorylated protein levels was generally performed first. However, 





membrane by application of a Western blot Restore PLUS stripping buffer. 
Membranes were washed in TBST to remove excess substrate solution, and 
subsequently incubated in 10mL of stripping buffer at room temperature for 10 
minutes with gentle agitation. After three 5 min washes in TBST, 5% TBST-BSA was 










Β-actin Mouse 1:3000 43 Cell Signalling #4970 
Mouse SHIP2 Rabbit 1:1000 160 Gift from Stephane 
Schurmans, University 
of Liege 
Human SHIP2 Rabbit 1:1000 139 Abcam ab166916 
Nox2 Mouse 1:1000 65 Abcam ab129068 
Total AKT  Mouse 1:1000 60 Cell Signalling #4685 
pAKT (T308) Rabbit 1:1000 60 Cell Signalling #4060 
Total eNOS Mouse 1:1000 140 BD Biosciences #610296 
peNOS (S1177) Rabbit 1:1000 140 BD Biosciences #612393 
Total ERK Mouse 1:1000 42 Cell Signalling #9102 









Table 4-5 – Primary and secondary antibodies used for Western blotting. 
 
4.11 Tamoxifen induction 
The utilisation of Cre to mediate recombination between its loxP target sites has 
transformed genomic manipulation of mice [444]. Its inducible nature enables 
temporally controlled modulation of the genome. Generation of the SHIP2iΔ/+  colony 
involved ubiquitous expression of a mutated fusion protein of Cre and the human 
oestrogen receptor (Cre-ERT2+/0) [433]. As mentioned, this protein was driven by a 
CAG promoter-enhancer which was insensitive to endogenous oestrogens. Instead, 
rapid and efficient Cre-mediated recombination could be induced by administration of 
tamoxifen [433].  
In view of its hazardous nature and potential teratogenic effects, protected handling 
of tamoxifen was conducted in a fume cupboard at all times. Samples were initially 
produced at a concentration of 10 mg/mL, dissolved in corn oil, and maintained as 
1mL aliquots. They were thoroughly vortexed prior to incubation at 37°C overnight to 
enable proper dissolution of crystals, and kept as 1mL aliquots at 4°C until use. In view 
of its degradation by bright light, vials were wrapped in aluminium foil. Injections 
were performed in a designated facility with strict adherence to local regulations, 
including use of gown and skin protection using a double-gloved technique when 
handling.  
Secondary antibody Dilution Manufacturer 
Polyclonal goat anti-mouse IgG 1:20000 Dako #P0161 





Mice were selected for experimentation based on genotype confirmed via polymerase 
chain reaction (PCR). Additionally, they were required to be of a weight > 24 grams to 
tolerate the procedure, with a typical age of 9 weeks. Once identified, they were 
separated into a distinct cage and transferred to the facility a day prior so that they 
were accustomed to surroundings. Tamoxifen was injected intraperitoneally (IP) at a 
concentration of 40 mg/kg for five consecutive days. Cre-positive control mice were 
exposed to an identical regimen, but their absence of loxP sites prevented targeted 
recombination. After the final injection, mice were maintained in their usual 
environment and monitored on a daily basis for a week. They were subsequently 
transferred to fresh cages in preparation for further testing.  
 
4.12 Metabolic profiling 
4.12.1 Gross body weights 
All metabolic profiling was performed on SHIP2iΔ/+ mice. They were weighed using 
electronic scales on a weekly basis from 1 to 3 months of age. This included baseline 
weights at commencement of tamoxifen induction to ensure that dosing was 
appropriate and tolerable. Measurements were also undertaken at the end of the 5 
day course to ensure that the induction regime had not compromised growth. If 
multiple readings were taken within a particular week, the mean value was used for 
statistical purposes. 
 





This was performed after overnight fasting, with transfer into new cages conducted to 
prohibit consumption of chow fragments on cage floors. Access to water was 
maintained throughout. On the day of testing, which occurred at 8am, 20% glucose 
was made by filtering 2g of glucose into 10mL of sterile PBS and vortexing thoroughly 
to ensure adequate dissolution. This was transferred to the animal facility in ice.  
To calculate required volumes, a baseline weight was obtained for each mouse in 
grams, and this value was multiplied by a factor of 4 to produce a volume (in µL) 
equating approximately to 1mg/g. Capillary blood sampling was performed by 
obtaining blood droplets from a superficial tail incision, performed using a sterile size 
22 scalpel. Mice were consciously restrained in a plastic box with protective padding 
and a small hatch to adequately expose the tail. Readings were processed using a 
glucometer and Accu-Chek testing strips.  
At commencement, a baseline blood glucose reading provided a fasting glucose value 
(in mM). Subsequent IP injection of glucose at the desired volume was conducted, 
with restraining of mice by a scruffing technique. This was followed by repeat glucose 
readings at 30 minutes, 60 minutes, 90 minutes and 120 minutes. Sampling was 
invariably achieved using the original tail incision with gentle massaging, but if this 
proved troublesome, a further incision proximal to the initial site was performed. 
Gentle mopping of dried blood ensured that fresh samples were being tested at each 
individual time point. Between readings, mice were relocated to their original cages 
and maintained in a quiet environment so that distress was minimised. Throughout 
this period, access to water was maintained but they remained fasted until 





evidence of symptomatic hypoglycaemia, such as somnolence or seizures, blood 
testing was immediately performed and if this was < 2mM, a repeat injection of IP 
glucose was administered and mice excluded from further testing. At the end of the 
experiment, tail tips were assessed to ensure adequate haemostasis and mice 
transferred to fresh cages with free access to chow.  
 
4.12.3 Insulin tolerance testing (ITT) 
ITT was performed one week after GTT to ensure normalisation of metabolic and 
haemodynamic physiology, and to allow adequate healing of tissue within the tail tip. 
The protocol was comparable to GTT, but mice were fasted from 8am for 2 hours only. 
Human recombinant insulin solution was produced by mixing 20µL of 100 IU/mL 
Actrapid in 10mL of sterile PBS. The sample was vortexed before transfer in ice. 
Baseline weights were utilised once more to calculate injecting volumes, which was a 
3.75 multiplication of body weight in grams. This derived an administration dose of 
0.75 IU/kg. Once again, a fasting glucose measurement was obtained prior to IP 
administration of insulin. This was followed by subsequent readings at stages of 30 
minutes, 60 minutes, 90 minutes and 120 minutes. Glucose solution was kept readily 
available at all times, and mice were observed stringently in case of significant 
hypoglycaemia. Similar animal husbandry to GTT was observed at the end of 
experimentation. Euthanasia was then performed using Home Office approved 
scheduling as outlined previously.  
 





This was derived from SHIP2iΔ/+ mice that had undergone tamoxifen induction but no 
prior metabolic testing. Mice were fasted overnight prior to intra-cardiac puncture 
under isoflurane anaesthesia, with a 27G needle attached to a 1mL syringe that was 
pre-filled with 100µL of 1000 IU/mL sterile liquid heparin. This enabled collection of 
800-900µL whole blood into 1.5mL microcentrifuge tubes, of which a drop was 
applied onto a Accu-Chek testing strip and processed using a glucometer to derive a 
corresponding blood glucose reading in mM. The remainder of the samples were 
transferred on ice and centrifuged at 6000 rpm for 5 minutes to isolate plasma from 
cell debris. Samples were stored at -80°C until time of use. 
An ultra-sensitive mouse insulin ELISA kit was used for quantification of plasma 
insulin, with ‘low-range’ assay conditions (defined as 0.1-6.4 ng/mL). All reagents were 
brought to room temperature prior to use. The lyophilized mouse insulin standard 
was reconstituted in 100µL distilled water to produce a stock solution containing 
25.6ng/mL of mouse insulin, which was then serially diluted. 5µL of each standard was 
dispensed in duplicate into wells of a microplate which was pre-coated with guinea pig 
anti-insulin antibody and loaded with 95µL of sample diluent. This enabled a standard 
curve to be constructed, and the remaining wells were filled in duplicate with 5µL of 
each sample. The microplate was incubated for two hours at 4°C, before aspiration of 
well contents and five washes with 300µL wash buffer to remove unbound material. 
Once complete, 100µL of horse radish peroxidase (POD)-conjugated anti-insulin 
antibody solution was dispensed and incubated for 30 minutes at room temperature. 
Wells were subsequently washed seven times to remove excess POD-conjugate, prior 





Samples were covered in foil to protect against light and incubated for 40 minutes at 
room temperature. The reaction was terminated with 100µL of enzyme reaction stop 
solution, and absorbance was measured for individual wells within 30 minutes using a 
96-well DMX TC microplate reader.  
Analysis was performed using Revelation software with colorimetric analysis at 450nm 
wavelength. A linear fit for the insulin standard curve was constructed by plotting the 
mean absorbance for each standard (y axis) against the corresponding standard 
insulin concentration (x axis). This was accepted if the correlation coefficient (r2) 
exceeded 0.99. It was utilised to derive mean plasma insulin concentrations for each 

















4.12.5 Homeostasis model assessment (HOMA) 
Readings derived from fasting glucose and insulin measurements were applied to a 
homeostatic model (HOMA-IR) to enable a crude quantification of systemic insulin 
resistance. The accuracy and precision of this estimate has been corroborated with 
use of euglycaemic clamps (r = 0.88), albeit only in humans and reliant on the 
hypothesis that basal glucose and insulin interactions are primarily determined by a 
simple feedback [445]. 
The following formula was applied: 
    HOMA-IR  =    Glucose (mmol/L)  ×  Insulin (U/L)  
                       22.5 
 
4.13 Angiogenesis after hindlimb ischaemia 
In vivo assessment of the angiogenic phase of vascular regeneration after hindlimb 
ischaemia was performed in the SHIP2iΔ/+ colony. Mice were 11 weeks of age to 
enhance likelihood of tolerating the procedure. Initially, at 9 weeks, a 5 day course of 
IP tamoxifen was administered as outlined previously. After the final dose, mice were 
observed for a period of 1 week. At this stage, surgery was performed in designated 
operating theatres using inhalation of isoflurane anaesthetic. This procedural work 
was performed by Dr Nadira Yuldasheva, and is consistent with techniques published 






4.13.1 Induction of anaesthesia 
24-48 hours pre-procedure, mice were shaved bilaterally from the lower abdominal 
wall to hindlimbs using an electric razor followed by topical application of Veet cream 
to remove residual fur. Mice were placed in an induction chamber and exposed to 5% 
isoflurane with concurrent administration of oxygen at 2L/min. Isoflurane was chosen 
due to its volatile properties allowing rapid induction and recovery. Adequate 
anaesthesia was confirmed by loss of muscle tone and absence of purposeful 
movements, in conjunction with changes in depth and frequency of respiration and a 
lack of response to averse stimuli such as tail pinch. Mice were transferred to the 
operating table, which had been pre-warmed to 38°C, and connected to a nose cone, 
which emitted 2% isoflurane that had been diverted away from the induction 
chamber via a valve. They were secured in a supine position using microporous 
surgical tape and injected with additional analgesia using IP buprenorphine at 
0.25mg/kg. Depending on feedback from the mouse’s behaviour, the concentration of 







Figure 4-13 – Apparatus for general anaesthesia. 
 
4.13.2 Femoral artery excision 
Once adequately anaesthetised and secured onto the operating table, the area of 
interest was disinfected with 0.75% povidone-iodine solution. An incision in the mid-
thigh was made through the skin layers to enable exposure of the left femoral artery. 
Vicryl sutures were applied proximally at the level of the inguinal ligament and distally 
at the bifurcation of the saphenous and popliteal vessels. This enabled ligation of the 
femoral artery, which could subsequently be excised as a whole intervening segment. 
This is a standard procedure performed in our facility, and laser Doppler imaging has 
shown that it reduces distal limb perfusion to < 10% of the contralateral limb. The 
wound was closed in layers using a continuous 6.0 Vicryl suture. The right limb was 
used for control purposes and did not undergo any procedure. After discontinuation 





administered for post-operative analgesia. This was followed by a period of monitored 
recovery, with the provision of a soaked diet for 24 hours prior to transfer into their 
usual cages. 
 
4.13.3 OCT embedding of muscle specimens 
This was performed on mice 1 week after hindlimb ischaemia. Sch1 was performed 
using isoflurane anaesthesia and intracardiac puncture and blood aspiration. 1mL of 
PBS was slowly injected via a cardiac puncture prior to slow administration of 1mL 4% 
PFA. After 5 minutes, gastrocnemius muscle was carefully harvested from both limbs 
(ischaemic and non-ischaemic). Spleen was also harvested for the first experiment as a 
positive control. Tissue was immediately placed into ice cold 4% PFA for 2 hours, after 
which it was washed and maintained in PBS.  
Embedding was performed with optimal cutting temperature (OCT) compound. First, 
2-methylbutane (isopentane) was poured into a glass beaker and placed into a plastic 
beaker containing liquid nitrogen using long forceps. The correct temperature for use 
was established by observing the formation of crystals. 20mm cork plates were used 
to mount the muscle specimens. Each was labelled before making a platform of OCT 
compound in the centre and lowering into the isopentane. Once frozen, the specimen 
was placed on top and layered in a circumferential fashion with OCT compound. This 
was continued until the sample was fully covered. Once complete, specimens were 








This was performed on a CM1900 cryostat. At commencement, the temperature of 
the apparatus was reduced to -20°C. A stainless steel S35 microtome blade was 
carefully placed in its holder. The embedded tissue specimen was subsequently 
mounted onto a metal platform and locked onto its respective holder. The cryotome 
was adjusted to obtain thicker 50µM sections initially. Once the central region of 
tissue was reached, sections were reduced to 10µM thickness. A fine paintbrush was 
utilised to gently manoeuvre sliced sections underneath the anti-roll glass sheet. From 
here, they were directly loaded onto Superfrost Plus slides by heating the area of 
attachment with the fingertip. This was repeated to obtain roughly 5-6 sections per 
slide. A separate slide was utilised for control non-ischaemic limb tissue. All samples 
were maintained at -80°C until time of staining.  
 
4.13.5 Isolectin B4 staining  
At the time of staining, slides were first allowed to dry at room temperature for 30 
minutes. A PAP pen was used to draw a thin water-repellent region around the 
mounted tissue specimens on each individual slide, and then allowed to dry 
completely. A small gap was left between the margins and the tissue sections to 
ensure that there was sufficient space to accommodate 200µL of liquid, which was 
used for all wash and incubation steps in the protocol.  
After addition of 200µL PBS for rehydration, specimens were permeabilised in 0.25% 
Triton-X100 with 5% goat serum for one hour at 4°C. After three 5 minute washes in 





left overnight at 4°C. Once this was washed three times in PBS, Hoescht 33342 diluted 
1:2000 in PBS was applied for 15 minutes at room temperature. After a final set of 
washes, the slides were mounted with individual 22 x 64mm coverslips using Prolong 
Gold and sealed with nail varnish in preparation for confocal imaging. This final step 
was performed by Dr Richard Cubbon. 
 
4.13.6 Quantification of vascularity 
Analyses were performed using Image J software, with acquisition at 20X 
magnification. Total vascular area was quantified as the proportional area of isolectin 
B4 staining within a 400µm x 400µm region of interest. Horizontal lines were drawn 
across the width of the image, and used to quantify the number of vessels with the 
average of four readings used for statistical analyses. The threshold of each image was 
subsequently altered to black and white (black = non-endothelial, white = endothelial) 
and transformed using the ‘distance map’ binary function. For each individual pixel 
within the image, this illustrates the number of pixels required to reach a black pixel 
and this was quantified using the frequency histogram function. This was used to 
derive a proxy of vessel wall thickness by presenting the distance to non-vascular 
pixels from every vascular pixel. The average of multiple images (≥ 3) per genotype 







Figure 4-14 – Representative image of skeletal muscle (20X magnification) stained  
for endothelium with isolectin B4. Four horizontal lines (white) were drawn at equal  
distances across the image width and used to quantify vessel number. 
 
4.14 Vascular repair after denuding injury 
In vivo assessment of endothelial repair was performed after vascular injury, using 
methodology comparable to other protocols in published literature [447] [448]. Mice 
in the SHIP2iΔ/+ colony were 11 weeks of age to enhance likelihood of tolerating the 
procedure. Initially, at 9 weeks, a 5 day course of IP tamoxifen was administered at a 
dose of 40 mg/kg as outlined previously. After the final dose, mice were observed for 
a period of 1 week. At this stage, vascular injury was performed in designated 
operating theatres using anaesthestic induction as described previously. This 






4.14.1 Surgical arteriotomy 
Surgery was aided by use of a OPMI 1-FC dissecting microscope. An aseptic technique 
was maintained throughout. First, the area of interest was established by removing 
fur with Veet cream. 0.75% providone-iodine solution was topically administered to 
sterilise the region. Access was via a small incision in the left mid-thigh with use of fine 
Iris scissors to perform meticulous and gentle dissection through the tissue layers until 
the common femoral artery was identified. Crucially, great care was taken to avoid 
manipulation of the epigastric artery which was vital in maintaining limb perfusion 
throughout the procedure. After careful isolation, the left femoral artery was 
differentiated using a loosely tied 8.0 Vicryl suture and a proximal clamp placed at the 
site of the inguinal ligament. Additionally, there was distal ligation at the sapheno-
popliteal bifurcation. A single topical drop of Lignol (1% lidocaine and adrenaline) was 
applied prophylactically in the proximal region to minimise propensity for vasospasm. 
Subsequently, an arteriotomy incision was made in the profunda femoris using spring 
scissors. Once access had been obtained, a 200XT angioplasty guide wire of 0.014 inch 
diameter was inserted. Once the clamp had been relieved, advancement of the wire 
for a distance of 1.5-2cm was performed with three repetitions. After removal, the 
suture was tightened to ligate the vessel proximal to the arteriotomy site. Skin was 
closed in layers using a continuous 6.0 Vicryl suture. The right limb was used for 
control purposes and underwent a comparable procedure but without use of a guide 
wire so that no denudation occurred. After discontinuation of isoflurane and 





injected IP to optimise hydration. A period of monitored recovery was conducted, 
with the provision of a soaked diet for 24 hours prior to transfer into their usual cages. 
 
4.14.2 Evans blue staining of residual endothelial injury 
Four days after vascular injury, mice were once again anaesthetised using isoflurane 
as documented. After an incision along the linea alba to expose the inferior vena cava 
(IVC), 50µL of 5% Evans blue solution was injected. This binds with high affinity to 
serum albumin, which is unable to penetrate intact endothelium. However, in areas of 
persisting denudation (i.e. absence of regeneration), albumin can penetrate and 
embed into the subendothelial ECM to allow visualisation. After a duration of 2 
minutes, 4% PFA mixed in PBS was administered directly into the left ventricle using a 
27G needle under mechanical pressure. This mediated fixation of tissues, which was 
confirmed by visualisation of muscle fasciculations. Subsequently, both femoral 
arteries and surrounding soft tissue could be carefully excised longitudinally up to the 
aortic bifurcation proximally. Maintenance storage was in 4% PFA until time of 
analysis. 
Images were obtained by Dr Nadira Yuldasheva using an SZ61 Dissecting Stereo 
microscope with a QiCam digital camera. Careful visualisation enabled dissection of 
arteries from its surrounding tissue. At 20X magnification, a 5mm measurement from 
the aortic bifurcation was established as the proximal point of interest. A 5mm 
segment of artery from this point distally provided the vessel length for analysis. This 
was performed using ImagePro Plus 6.2 software. Firstly, the control vessel was 





quantified and calculated as a percentage of the total area. This value could then be 
subtracted from 100 to identify % endothelial regeneration.  
 
 
Figure 4-15 – Representative image of femoral artery for assessment of vascular  
repair. A 5mm segment was identified (green), and the proportion stained with  
Evans solution (blue) was quantified. 
 
4.15  Statistical analyses 
All graphs were produced using GraphPad Prism. This software was also used for 
statistical analyses, in addition to Microsoft Excel 2013. Continuous data are 
expressed as means with subsequent values in brackets and corresponding error bars 
denoting standard error of mean (SEM). Unless otherwise stated, analyses were 
performed with the assumption of normal distribution using two-tailed unpaired or 
paired Student’s t-tests. In the context of unequal variance, unpaired t-testing with 
Welch’s correction was applied. For GTT and ITT, the area under curve (AUC) was 
calculated. For comparison of proportions, chi-square testing was performed. A p-
value of < 0.05 was considered to be of statistical significance and is denoted by a * 
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For the purposes of this subsection, ‘WT’ denotes control mice whilst ‘ECSHIP2Δ/+’ 
refers to mice with germline endothelium-specific SHIP2 catalytic domain 
haploinsufficiency. 
 
5.1   Genotyping 
All ECSHIP2Δ/+ (and SHIP2iΔ/+) mice required for breeding and experimental purposes 
had their genotype confirmed by DNA PCR. A 1000 base pair ladder was utilised to aid 
correct identification of bands observed. 
A representative image for Cre PCR with three mice (IDs 130, 131, 132) is shown 
below (Figure 5-1). 131 and 132 do not generate any distinct bands and represent the 
native gene. 130 generates a transgene (applicable for both Tie2-Cre and CAGG-
CreERT2) and is visualised as a single band at 408 base pairs. All gels were 










A representative image for SHIP2 PCR with the same three mice is shown in Figure 5-
2). 130 and 132 generate a single band at 411 base pairs and reflect the native gene. 
131 has loxP sites inserted in one allele of the SHIP2 gene, reflected by a second band 
at 500 base pairs. Again, all gels were accompanied by negative (-ve) and positive 
(+ve) controls for verification purposes. 
 
 
Figure 5-2 – SHIP2 PCR. 
 
5.2   SHIP2KD validation 
5.2.1 SHIP2 protein expression in PECs 
To confirm adequate SHIP2KD in the vasculature of ECSHIP2Δ/+ mice, PECs were 
harvested and Western blotting of lysates performed to quantify protein expression 
using densitometry. These data were generated in conjunction with Dr Nicole Watt. 
SHIP2 protein abundance was nominally reduced in SHIP2KD mice compared to WT 
(69 [+/- 9] vs 100 [+/- 13]; p=0.06), although notably, Dubois et al have shown that this 
antibody may still bind truncated SHIP2 (i.e. without its catalytic domain) [377]. 
Consistent with their observation, however, our representative blot does illustrate a 





truncating the catalytic region. Our laboratory has previously attempted to quantify 
native and truncated SHIP2 protein levels separately, but testing with multiple 
antibodies has not unfortunately provided reliable discrimination.  
 
 
Figure 5-3 – SHIP2 protein expression in ECSHIP2Δ/+ colony (n=5,8).  
 
 
Our laboratory has also published data on truncated SHIP2 mRNA expression in PECs 
using quantitative PCR [449]. This was shown only to be detectable in endothelial cells 
derived from ECSHIP2Δ/+ mice, with no expression in WT mice and barely detectable 
signal in lung non-endothelial cells or circulating CD11b+ myeloid cells.  
 
5.2.2 SHIP2 activity in PECs 
To corroborate findings at protein level and confirm concurrent reduction in catalytic 
activity, PEC lysates were used to perform a SHIP2 activity assay. This data was 





reduced enzymatic activity as quantified by PtdIns(3,4)P2 formation/mg protein (516 
[+/- 34] vs 888 [+/- 184]; p=0.03).  
 
 
Figure 5-4 – SHIP2 activity assay in ECSHIP2Δ/+ colony (n=9,12).  
 
5.3   Vascular formation in retinas 
For initial assessment of vascular structure, 5 day old pups from the ECSHIP2Δ/+ colony 
were used to evaluate developmental angiogenesis. Retinas were stained with 
isolectin B4 to highlight endothelial cells and flat-mounted for visualisation with 
confocal microscopy. Baseline body weights were comparable between WT and 
SHIP2KD mice (2.62g [+/- 0.28] vs 2.85g [+/- 0.34]; p=0.19).  
Retinas derived from mice with SHIP2KD demonstrated a trend towards impaired 
radial outgrowth compared to WT (1242µm [+/- 106] vs 1371µm [+/- 108]; p=0.41). As 
the extent of radial outgrowth differs substantially depending on precise timing of 
harvest, measurements were normalised to body weight to account for inter-litter 





SHIP2KD (400µm/g [+/- 42] vs 524µm/g [+/- 38]; p=0.048). Frontal regions showed 
nominally reduced vascular area in the context of SHIP2KD, although this was not 
statistically significant (42% [+/- 2] vs 46% [+/- 2]; p=0.20). No differences were 
evident in more mature central retinal regions between SHIP2KD and WT mice (37% 
[+/- 1] vs 37% [+/- 1]; p=0.53). Quantification of branch points per 0.04 mm2 region of 
interest showed a statistically significant reduction in frontal regions with SHIP2KD (55 
[+/- 2] vs 66 [+/- 1]; p=0.002), with a similar pattern observed in central regions (59 
[+/- 2] vs 69 [+/- 2]; p=0.003). Mice with SHIP2KD had nominally fewer tip cells per 
mm of vascular front (16 [+/- 1] vs 19 [+/- 1]; p=0.06), and significantly reduced 
numbers of filopodia per 100µm of angiogenic front (19 [+/- 1] vs 23 [+/- 1]; 
p=0.0007). The number of filopodia per individual tip cell was similar between WT and 




Figure 5-5 – Representative image of mounted retina from WT mice (Panel A) and  








Figure 5-6 – Retinal analysis, with measurements of radial outgrowth (Panel A), total  
vascular area (Panel B), number of branch points (Panel C), tip cell abundance (Panel  
D), filopodia abundance (Panel E) and filopodia per tip cell (Panel F) (n=11,7). 
 
5.4   Oxidative stress in PECs 
The data presented above provides evidence of impaired angiogenesis in the context 
of SHIP2KD. Our other published work has also demonstrated endothelial dysfunction 
and reduced NO bioavailability in these mice [449]. One potential common 
explanation for these observations is oxidative stress, and this was therefore assessed. 









Figure 5-7 – DHE fluorescence, measured in arbitrary units (AU) (n=3,9). 
 
Nox2 is a critical pathophysiological source of superoxide in models of systemic insulin 
resistance, and its Rac1 subunit can be activated by PI3K. In view of this, expression of 
the Nox2 catalytic gp91 subunit was assessed using Western blotting. This data was 
generated in conjunction with Dr Nicole Watt. PECs derived from SHIP2KD mice had 







Figure 5-8 – Nox2 protein expression in ECSHIP2Δ/+ colony (n=9,10).  
 
Notably, increased superoxide production in the context of SHIP2KD appeared to be 
suppressed by concomitant administration of the specific Nox2 antagonist, Gp91ds-tat 
(0.98 [+/- 0.08] vs 1.25 [+/- 0.09]; p=0.04), suggesting that production was primarily 







Figure 5-9 – DHE fluorescence assay with or without Nox2 inhibition via gp91ds-tat. All  
mean fluorescence values are in arbitrary units (AU) and are adjusted for WT without  
gp91ds-tat (black bar) (n=4,7). 
 
Superoxide abundance in the context of SHIP2KD was also normalised by 
administration of the PI3K inhibitors Wortmannin (0.93 [+/- 0.14] vs 1.43 [+/- 0.15]; 
p=0.03) and LY294002 (0.96 [+/- 0.12] vs 1.29 [+/- 0.07]; p=0.03). This suggests that 
increased signalling through the PI3K/AKT axis, which we have demonstrated in 
SHIP2KD endothelial cells [449], contributes towards this oxidative stress. 
 
 
Figure 5-10 – DHE fluorescence assay with or without PI3K inhibition via  
Wortmannin (Wt) or LY294002 (LY). All mean fluorescence values are in arbitrary   
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For the purposes of this subsection, ‘control shRNA’ refers to HUVECs expressing GFP-
targeting shRNA whilst ‘SHIP2 shRNA’ denotes those expressing SHIP2-targeting 
shRNA. Similarly, ‘vehicle’ refers to cells treated with vehicle control, whilst ‘SHIP2 
SMI’ denotes those treated with SHIP2 SMI. 
 
5.5   SHIP2KD validation 
5.5.1 Lentiviral dose optimisation 
A complementary model using HUVECs was used to validate and extend the 
mechanistic data derived from ECSHIP2Δ/+ PECs. SHIP2KD was achieved with lentiviral 
vectors delivering SHIP2-targeting shRNA, with GFP-targeting shRNA serving as a 
control. Initially, HUVECs were exposed to different SHIP2 shRNA viral vector 
concentrations (5 MOI, 10 MOI or 20 MOI) or equivalent control shRNA viral vector, 
with 4 days elapsing prior to collection of cell lysates for Western blotting. 
Densitometry of bands was performed to quantify total SHIP2 expression. 
SHIP2-targeting shRNA reduced total SHIP2 protein expression: 0.28 [+/- 0.04] vs 0.46 
[+/- 0.05; p=0.005) at 5 MOI, 0.10 [+/- 0.008] vs 0.38 [+/- 0.05; p=0.008) at 10 MOI, 
and 0.11 [+/- 0.006] vs 0.44 [+/- 0.10]; p=0.03) at 20 MOI. When normalised to control 
shRNA, SHIP2 shRNA resulted in 40% SHIP2KD at 5 MOI, 74% SHIP2KD at 10 MOI and 
75% knockdown at 20 MOI, respectively. Based on this preliminary data, 10 MOI was 
used for all subsequent lentiviral transduction experiments as a viral load likely to 








Figure 5-11 – SHIP2 protein expression at different MOI, adjusted to β-actin (Panel  
A) and control (Panel B). Data for control shRNA (black bar) and SHIP2-targeting  
shRNA (pink bar) represented. MOI = multiplicity of infection (n=5,5). 
 
5.5.2 SHIP2 activity in HUVECs 
To corroborate that protein knockdown was associated with reduced SHIP2 catalytic 
function in HUVECs, an activity assay was performed. Compared with control, shRNA 
knockdown of SHIP2 resulted in a 51% reduction in enzymatic activity, as quantified by 








Figure 5-12 – SHIP2 activity assay in HUVECs (n=4,4).  
 
5.6   HUVEC signalling intermediates 
5.6.1 PI3K/AKT axis 
Given the key role of PI3K/AKT signalling in angiogenesis, and its regulation by SHIP2, 
HUVEC lysates were used to measure key components of the PI3K/AKT axis. Band 
densitometry was used to define phosphorylated protein abundance as a proportion 
of its respective total protein. Cells expressing SHIP2-targeting shRNA had a significant 
increase in basal pAKT (T308) expression (41 [+/- 6] vs 26 [+/- 9]; p=0.01), peNOS 
(S1177) expression (134 [+/- 39] vs 99 [+/-9]; p=0.04) and pERK (Y202/204) expression 
(79 [+/- 12] vs 42 [+/- 5]; p=0.009). Paradoxically, such increases in signalling have 
previously been implicated in increased cell survival, migration, proliferation and 







Figure 5-13 – Expression of basal downstream signalling intermediates. All values              
have been adjusted for β-actin, with phosphorylated protein levels expressed as % of  
total (n=5,5).   
 
5.6.2 Nox2 protein expression 
In order to corroborate observations in PECs that SHIP2KD was associated with 
increased Nox2-derived superoxide, Nox2 protein (gp91 subunit) expression was 
quantified. HUVECs expressing SHIP2-targeting shRNA had increased Nox2 protein 









Figure 5-14 – Nox2 protein expression, adjusted for β-actin (n=3,3). 
 
5.6.3 Superoxide production 
To ascertain whether increased Nox2 protein was associated with increased 
superoxide abundance, DHE fluorescence was then quantified. Compared to controls, 
HUVECs expressing SHIP2-targeting shRNA exhibited increased DHE fluorescence (1.42 
vs 1.00; p=0.02). Pertinently, superoxide formation in the context of SHIP2KD 
appeared to be suppressed by the Nox2-specific inhibitor gp91ds-tat (0.93 vs 1.42; 







Figure 5-15 – DHE fluorescence assay. All mean values are measured in arbitrary units  
(AU) and are adjusted for control shRNA (black bar) (n=6,6). 
 
Superoxide abundance in the context of SHIP2KD was also suppressed by 
administration of the PI3K inhibitors Wortmannin (0.87 [+/- 0.15] vs 1.42 [+/- 0.15]; 
p=0.01) and LY294002 (1.30 [+/- 0.09] vs 1.50 [+/- 0.11]; p=0.049). This suggests that 
the increased signalling observed through the PI3K/AKT axis contributes towards the 







Figure 5-16 – DHE fluorescence assay with or without PI3K inhibition via  
Wortmannin (Wt) or LY294002 (LY). All mean fluorescence values are in arbitrary  
units (AU) and are adjusted for HUVECs expressing control shRNA (black bar)  
(n=5,5). 
 
5.7   Cell migration 
5.7.1 Scratch wound assay 
In order to assess whether impaired cell migration may underpin the reduced retinal 
angiogenesis observed with endothelial SHIP2KD, initial screening experiments 
defined scratch wound closure in our HUVEC model system. SHIP2 shRNA resulted in 








Figure 5-17 – Scratch wound closure in HUVECs exposed to control or SHIP2 shRNA  
(n=4,4).  
 
Assays were also repeated in the context of pharmacological SHIP2 inhibition using 
two commercially available SMI, AS1949490 and AS1938909. Consistent with prior 
experiments, scratch wound closure was assessed over an 18 hour duration. Increased 
concentrations of SHIP2 SMI broadly resulted in more significant reductions in wound 
closure versus vehicle control, and this was replicated with both inhibitors. Wound 
closure in the context of AS1949490 at 10µM was 21% [+/- 1] compared to 43% [+/- 4] 
for controls; p=0.005. Similarly, AS1938909 at the same concentration resulted in 21% 
[+/- 1] wound closure compared to 38% [+/- 4] for controls; p=0.02. Given these 
comparable data, AS1938909 was selected for use in all subsequent assays involving 









Figure 5-18 – Wound closure at 18 hours after independent exposure of HUVECs to  
two SHIP2 SMI, AS1949490 (Panel A) and AS1938909 (Panel B). An equivalent  
concentration of DMSO was used for controls (n=4,4). 
 
5.7.2 Boyden chamber assay 
Although the scratch assay has clear advantages in being a simple and relatively 
economical method to study cell migration in vitro, it does not incorporate a 
chemotactic gradient. To circumvent this, we also performed Boyden chamber assays 
with HUVECs expressing control or SHIP2-targeting shRNA in the context of a 50ng/mL 
VEGF chemotactic stimulus (or vehicle control). SHIP2KD reduced net number of 







Figure 5-19 – Net number of migrating cells per microscopic field (300µm x 250µm)  
in Boyden chamber assay, defined as difference in HUVECs with and without  
exposure to VEGF (n=4,4). 
 
5.8   Cell proliferation 
Given that cell proliferation can contribute to angiogenesis and scratch wound 
closure, this phenomenon was quantified by assessing EdU incorporation. HUVECs 
expressing SHIP2 shRNA exhibited no differences in the proportion incorporating EdU 
versus control shRNA (14% [+/- 6] vs 17% [+/- 8]; p=0.43). Similarly, no differences 
were observed between cells exposed to AS1938909 SMI or vehicle control (25% [+/- 
3] vs 26% [+/- 3]; p=0.87). This implies that defects in angiogenesis and scratch wound 







Figure 5-20 – Proliferating cells defined by EdU incorporation, in the context of  
SHIP2-targeting shRNA (Panel A) or SMI (Panel B) (n=7,7). 
 
5.9   Cell sprouting 
As outlined in the ‘introduction’ section, angiogenesis is a multi-faceted process. 
Hence, the 2-dimensional (2D) assays of cell migration and proliferation described 
only model certain stages of angiogenesis. For this reason, a three-dimensional (3D) 
fibrin gel bead sprouting assay using HUVECs has been optimised to recapitulate the 
early stages of angiogenesis, including vessel lumen formation and polarisation of 
endothelial cells [450]. Some more progressive stages including vessel branching and 





In beads coated with HUVECs expressing SHIP2-targeting shRNA, there was a 
reduction in mean number of sprouts per bead after 24 hours incubation (4.7 [+/- 0.7] 
vs 7.6 [+/- 1.8]; p=0.01). No differences were observed in mean sprout length (76µm 
[+/- 7] vs 77µm [+/- 7]; p=0.65). Similarly, addition of SHIP2 AS1938909 SMI resulted in 
a reduction in mean number of sprouts per bead (3.9 [+/- 0.2] vs 5.2 [+/- 0.2]; p=0.03) 
but no statistically significant difference in mean sprout length (69µm [+/- 4] vs 76µm 
[+/- 3]; p=0.16). 
 
 
Figure 5-21 – Bead sprouting assay in HUVECs. Quantification of sprout abundance  
with shRNA (Panel A) and SMI (Panel C), and sprout length with shRNA (Panel B) and  








Figure 5-22 – Representative images of control beads (left) or those with SHIP2KD  
via shRNA (top right) or SMI (bottom right).  
 
5.10 Cell morphology 
Since the data presented above indicates that cell migration may contribute to 
impaired angiogenesis in the setting of SHIP2 knockdown, further experiments were 
planned to characterise cell motility. As outlined in the introduction, cell migration is a 
highly orchestrated process involving a well-defined process of cytoskeletal 
remodelling. The cytoskeleton therefore lends itself as a target to understand the 
molecular processes occurring during cell migration with greater clarity. 
Sparsely seeded HUVECs were exposed to a pro-migratory stimulus of 50ng/ml human 





define filamentous actin. Direct visualisation with confocal microscopy enabled 
identification of individual cells for morphological assessment. In particular, 
measurements were obtained of total cell and lamellipodial area and perimeter in 
addition to a semi-quantitative assessment of lamellipodial distribution. Cells with 
SHIP2KD were nominally larger in area, and this was observed both with VEGF 
(3110µm2 [+/- 445] vs 1900µm2 [+/- 186]; p=0.04) and without VEGF (2524µm2 [+/- 
404] vs 1774µm2 [+/- 195]; p=0.08). Nominally increased total cell perimeter was also 
noted in the context of SHIP2 shRNA, both with VEGF (308µm [+/- 40] vs 270µm [+/- 
17]; p=0.28) and without VEGF (278µm [+/- 28] vs 238µm [+/- 24]; p=0.13). However, 
this did not approach statistical significance. 
Total lamellipodial area was significantly greater in cells with SHIP2KD, both with VEGF 
(197µm2 [+/- 20] vs 76µm2 [+/- 3]; p=0.03) and without VEGF (107µm2 [+/- 10] vs 
58µm2 [+/- 4]; p=0.04). The total perimeter of lamellipodia was also increased in the 
context of SHIP2KD, and again, this was preserved with VEGF (123µm [+/- 17] vs 51µm 
[+/- 3]; p=0.04) and without VEGF (82 [+/- 3] vs 33 [+/- 7]; p=0.009). When 
lamellipodia were quantified as a proportion of cell area, no significant differences 
were detectable without VEGF (4.1% [+/- 0.4] vs 3.3% [+/- 0.2]; p=0.31). However, in 
the context of VEGF treatment, there appeared to be higher proportions though this 
enhancement did not reach statistical significance (5.6% [+/- 0.9] vs 4.0% [+/- 0.4]; 
p=0.32). When lamellipodia as a proportion of total cell perimeter was calculated, a 
similar statistically significant pattern was noted, both with VEGF (40.7% [+/- 5.6] vs 







Figure 5-23 – Representative image of single HUVEC (80X magnification) with  








    
Figure 5-24 – HUVEC morphology of cells treated with control shRNA and SHIP2- 
targeting shRNA. Assessment made of total area (Panel A), total perimeter (Panel B),  
lamellipodia area (Panel C), lamellipodia perimeter (Panel D), and lamellipodia as % of  
total area (Panel E) and total perimeter (Panel F). VEGF = vascular endothelial growth  
factor (n=3,3). 
 
An increase in lamellipodial area is often used to infer increased migratory activity, 
which is at odds with the hypothesis that SHIPKD impairs cell migration. However, 
polarisation of lamellipodia is also an essential element of migration, and therefore, 
an increase in lamellipodial perimeter may suggest a failure of polarised migration. To 
explore this, a semi-quantitative measure of lamellipodial distribution was made by 
dividing the image of a single cell into quadrants. This enabled quantification of the 
area of lamellopodia in each, which could be expressed as a proportion of the total. All 
measurements were made in cells treated with VEGF. Control cells appeared to have a 
skewed distribution (Q1 32%, Q2 30%, Q3 18%, Q4 12%; p=0.46). In contrast, cells 
with SHIP2KD had a more homogenous distribution of lamellipodia (Q1 27%, Q2 23%, 







Figure 5-25 – Distribution of lamellipodial area in each quadrant in the context of  
HUVECs with control (Panel A) or SHIP2-targeting shRNA (Panel B) (n=3,3). 
 
5.11 Cell polarisation 
To define polarity in more detail, the scratch wound assay was used again. In order to 
close the wound, cells must polarise towards the wound before migrating forwards. 
The polarity of an individual cell can be easily defined by drawing a line from the 
nucleus to the Golgi apparatus, and the dynamic correlation between polarisation and 
directional cell migration has been confirmed in live imaging of transgenic zebrafish 
embryos [451]. Confluent HUVECs 30 minutes after a mechanical scratch were stained 
with anti-GM130 antibody (Golgi marker) and Hoescht (nuclear DNA stain) to 





that were forward facing towards the site of scratch (i.e. between -45° and +45° to a 
line perpendicular to the scratch).  
Frequency histograms of raw data for individual cell polarity is shown, both in regions 
at the site of scratch and in control areas remote from the scratch (see Figure 5-26). 
Visual analysis of confluent regions of interest distant from the scratch did not reveal 
any apparent difference in polarity between control and SHIP2KD, both in the context 
of SHIP2 shRNA and SMI. However, there was apparent disparity at the site of scratch. 
As depicted in Figure 5-27, HUVECs expressing SHIP2-targeting shRNA had a lower 
proportion of forward facing cells (25% [+/- 3] vs 39% [+/- 4]; p=0.01). Importantly, no 
differences in scratch wound polarisation were observed in the context of SHIP2 SMI 









Figure 5-26 – Frequency histograms for individual cell polarity at the site of scratch and in remote areas. Data shown in context of shRNA (Panel  







Figure 5-27 – Proportion of forward facing cells at site of scratch in context of SHIP2  
shRNA (Panel A) or SMI (Panel B) (n=4,4). 
 
5.12 SHIP2 localisation 
To determine whether SHIP2 localised to the leading edge of cells shortly after scratch 
wound formation, plated cells were fixed and stained 30 minutes and 1 hour after 
wounding. Representative images are provided in Figure 5-28, with comparison of 
confluent cells and those at the site of scratch. In confluent cells, SHIP2 appears to be 
predominantly peri-nuclear, whilst expression appears increased at the plasma 





SHIP2 may be spatially orchestrated to interact with binding partners at the leading of 
cells and drive the cell to mobilise precisely and dynamically to external cues. 
However, high resolution immunofluorescence images proved insufficient to quantify 










Figure 5-28 – Figure panel (20X magnification) depicting HUVECs stained for  
endothelium (green), SHIP2 (red) and nuclei (blue). A merged image is provided on  








Figure 5-29 – Image of confluent HUVECs at site of scratch (63X magnification),  















Exploring in vivo metabolic and 
vascular function in mice with 













For the purposes of this subsection, ‘WT’ denotes control mice whilst ‘SHIP2iΔ/+’ refers 
to mice with systemic inducible SHIP2 catalytic domain haploinsufficiency. 
 
5.13 SHIP2KD validation  
Published literature suggests that global SHIP2 silencing may enhance insulin 
sensitivity and glucose tolerance [374], prompting hypotheses that SHIP2 inhibition 
may be a valuable strategy for patients with metabolic syndrome. However, data 
presented in the first section of this thesis (and also in a broader publication that 
includes this data [449]) suggests that endothelium-restricted SHIP2KD may have 
adverse effects. It is therefore important to consider the impact on metabolic and 
vascular function of whole body SHIP2KD. We sought to explore this by tamoxifen-
inducible whole body deletion of the SHIP2 catalytic domain (SHIP2iΔ/+ mice), 
effectively mimicking the likely impact of a therapeutic agent. 
Firstly, harvesting of liver, aorta, white adipose tissue (WAT) and skeletal muscle 
(quadriceps) was performed to confirm appropriate reduction in SHIP2 protein in 
diverse metabolic and vascular tissues. Total SHIP2 protein expression appeared to be 
reduced in all organs: liver (0.82 [+/- 0.10] vs 1.23 [+/- 0.64], p=0.56), aorta (2.04 [+/- 
0.03] vs 3.24 [+/- 0.91]; p=0.24), WAT (6.63 [+/- 0.92] vs 20.73 [+/- 1.68]; p=0.001) and 
skeletal muscle (0.67 [+/- 0.09] vs 1.12 [+/- 0.04]; p=0.008), although efficiency of 








Figure 5-30 – SHIP2 protein expression in harvested organs, with values adjusted to  
β-actin. WAT = white adipose tissue (n=5,5). 
 
5.14 Metabolic characterisation 
5.14.1  Gross body weights 
Total body weight was measured on a weekly basis from 1 to 3 months of age (i.e. 
pre- and post- tamoxifen induction). Growth was comparable throughout this period, 
with similar mean weight at 3 months of age between WT and SHIP2iΔ/+ mice (28.5 








Figure 5-31 – Body weights for WT and SHIP2iΔ/+ mice with growth curves up to 3  
months (Panel A) and mean body weight at 3 months of age (Panel B) (n=8,8). 
 
There were no differences in body weights measured for 3 weeks post-tamoxifen 
induction. Mean weight at 3 weeks post-induction was comparable between WT and 








Figure 5-32 – Weekly body weights subsequent to tamoxifen induction (Panel A) and  
mean body weights at 3 weeks post-induction (Panel B) (n=8,8). 
 
5.14.2  GTT and ITT 
SHIP2 is a known regulator of the PI3K/AKT axis (demonstrated earlier in murine and 
human endothelial cells), and signalling via this axis mediates the effects of insulin on 
glucose metabolism. For this reason, formal assessment of whole body 
glucocompetence was made after tamoxifen-induced SHIP2KD. SHIP2iΔ/+ mice 
demonstrated significantly enhanced glucose tolerance and insulin sensitivity, as 
evidenced by GTT (AUC 852 [+/- 22] vs 1104 [+/- 90]; p=0.04) and ITT (AUC 768 [+/- 








Figure 5-33 – Whole body glucocompetence assessment post-tamoxifen induction,  
with GTT (Panel A) and associated AUC (Panel B), and ITT (Panel C) and associated  
AUC (Panel D) (n=5,5). 
 
5.14.3  Fasting glucose and insulin  
No differences in fasting plasma glucose concentration were observed between 
SHIP2iΔ/+ and WT mice (4.9 mmol/L [+/- 0.4] vs 4.6 mmol/L [+/- 0.4); p=0.60). 
However, mice with SHIP2KD had lower fasting plasma insulin levels (0.36 ng/mL [+/- 








Figure 5-34 – Fasting glucose (Panel A) and fasting insulin concentrations (Panel B)  
(n=5,5). 
 
5.14.4  HOMA-IR 
Fasting plasma glucose and insulin concentrations were then used in the HOMA model 
to provide an approximation of systemic insulin resistance. Overall, HOMA-IR score 
was nominally lower in SHIP2iΔ/+ compared to WT mice (2.25 [+/- 0.15] vs 2.95 [+/- 
0.39]; p=0.13). Both mean values were suggestive of preserved insulin sensitivity, 
being within the ‘normal’, non-insulin resistant range (< 3). Overall, these data support 
published work suggesting that SHIP2 loss of function is associated with augmented 







Figure 5-35 – HOMA-IR in WT and SHIP2iΔ/+ mice (n=5,5). 
 
5.15 Angiogenesis after hindlimb ischaemia 
As we observed significant defects in retinas from mice with SHIP2KD, we sought to 
characterise this further in SHIP2iΔ/+ mice using a model of hindlimb ischaemia which 
may be more translationally relevant. Isolectin B4 staining of skeletal muscle one 
week after induction of ischaemia was performed to assess the angiogenic phase of 
vascular regeneration. Vascular area as a percentage of total image area was 
surprisingly increased in the context of SHIP2KD post-ischaemia (16.9% [+/- 2.0] vs 
9.9% [+/- 0.6]; p=0.01). No differences in the number of vessels per image width was 








Figure 5-36 – Quantification of vascularity (as % of total area) (Panel A) and number  
of vessels (per image width) (Panel B) (n=5,6). 
 
On visualisation, SHIP2KD neovessels post-ischaemia appeared structurally abnormal 
as depicted by the representative images in Figure 5-37. As increased total vascular 
area was found in the context of SHIP2KD but without a concurrent increase in vessel 
number, vessel thickness was determined in ischaemic muscle. In the context of 





(27.3% vs 20.0%; p<0.001). This is possibly suggestive of abnormal structure in newly 










Figure 5-37 – Neovessel formation in ischaemic muscle, stained with isolectin B4  
(green). Representative images of WT mice with whole (Panel A) and magnified  
segment (Panel C), and SHIP2iΔ/+ mice with whole (Panel B) and magnified  







Figure 5-38 – Distribution of vessel thickness determined in ischaemic muscle of WT  
(black) and SHIP2iΔ/+ (pink) mice. Measurements were performed in terms of number  
of pixels (n=5,6). 
 
5.16 Vascular repair after denuding injury 
Metabolic insulin sensitivity was enhanced in SHIP2iΔ/+ mice, but endothelium-
restricted SHIP2KD impeded vascular function and scratch wound closure. We 
therefore sought to define the net impact of global SHIP2KD on recovery from 
endothelial injury. The procedural work was conducted by Dr Nadira Yuldasheva using 
an established in vivo model of vascular injury. SHIP2iΔ/+ mice did not demonstrate any 




Figure 5-39 – Comparison of endothelial repair after vascular injury in WT and  









































6.1   Summary of key findings 
The broad aim of this project was to add to existing literature on the role of SHIP2 
modulation on metabolic and vascular biology, with a view to informing decisions 
about the potential for clinical translation. 
Studies were initially performed on mice with germline endothelium-specific SHIP2 
catalytic domain haploinsufficiency (ECSHIP2Δ/+). These have impaired vascular 
formation in developing postnatal retinas, associated with increased endothelial 
PI3K/AKT signalling and Nox2-mediated vascular oxidative stress.  
The relevance of these observations to human pathophysiology was explored in a 
complementary model using HUVECs, which were manipulated using SHIP2-targeting 
shRNA introduced with lentiviral vectors or a complimentary approach of 
pharmacological SHIP2 catalytic inhibition. Alterations in signalling intermediates and 
superoxide generation were recapitulated. This was broadly associated with defects in 
cell migration and polarisation, though no differences in proliferation were observed. 
Preliminary studies also suggested that SHIP2 expression may be increased in control 
cells at the leading edge of a fresh scratch wound.  
The impact of whole body SHIP2 deletion was assessed by using mice with inducible 
knockdown of the SHIP2 catalytic domain (SHIP2iΔ/+), to ascertain the value of 
pursuing pharmacological SHIP2 antagonists as a therapeutic option. Metabolic 
characterisation of these mice confirmed enhanced whole body glucose disposal and 
insulin sensitivity, without differences in body weight. SHIP2iΔ/+ mice exhibited skeletal 





ischaemia, although no differences in re-endothelialisation after denuding arterial 
injury were apparent. 
 
6.2   Effects of endothelium-specific SHIP2KD on angiogenesis 
The retina has proved to be a powerful experimental system for vascular phenotypic 
analysis [436]. It has the inherent advantage of whole plexus visualisation in a uniform 
plane, and defines the diverse processes implicated in angiogenic blood vessel growth. 
Additionally, it incorporates intricacies such as blood flow and mural cell interactions 
that are not recapitulated by in vitro models such as those utilised in this project. 
Assessment of retinas harvested from 5 day old pups has shown that endothelium-
specific SHIP2KD impairs developmental angiogenesis. Of parameters measured, 
radial outgrowth is deemed to be the most sensitive correlate of post-natal 
vasculogenesis. Challenges in accurately defining the fifth postnatal day can result in 
significant relative inter-litter variation in age, which adds to variability in the age-
dependent phenomenon of radial outgrowth. To circumvent this limitation, 
measurements of radial outgrowth were normalised to body weight and this 
confirmed significant reduction in radial outgrowth in the context of SHIP2KD. 
Moreover, vascularity and branching complexity was impaired in the less mature 
frontal regions of the retinas. Notably, there was also nominally reduced abundance 
of tip cells at the vascular front and significantly fewer filopodia normalised to the 
angiogenic front.  
As highlighted in the introduction section, endothelial cells at the angiogenic front use 





Defects in their abundance would therefore be consistent with impairment in vascular 
growth during primitive plexus formation. We pursued a harder fixation (2 hours at 
room temperature) to enable stronger isolectin B4 staining of precise features such as 
tip cells and filopodia. However, this meant that we were unable to immunostain 
retinas for proteins of interest, such as Golgi apparatus markers, and so further litters 
will be required to extend our observations. 
To the author’s best knowledge, our data is novel in assessing the impact of 
endothelium-restricted SHIP2 silencing on primitive vascular plexus formation. 
Interestingly, others have explored the role of PTEN in murine vascular development. 
As outlined previously, PTEN acts as a separate negative regulator of PI3K signalling by 
hydrolysing PIP3 at the 3-position to form PtdIns(4,5)P2, and is also a frequently 
mutated tumour suppressor [360]. Endothelium-specific germline PTEN knockdown in 
mice results in enhanced tumorigenesis driven by increased angiogenesis, which 
correlates with augmented migratory and proliferative capacity in vitro. Significantly, 
early neonatal mortality occurred in germline endothelial PTEN null mice due to 
cardiac failure and bleeding arising from insufficient morphogenesis of the myocardial 
wall and blood vessels [452]. Zebrafish embryos lacking functional PTEN also exhibit 
enhanced angiogenesis. This appeared to be driven by enhanced PI3K/AKT signalling 
as it could be suppressed by treatment with the PI3K inhibitor LY294002 [453]. Further 
mechanistic insights from the postnatal retina indicate that endothelial PTEN is a 
negative regulator of stalk cell proliferation via Notch/Dll4 signalling, with deletion 





patterning [454]. PTEN appears to exhibit dual function in contributing to this 
observed phenotype, with both phosphatase-dependent and -independent activity. 
It is apparent from the conflicting data presented above that angiogenesis is a 
complex and tightly regulated phenomenon which is likely to exhibit variability 
depending on factors such as vascular bed, angiogenic programme (e.g. 
developmental versus pathological) and PI3K manipulating stimuli. Genetic 
manipulation in the ECSHIP2Δ/+ colony was specifically targeted at the catalytic 
domain, and so may have preserved non-catalytic activities such as protein-protein 
interactions. My work solely characterised vascular morphology using endothelial 
staining, without formal assessment of cell proliferation, cell polarity or vessel 
regression. Moreover, it remains unclear whether observed defects are a result of 
aberrant SHIP2 signalling in endothelial cells or also arising from secondary alterations 
in the pro-angiogenic milieu (e.g. VEGF expression) influenced by broader 
perturbations in vascular network formation.  
 
6.3   Effects of SHIP2KD on human endothelial cell biology  
HUVECs provide a useful experimental analogue of adult human endothelial cells and 
can therefore provide complimentary support for the relevance of findings in vivo to 
human pathophysiology. Moreover, they are relatively cost-effective, readily available 
and behave predictably in defined tissue culture conditions. For these reasons, we 
performed functional in vitro assays on HUVECs to extend the observations made in 






6.3.1 Cell migration and proliferation 
SHIP2KD with shRNA and pharmacological inhibition of SHIP2 both impaired 
endothelial scratch wound closure. This simple assay crudely mimics the migration 
and proliferation of cells that are induced during vascular remodelling in vivo. In 
particular, it incorporates haptotaxis and mechanotaxis via cell-ECM and cell-cell 
interactions. However, it does not involve a chemotactic gradient. For this reason, 
Boyden chamber assays were also performed to define migration directed towards a 
VEGF stimulus, and a similar reduction in net migration was found.  
Scratch wound closure and angiogenesis also involve cellular proliferation, and this 
was formally explored by quantifying EdU incorporation. No differences were induced 
by SHIP2 shRNA or SMI. However, this data must be appraised with a degree of 
caution as the 4 hour incubation with EdU was not performed in serum-free media so 
may mask a proliferation advantage of diminished SHIP2 activity. Scrutiny of the raw 
data also confirmed presence of significant inter-experiment variability, which may 
relate to factors such as baseline confluence and cell passage even though efforts 
were made to ensure consistency between experiments. A complimentary approach 
may therefore be to quantify population doubling time before commencing this assay 
to ascertain whether there is agreement.  
The aforementioned assays only incorporate specific elements of angiogenesis, which 
is a complex, multi-step process. The more sophisticated 3D fibrin gel bead sprouting 
assay recapitulates many of the crucial early stages of angiogenesis, including lumen 
formation and vessel branching, and hence more closely models the in vivo process. 





sprouts per bead, but without associated changes in sprout length. The disparity 
between sprout abundance and length is not entirely surprising as initial sprouting 
relies primarily upon cell motility in response to directional cues whereas the latter is 
more proliferation-dependent, supporting data produced by the EdU incorporation 
assay. Findings could be extended by repeating the assay with use of fibroblasts, 
layered on top of the gel, to provide additional soluble factors that promote vascular 
network formation. This is reported in the original protocol [450], but was deemed 
undesirable in this project as the pro-angiogenic environment is less controlled. 
Moreover, interpretation of SMI data would be challenging due to effects on 
fibroblast function. 
As outlined in the introduction, most of the published data on the role of SHIP2 in 
endothelial function per se has been reported in the context of in vitro 
lymphangiogenesis. A recent study has presented comparable findings, with SHIP2KD 
using siRNA and SMI resulting in impaired cell migration as assessed via scratch wound 
and Boyden chamber assays [394]. In addition, cell proliferation was impaired when 
evaluated using a tetrazolium salt colorimetric assay (MTS) although this is a more 
indirect marker of proliferation than EdU incorporation. Matrigel tubulogenesis, cell 
adhesion and survival were also reduced. Notably, over-expression of wild-type SHIP2 
did have some opposing effects but only discernible in the context of cell migration 
and adhesion. Most recently, SHIP2 expression has been manipulated in colorectal 
cancer lines. Reduced expression via lentiviral shRNA transduction has been shown to 







6.3.2 Cell morphology and polarity 
The process of cell migration is highly orchestrated and involves a well-defined 
sequence of cytoskeletal remodelling. To characterise this further, morphological 
assessment of cell dimensions was made. In addition, phalloidin was used as a tool to 
investigate the abundance and distribution of filamentous actin within individual 
HUVECs and, more specifically, for assessment of lamellipodia. In contrast with 
antibodies, phalloidin is much smaller and can therefore more densely label cellular 
proteins for fluorescent microscopy to enhance image resolution. 
Cells expressing SHIP2-targeting shRNA and exposed to VEGF were larger, as 
determined by total area and perimeter. Abundance of lamellipodia was also greater, 
but distribution was more homogenous. As a technique, phalloidin staining does have 
the inherent limitation that its binding inhibits actin dynamics and function meaning 
that only fixed cells can be assessed. Live cell imaging using compatible probes, such 
as LifeAct, is therefore better placed for further exploratory studies. Nonetheless, our 
analysis does generate interesting discussion. An increase in lamellipodial area is often 
used to infer increased migratory capacity, which may seemingly contradict our 
results. However, polarisation is also an essential element and the more homogenous 
distribution in the context of SHIP2KD is possibly suggestive of a loss of cell polarity. 
Notably, this experiment was performed using sparsely seeded cells exposed to VEGF 
as a chemotactic stimulus, but it would be interesting to assess whether findings were 
recapitulated in the context of a scratch wound or angiogenic sprouting, for instance. 





As alluded to, it was important to define polarity more directly in view of the defects 
observed thus far. This was achieved by staining the Golgi apparatus and assessing its 
position relative to the nucleus. In the context of a mechanical scratch, cells 
expressing SHIP2-targeting shRNA had a lower proportion of cells polarised towards 
the wound. This disparity was not observed in confluent areas remote from the site of 
the wound, where a more uniform distribution of polarisation was observed as 
expected. Notably, no such trends were observed in the context of SHIP2 SMI. Use of 
a SMI involves competitive inhibition of the catalytic domain, whilst lentiviral 
manipulation results in reduced expression of the entire protein. Hence, these 
findings infer that cell polarity may be primarily mediated by a non-catalytic role of 
SHIP2, for instance, via intrinsic docking sites mediating protein-protein interactions 
[351]. 
 
6.3.3 SHIP2 localisation 
Spatial orchestration of SHIP2 has been shown in multiple cell types, including human 
astrocytomas, COS-7 cells, HeLa cells and gliomas. We sought to assess this formally in 
the context of scratch wound formation using antibody-labelled SHIP2. Images were 
obtained 30 mins and 1 hour post-scratch. Whilst confluent cells in remote regions 
showed SHIP2 to be predominantly peri-nuclear, localisation appeared more 
concentrated at the plasma membrane in regions directly adjacent to the wound. The 
primary limitation of this approach relates to resolution and signal when attempting 
to quantify membrane localisation, as reflected by representative images in the panel 





Nonetheless, the notion of localised accumulation at the leading edge of migrating 
cells is potentially of relevance. PIP3 has been shown to amass at the leading edge of 
migrating cells, i.e. at the sites of actin polymerisation, cross-linkage and lamellipodial 
formation [105]. LL5β also appears to be recruited to this submembranous region by 
PIP3, enabled by its PH domain [396]. This has been shown to mediate the binding of 
filamin, which has affinity for SHIP2, and can also facilitate its translocation from the 
cytosol to the cell membrane [367]. Notably, staining in our experiments was only 
performed in non-manipulated HUVECs and it would therefore be prudent to explore 
this further in the context of SHIP2KD to see if there are any disparities. The use of 
fluorescent phosphoinositide biosensors, linking fluorescent proteins to PH domains 
specific to PIP3 or PtdIns(3,4)P2, may prove valuable to define this in future live cell 
imaging experiments. However, this technique is challenged by the requirement for 
GFP-tagging which would compromise its use in HUVECs treated with control GFP-
targeting shRNA. A potential alternative method for consideration is fluorescence 
recovery after photobleaching (FRAP), a useful technique in biological studies to 
determine the kinetics of diffusion through tissues and individual cells [456]. However, 
this also relies on use of GFP fusion proteins.  
 
6.4   Effects of temporal SHIP2KD on whole body biology 
6.4.1 Metabolic function 
There is the suggestion in published literature that SHIP2 silencing may improve 
insulin sensitivity and glucose tolerance [374]. This prompts the hypothesis that 





long-term endothelium-restricted SHIP2KD appears to be broadly detrimental to 
vascular function and systemic insulin sensitivity [449]. We therefore explored the 
impact of whole body SHIP2KD on metabolic and vascular biology, using inducible 
inhibition (SHIP2iΔ/+ mice) to mimic the potential short-term role of a therapeutic 
pharmacological agent.  
In direct contrast with germline SHIP2 catalytic domain haploinsufficiency [377], the 
inducible transgene allowed us to avoid confounding developmental abnormalities. 
The tamoxifen induction regime was well tolerated, and no differences in body weight 
occurred in the following 3 weeks. However, whole body glucocompetence was 
enhanced in the context of SHIP2KD, as evidenced by GTT and ITT, along with lower 
fasting plasma insulin levels and HOMA-IR scores. This data is broadly consistent with 
published work suggesting that SHIP2 is a negative regulator of metabolic insulin 
sensitivity.  
Of note, metabolic profiling was conducted 1 week after completion of the tamoxifen 
induction regime. It is therefore unclear whether prolonged SHIP2 silencing would 
have different effects. Our own laboratory has explored the impact of longer-term 
suppression of endothelial SHIP2 activity by using 10 month old ECSHIP2Δ/+ mice [449]. 
Compared with control, ECSHIP2Δ/+ mice had impaired glucose normalisation during 
GTT, higher fasting glucose concentrations and higher HOMA-IR scores. 
Hyperinsulinaemic-euglycaemic clamp studies suggested insulin resistance, with an 
approximate 25% reduction in glucose concentrations required to maintain 
euglycaemia. Moreover, glucose uptake into peripheral organs, namely adipose tissue 





concentrations, ITT, levels of serum FFAs and triglycerides and hepatic glucose output. 
Hence, long-term whole body genetic (or pharmacological) reduction in SHIP2 activity 
may conceivably have adverse effects on systemic glucose metabolism, in contrast 
with the short-term effects observed. 
 
6.4.2 Vascular regeneration 
6.4.2.1 Angiogenesis after hindlimb ischaemia 
As significant defects were observed in developmental retinal angiogenesis in the 
context of endothelium-specific SHIP2KD, we sought to define the impact of whole-
body inducible knockdown. This was achieved by assessment of ‘pathological 
angiogenesis’ in skeletal muscle one week after induction of hindlimb ischaemia. 
These results somewhat contradicted the retinal data, with increased vascular area in 
SHIP2KD when defined by total area although this was driven by increased vessel 
diameter rather than number. It is difficult to dissect the relative contribution of SHIP2 
manipulation per se to the differing phenotypes observed with endothelium-specific 
and whole body knockdown, as the duration and cell lineage of knockdown differed 
along with angiogenic stimulus and vascular bed studied. In addition, isolectin B4 is 
not entirely specific for endothelial cells as it is also weakly positive for macrophages 
which can themselves modulate angiogenesis. The thresholding approach applied 
during data analysis allows such weak staining to be ignored, but nonetheless, it 
would be useful to quantify recruitment of these cells. We did attempt to separately 
stain for macrophages using anti-CD45 antibody and a more selective anti-F4/80 





Interestingly, the diameter of neovessels was also increased in the context of 
SHIP2KD. There is abundant data to support the notion that neovessel quality, in 
addition to quantity, is important to achieve adequate perfusion of ischaemic tissues 
[428]. Indeed, excessive but disordered vasculature is implicated in pathophysiological 
states including diabetic retinopathy and cancer [76]. It would therefore be relevant 
to assess vessel coverage with pericytes and VSMCs in future studies. Staining for VE-
cadherin could also be performed, which is an endothelium-specific intercellular 
adhesion molecule and deemed important for regulation of vascular permeability and 
leukocyte extravasation [457]. FITC-dextran extravasation could be assessed using 
fluorescent microscopy as a surrogate for vascular permeability. It is also not apparent 
whether the increased vascularity in the context of SHIP2KD is the consequence of a 
persistently hypoxic milieu and/or heightened oxidative stress. It may therefore be 
relevant to explore these processes histologically. 
 
6.4.2.2 Vascular repair after injury 
To explore effects of temporal whole body SHIP2 manipulation further, we assessed 
recovery after endothelial denudation in the femoral artery. No differences in 
recovery were present between WT and SHIP2KD mice. Although these findings may 
seem unexpected, it must be borne in mind that the inflammatory response with 
recruitment of bone marrow-derived cells, particularly leukocytes, is critical in 
mediating vascular repair via predominantly paracrine mechanisms. This has not been 
explored in this project, but future experiments could explore leukocyte abundance in 





cytokines, such as IL-6 and TNF-α, in the repairing arterial wall. Direct anti-F4/80 
staining of denuded endothelium could also be performed to assess recruitment and 
mobilisation of macrophages to the site of injury. 
 
6.5   Effects of SHIP2KD on cell signalling 
6.5.1 PI3K/AKT axis 
As PI3K/AKT signalling is regulated by SHIP2 and has a pivotal role in metabolic and 
vascular biology, we used HUVEC lysates to assess basal activation of these signalling 
nodes. SHIP2KD resulted in increased activatory phosphorylation of AKT, eNOS and 
ERK protein. In some ways, these results may appear paradoxical as such increases in 
signalling have previously been shown to induce a portfolio of cellular processes 
including migration, proliferation and angiogenesis [458]. However, this data is 
consistent with published data in our own laboratory from work with ECSHIP2Δ/+ mice 
[449]. PECs derived from 10 month old mice had increased basal expression of pAKT, 
peNOS, pPDK1 and pRICTOR. However, insulin- and shear-stimulated induction of 
peNOS was impaired. This is suggestive of increased basal signalling but a failure to 
augment this appropriately in response to diverse physiological stimuli. Of note, the 
effects of SHIP2 inactivation on proximal insulin signalling, such as insulin receptor and 
IRS1/2 expression and phosphorylation, was not explored in this project. However, no 
differences were observed in ECSHIP2Δ/+ mice-derived PECs [449].  
There is reasonably convincing data to support the suggestion that chronic activation 
of the PI3K/AKT axis can be detrimental to cellular physiology. In mice with induced 





phase but sequentially resulting in impaired angiogenesis and pathological 
cardiomyopathy [459]. In mice rendered obese with a high-fat diet, chronic AKT 
activation increased vascular senescence and susceptibility to ischaemic injury [460]. 
Sustained signalling during vascular development has also been shown to disrupt 
normal vessel hierarchy and patterning and result in vascular malformations [461]. 
 
6.5.2 Oxidative stress 
Data derived both from PECs and HUVECs has consistently shown that SHIP2KD is 
associated with increased superoxide abundance, produced in a Nox2 and PI3K/AKT-
dependent manner. Quantification was reliant on the DHE fluorescence assay, which 
is primarily limited by the fact that DHE oxidation yields at least two products which 
have differing specificity for superoxide. Nonetheless, our laboratory has also formally 
assessed superoxide abundance in ECSHIP2Δ/+ PECs via lucigenin-enhanced 
chemiluminescence and results were complementary [449]. If greater precision was 
sought, high performance liquid chromatography (HPLC) could be considered to 
derive the fluorescent product of interest. Nonetheless, the complete normalisation of 
DHE fluorescence by gp91ds-tat strongly supports the argument that superoxide 
abundance is genuinely increased. 
Others have shown an association between enhanced AKT signalling and oxidative 
stress [462]. This correlated with increased abundance of the scavenger receptor 
CD36, which may trigger a detrimental positive feedback loop. Murine research in 
redox signalling has also highlighted a critical role of oxidant free radicals in the 





appear essential. Re-endothelialisation of injured carotid arteries is enhanced by 
hypoxia-induced mobilisation of EPCs but this benefit is suppressed in the context of 
Nox2 inhibition [324]. Vascular regeneration after hindlimb ischaemia is also impaired 
in mice with Nox2 deletion, and correlates with reduced superoxide abundance [463]. 
However, effects appear to be more conflicting in the context of pathological states 
such as DM. In mice with type 1 DM, for instance, inhibition of Nox2-derived ROS 
overproduction has been shown to improve neovascularisation after hindlimb 
ischaemia [464]. This has been corroborated by a more recent study where the 
pathological insult was exposure to cigarette smoke [465].  
This intricacy and underlying complexity of oxidative signalling is best considered by 
the ‘redox window’ hypothesis, where perturbations have differing effects depending 
on the setting. It also underscores the effects of unrestrained signalling at multiple 
nodes in ubiquitous signalling cascades, which are likely to have detrimental effects on 
vascular function. It would be particularly valuable to assess if Nox2 (and PI3K/AKT) 
inhibition could rescue the defects in angiogenesis, migration and polarisation 
observed in SHIP2KD cells. 
The potential effects of oxidative stress on actin cytoskeletal remodelling are poorly 
understood, but oxidative modification is known to be important during normal 
physiological actin remodelling [466]. However, LDL cholesterol-induced production of 
ROS results in cytoskeletal disruption and inhibits endothelial cell migration in vitro 
[467]. This appears to be primarily through a superoxide-dependent mechanism, 
though generation of peroxynitrite has also been reported to directly inhibit actin 





HUVECs results in larger cells with more abundant yet homogenous lamellipodia may 
relate to heightened signalling via the PI3K/AKT axis but with a concurrent increase in 
oxidative stress. Although the actin cytoskeleton has been traditionally visualised with 
chemical tools such as fluorescently-labelled phalloidin, they have limited application 
in living cells. Further exploration using techniques with live cell-compatible probes 
may therefore be particularly instructive in the temporo-spatial study of actin 
dynamics [469]. 
 
6.6   Project limitations 
6.6.1 Use of murine models  
In vivo work in this project relied on use of ECSHIP2Δ/+ and SHIP2iΔ/+ mice that had 
been genetically modified. Although these models aimed to evaluate SHIP2 
manipulation in the context of germline endothelium-restricted or inducible global 
knockdown, respectively, they cannot fully mimic the nuances that exist in human 
patho(physiology) for which there is no direct corollary. The effects of compensatory 
mechanisms that may arise secondary to gene knockdown, such as via PTEN or SKIP, 
cannot be neglected although temporal inhibition and deletion of only one allele 
should circumvent the risk of genetic redundance traditionally associated with murine 
knockout models [470]. This project was also subject to inherent limitations 
associated with murine work, such as unpredictable drifting of the ECSHIP2Δ/+ colony, 
that caused unavoidable experimental delays.  
The models of vascular disease adopted for experimentation purposes are 





hindlimb ischaemia model is performed via an acute interruption of blood flow, whilst 
in humans, peripheral vascular disease has a more indolent and chronic progression 
which enables collateral vessel formation. Moreover, many strains of mice are far 
more tolerant of limb ischaemia than humans due to greater collateral vessel 
abundance [471]. Similarly, femoral artery denudation was used as a mimic of 
endothelial injury arising from atherogenesis or stent deployment. However, this 
approach is unlikely to reflect the diverse, non-homogenous distribution of insults that 
arise in human vasculature and are influenced by shear stress and presence of branch 
points, for instance. Moreover, no formal assessment of long-term recovery was 
obtainable.  
This project analysed endothelial cells derived from macrovascular, microvascular and 
venous circulations. One could legitimately argue that these systems are exposed to 
differing haemodynamic pressures and are therefore likely to express cellular and 
molecular heterogeneity that may influence observed phenotypes [472]. Nonetheless, 
a pragmatic approach was adopted based on our laboratory’s familiarity with 
protocols. The agreement between the different approaches in our work suggest that 
the issues described were not major limitations of the project. 
Overall, there is sufficient credence to justify the use of mice for this project. The 
processes of vascular repair and regeneration after hindlimb ischaemia are highly 
complex and require orchestration of multiple cell lineages in a 3-dimensional 
structure. Whole body metabolic function also requires the integrated activity of 
multiple organ systems. Moreover, we sought to temporally manipulate gene 





pharmacological agent. All of these requirements infer that alternative experimental 
techniques are inadequate to address the fundamental aims and hypotheses of this 
project. Mice were considered the most pragmatic choice of animal, as larger 
mammals would necessitate additional logistical challenges such as longer breeding 
durations. Nonetheless, mechanistic data derived from the mice colonies were 
extended and validated through use of HUVECs, to support the relevance of our 
observations to human disease.  
 
6.6.2 Statistical methodology 
Sufficient numbers of mice from the required genotypes were utilised in key 
experiments to fulfil pre-defined power calculations, which sought to follow the 
principle of reducing animal numbers where possible (for example, by selecting a 
power of 0.9). This pragmatic approach to animal experimentation is consistent with 
defined ethical paradigms of the ‘three R’s’: reduce, refine and replace. This meant 
that in these experiments, there remains a chance that statistically non-significant 
observations represent false negative conclusions. Moreover, the mechanistic studies 
presented should be viewed as hypotheses generating, and it is impractical for all of 
these to follow strictly pre-defined power calculations. However, by using 
complementary approaches, the potential for reaching false positive conclusions was 
reduced. 
A further limitation arose from the risk of experimental bias. It was impractical for all 
researchers involved in the project to be fully blinded at all stages. Where possible, 





work and image acquisition was also performed by independent researchers who 
were blinded to genotype of treatment allocation, and if time permitted, analysis was 
duplicated by two independent researchers as a means of moderation. By 
incorporating such a strategy, the data derived in this project are likely to be robust 
and reproducible.  
 
6.6.3 Temporal manipulation of SHIP2 
A portion of the work presented in this thesis relied on temporal deletion of the SHIP2 
catalytic domain to ascertain the potential impact of a pharmacological inhibitor in 
clinically relevant contexts. However, other data are derived from mice with germline 
loss of the SHIP2 catalytic domain meaning that there was significant variation in the 
duration of knockdown across mice used throughout this project. For instance, retinal 
imaging was performed in ECSHIP2Δ/+ pups at 5 days of age (after an approximate 21 
day gestation with vascular development beginning around day 7), whilst metabolic 
and vascular profiling after tamoxifen induction in SHIP2iΔ/+ mice was performed one 
week after tamoxifen induction of Cre activation. Other data from ECSHIP2Δ/+ PECs 
reflect SHIP2 inactivation after approximately 10 months. Whilst this disparity was 
generally intended to define temporal differences in the phenotype of SHIP2 
inactivation and remove developmental defects of germline inactivation, logistical 
reasons necessitated study of angiogenesis and PEC function at different ages of 
ECSHIP2Δ/+ mice. Nonetheless, the data derived from these models are broadly in 





Similarly, HUVECs expressing SHIP2-targeting shRNA for 4 days mimicked many of the 
phenotypic traits observed in mice. However, it will be important for future studies to 
conduct a more detailed comparison of the impact of short- versus long-term SHIP2 
inactivation/inhibition given the literature suggesting that beneficial vascular effects 
of short-term PI3K/AKT activation may become detrimental over the longer term. 
 
6.6.4 Multiple functions of SHIP2 
6.6.4.1 Docking properties 
This project varied in the means by which SHIP2 was manipulated. In vivo work with 
murine colonies relied upon targeted genetic deletion of the catalytic domain. HUVECs 
treated with SMI similarly relied upon competitive inhibition of catalytic activity. In 
contrast, HUVECs expressing SHIP2-targeting shRNA had diminution of the whole 
SHIP2 mRNA sequence resulting in reduction of the full protein containing both 
catalytic and non-catalytic domains. As outlined, both the SH2 and proline-rich 
domains can interact with a range of effector proteins via intrinsic docking sites, 
including receptors, adaptors, kinases and cytoskeletal proteins. Certainly, non-
catalytic properties have also been reported for other phosphatases implicated in 
glucose metabolism, including PTEN, SHIP1 and inositol phosphate multikinase (IPMK) 
[351]. It may therefore be that some of the disparities observed between in vivo and 
in vitro data, and between shRNA and SMI manipulation of HUVECs, relate to catalytic 
versus non-catalytic roles of SHIP2. It will therefore be important to explore this 
further by genetically manipulating potentially relevant non-catalytic SHIP2 domains 






6.6.4.2 Regulation of phosphoinositide metabolism 
As highlighted, the catalytic function of SHIP2 is a 5-phosphatase to remove the 5’ 
phosphate group from PIP3 to generate the reaction product PtdIns(3,4)P2. The 
consequence of SHIP2KD should not solely be considered in terms of increased PIP3 
accumulation, as PtdIns(3,4)P2 formation will also be reduced. The latter can bind 
directly to lamellipodin, a cytoskeletal remodelling effector, and has also been broadly 
implicated in insulin signalling and cell membrane dynamics [473]. More specifically, it 
has been shown to be required for full activation of AKT, and may be implicated as a 
tumour oncogene in colorectal cancer by enhancing chemoresistance, cell migration 
and invasion [455]. Accumulating evidence has therefore supported the significance of 
PtdIns(3,4)P2 as an important component of the PI3K/AKT signalling network, though 
its relative contribution in specific cellular contexts remains uncertain. It should also 
be noted that an accumulation of PIP3 upon SHIP2KD may provide more substrate for 
PTEN, generating biologically active PtdIns(4,5)P2. This serves as a reminder that the 
phosphoinositide milieu is highly complex and inter-dependent, and so inhibition of 
SHIP2 catalytic activity will have complex effects related to altered abundance of 
many isoforms. 
The catalytic efficiency of SHIP2 towards Ins(1,3,4,5)P4 is almost 10-fold greater than 
its lipid derivative PIP3. Most significantly, SHIP2 has multiple target substrates aside 
from PIP3 [474]. For instance, it can also dephosphorylate PtdIns(4,5)P2 to produce 
phosphatidylinositol 4-phoshate (PI(4)P) [355]. This appears to participate in the 





function of these different substrates was not formally assessed in this project, though 
they are likely to have pertinent roles in cell signalling and regulation of multiple 
distinct pathways. The broad substrate specificity of SHIP2 also has important 
implications when considering the translation of selective SHIP2 pharmacological 
inhibitors for any therapeutic purpose. 
 
6.6.4.3 SHIP2 antibody 
An anti-SHIP2 antibody was kindly donated by our collaborator (Professor Stephane 
Schurmans, University of Liege) to quantify total murine SHIP2 protein expression in 
PECs, whilst a commercially available antibody was used for SHIP2 detection in HUVEC 
lysates. The challenge with this approach is that there is no antibody available that is 
specific to mutant truncated SHIP2 protein (i.e. without its catalytic domain), as the 
antibody utilised recognises an amino acid sequence that is retained in the truncated 
protein. Representative western blots obtained from PEC lysates do illustrate a subtle 
reduction in total protein abundance and size. The reduced abundance may relate to 
impaired transcription and translation of truncated SHIP2 and would be consistent 
with that reported by other researchers that studied the floxed SHIP2 mice we used 
[377]. Representative blots derived from transfected HUVEC lysates also demonstrate 
a significant reduction in total SHIP2 protein abundance when quantified by 
densitometry, supporting their mechanism of SHIP2 mRNA suppression. The 
associated impact on SHIP2 catalytic activity in both cases was corroborated by 






6.7   Future directions  
Beyond the topics that have already been highlighted, there are a multitude of areas 
that could be further explored to build upon the work described in this project. Before 
these are discussed, there are some general points to consider. Firstly, our work has 
been based upon SHIP2KD in a haploinsufficient manner. It would be particularly 
interesting to observe whether SHIP2 overexpression in these contexts has converse 
effects. As discussed, SHIP2 has multiple effector functions mediated through 5 
phosphatase activity in addition to its scaffolding properties and intrinsic docking 
sites. By characterising these interactions through immunoprecipitation, co-
localisation assays (e.g. fluorescence resonance energy transfer [FRET]) and site-
directed mutagenesis, a more detailed understanding of the effects of SHIP2 
manipulation will be achievable. No spliced isoforms of the SHIP2 protein have yet 
been reported, but if confirmed, their existence will add further layers of complexity. 
It also remains unclear if SHIP2, like PTEN, also has a role in nuclear regulation of gene 
expression. Lastly, enzyme abundance does not always correlate with activity. For this 
reason, SHIP2 activity assays were conducted to confirm adequate SHIP2 catalytic 
domain knockdown in transfected HUVECs and PECs. This, however, relies on 
byproduct quantification, and hence, the alternative malachite green phosphatase 
assay is a more complimentary strategy to directly measure liberation of phosphate as 
a consequence of SHIP2 enzymatic activity [475].  
 





We have sought to perform in vivo whole body metabolic phenotyping in the context 
of SHIP2 catalytic domain haploinsufficiency. However, the approaches used to 
perform profiling are limited by their relatively crude assessment of insulin sensitivity 
and lack of organ-specific glucose uptake data. It would therefore be instructive to 
conduct more sophisticated analyses such as hyperinsulinaemic-euglycaemic clamping 
[476], a method for which our laboratory has some familiarity [477]. However, we 
have performed HOMA-IR scores which has been shown to correlate well with this 
approach. Studies could also be extended by assessing hepatic glucose output, glucose 
uptake into peripheral tissues using tracer studies and measurement of serum FFA 
and triglycerides to discern lipid profile. A formal assessment of fat distribution, food 
intake and activity level could also be performed.  
A further option for in vivo analysis relates to SHIP2 SMI. Indeed, chronic treatment 
has already been performed in the context of diabetic db/db mice with AS1949490, 
and has been shown to lower plasma glucose concentrations and improve whole body 
glucose tolerance [370]. The administration regime in this study was as twice daily oral 
preparations for 7 or 10 days. However, a more sophisticated strategy may be to 
implant micro-osmotic pumps to enable continuous subcutaneous infusion so that the 
effects of chronic administration can be assessed [478]. Although this SMI has been 
shown to be potent and selective for SHIP2 relative to other intracellular 
phosphatases, the concern of potential off-target effects remains. Hence, further 
biological characterisation and pharmacokinetic analysis is warranted to understand 





Pertinently, all our in vivo studies have only been performed in metabolically 
unchallenged physiological conditions. It would therefore be useful to repeat the 
experiments after induction of systemic insulin resistance, and our laboratory has 
shown that this can be reliably achieved by using a high fat, high calorie diet for 2 
months after weaning [479].  
 
6.7.2 Vascular profiling 
An extensive exploration of the impact of SHIP2 manipulation on vascular function 
was achieved through use of PECs and HUVECs. Our initial data was generated from 
work on retinas with endothelium-restricted germline SHIP2 catalytic domain 
haploinsufficiency. This was performed in 5 day old pups to assess early vascular 
network formation, but ought to be extended to older mice to scrutinise vascular 
remodelling and plexus maturation. Although a clear impairment of vascular 
formation was elicited in the context of SHIP2KD, it is unclear whether this relates to 
retarded vessel formation per se as opposed to regression of new vasculature. Further 
explorative imaging could be considered with staining for EdU (proliferation), type IV 
collagen (regression) and caspase (apoptosis). An assessment of vessel maturation 
could be achieved by staining pericytes, for instance. In the context of SHIP2KD, we 
have observed clear defects in cell polarity that may impair cell migration. This could 
be scrutinised further at the angiogenic front through measurement of capillary 
diameters, and also combined nuclear and Golgi apparatus staining, though the latter 
approach may be challenging to interpret in a complex 3D system. The effects of 





stabilisation and regression are also of potential relevance, and could be investigated 
in the context of mouse retinas and zebrafish as documented in published literature 
[451]. 
Vascular function was determined predominantly in HUVECs, so it would be beneficial 
to explore vasomotor function more formally. This could be performed ex vivo using 
aortic rings, for instance. Indeed, this has been studied in 10 month old ECSHIP2Δ/+ 
mice and shown to exhibit blunted insulin-mediated vasodilation and less constriction 
when exposed to the non-selective NOS inhibitor L-NMMA, implying lower NO 
bioavailability [449]. In addition, the effects of SHIP2KD on macrovascular disease 
could be delineated by crossing with atherosclerosis-prone ApoE knockout mice. 
This project assessed vascular regeneration in the context of hindlimb ischaemia by 
quantifying vascular density in images of skeletal muscle. It would be helpful to extend 
this to a functional assessment of reperfusion, such as by performing laser Doppler 
analysis, and this work is planned for the future. Micro-CT is deemed the gold 
standard to quantify arteriogenesis in ischaemic limbs, a major driver of reperfusion, 
and the apparatus has recently been acquired for use in our laboratory. However, this 
is a technically challenging approach that will require time to establish and optimise 
[480]. It will also be important to consider hindlimb ischaemia recovery in ECSHIP2Δ/+ 
mice. 
There is evidence from our data to support the notion of broad enhancement of 
PI3K/AKT signalling and concurrent increase in oxidative stress, factors that have 





mechanistic insights may be derived from quantification of VEGF and other pro-
angiogenic ligands in primitive retinas and ischaemic muscle tissues. Given that 
Notch/DII4 signalling in response to VEGF (whose receptor signalling is also regulated 
by SHIP2) is strongly implicated in angiogenesis, an assessment of such signalling 
components would be equally relevant. The effects of SHIP2 modulation on responses 
to other stimuli aside from VEGF could be explored, as it is likely to exert a diverse 
range of responses to chemical and physical stimuli implicated in vascular function 
and remodelling. Lastly, it would be imperative to explore expression of both total and 
phosphorylated SHIP2 since they may have differing activity. Although there are 
highlighted challenges associated with antibody specificity, others report to have 
reliably discriminated between the two [393].  
The functional assays performed with HUVECs were based on established protocols 
that had been modified and optimised for the purposes of this project. Nonetheless, 
there are caveats to be borne in mind. For example, the scratch wound assay was 
performed manually using a pipette tip which was operator-dependent and not 
consistently reproducible. The IncuCyte imaging system would therefore add further 
refinement to this approach, and would confer the added benefit of real-time imaging 
and automated quantification software. Moreover, it is difficult to discriminate the 
relative contributions of cell migration and proliferation per se to observed wound 
closure. The IncuCyte tool provides an initial correction for the degree of proliferation 
observed in cells at close proximity to the wound edge to circumvent this limitation. 
The alternative approach would be to perform a manual scratch wound assay, but 





A concerted attempt was made to explore the effects of SHIP2KD on cell morphology 
and spatial orchestration. This could be detailed further using time-lapse live cell 
imaging. This approach has been reported by others, and has shown SHIP2 to recruit 
Mena (involved in actin filament elongation) to the leading edge of cancer cells to 
enable invasion and metastatic spread [482]. This could be used as an explorative 
strategy to assess for the interaction of SHIP2 with other substrates implicated in 
cytoskeletal remodelling, such as talin and filamin. As alluded to, the use of specific 
biosensors for PIP3 and PtdIns(3,4)P2 could also be considered to monitor spatial 
phosphoinositide dynamics during migration and polarisation in response to SHIP2 
inhibition or knockdown. This may help to test the hypothesis that dysregulated 
lamellipodial organisation and cell polarisation observed after SHIP2KD are associated 
with failure to adequately polarise phosphoinositides.  
Potential translational relevance of findings could be extended by studying SHIP2 
expression and modulation in vascular tissues derived from human disease specimens. 
As mentioned earlier, INPPL polymorphisms have been implicated in human clinical 
disorders including metabolic syndromes such as DM. The potential identification of 
genetic loci associated with diseases or traits could be performed using genome-wide 
association studies (GWAS), a well-established and effective strategy that has already 
identified reproducible loci implicated in cardiovascular disease and DM [483]. Indeed, 
the strategy of gene searching has already been applied to uncover genotype-







6.8   Concluding remarks 
SHIP2 is a known regulator of insulin signalling that is mediated predominantly via 5’ 
phosphatase activity. The aim of this project was to assess the effects of SHIP2 
modulation on metabolic and vascular biology, and this was achieved predominantly 
in murine models with endothelium-specific and whole body inducible SHIP2 catalytic 
domain haploinsufficiency. The relevance of observations to human pathophysiology 
was explored using HUVECs after SHIP2 silencing using lentiviral transduction or 
pharmacological inhibition. The primary hypothesis was that SHIP2 inhibition has 
favourable effects on insulin-mediated glucose lowering, vascular repair and 
regeneration. 
Endothelial SHIP2 silencing was shown to impair vascular formation in developing 
postnatal retinas, associated with increased endothelial PI3K/AKT signalling and 
vascular oxidative stress. Whole body SHIP2 deletion appeared to improve whole 
body glucose disposal and insulin sensitivity. Neovessel formation in ischaemic tissues 
also appeared enhanced, but with potential structural abnormalities. No differences 
were apparent in re-endothelialisation after denuding arterial injury. Alterations in 
signalling intermediates and superoxide generation were broadly recapitulated in 
HUVECs, and were associated with defects in cell migration and polarisation albeit 
with preserved proliferative capacity.  
In summary, SHIP2 activity appears to be critical in systemic metabolic homeostasis. It 
also has a crucial role in preserving mechanisms implicated in normal vascular biology, 





signalling. This suggests that caution needs to be exerted when considering SHIP2 
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